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Abstract 
It has been hypothesised that patients with long-term treated HIV infection may exhibit 
features of accelerated physiological ageing. Given previously established links 
between, a) anti-retroviral therapy and mitochondrial DNA (mtDNA), and b) mtDNA 
and ageing, I hypothesised that anti-retroviral therapy may lead to the accumulation of 
mtDNA mutations, in an acceleration of the molecular process seen in normal human 
ageing.  
Using a combination of single cell molecular analyses and ultra-deep sequencing 
(UDS), I demonstrated that HIV-infected patients with prior exposure to polymerase 
(pol) γ inhibiting NRTI (nucleoside analogue reverse transcriptase inhibitor) therapy 
show increased accumulation of somatic mtDNA mutations within cells, in a pattern 
similar to that seen much later in life due to normal ageing. Empirical data and in silico 
modelling suggested this is likely to be mediated by the accelerated clonal expansion of 
pre-existing (age-associated) mtDNA mutations, rather than by increased mutagenesis.  
I went on to further develop the UDS methodology, to explore more fundamental 
questions about the characteristics of mtDNA mutations in ageing, health and disease. 
In so doing, I showed that low-level mtDNA heteroplasmic mutation appears to be 
universal, and that many ostensibly somatic mutations may in fact have been maternally 
transmitted at very low levels.  
I explored the utility of serum FGF-21 (fibroblast growth factor 21) and phosphorus 
magnetic resonance spectroscopy (
31
P-MRS) as non-invasive measures of muscle 
mitochondrial dysfunction in anti-retroviral treated patients. Both showed significant 
abnormalities, although neither proved sensitive or specific in my patient group.  
Finally I explored the frequency and severity of fatigue in contemporary HIV-infected 
patients, showing that half of all patients have excessive fatigue despite good immune 
function and suppressed HIV viraemia. Patients with prior exposure to pol γ inhibiting 
NRTIs were almost universally fatigued, suggesting that persistent mitochondrial 
dysfunction due to accumulated mtDNA mutations may be important in driving fatigue 
in this patient group.  
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Doctoral Statement (Introduction) 
 
1.1 HIV and ageing, an overview 
It has recently been hypothesised that long-term HIV infection may cause a clinical 
syndrome resembling accelerated ageing (Casau, 2005; Effros et al., 2008). Such an 
observation has arisen from multiple considerations. Firstly, clinical and 
epidemiological data describes an excess of comorbid diseases which resemble those of 
older age (for example, cardiovascular disease, osteoporosis, cognitive impairment) 
(Currier et al., 2003; Thomas and Doherty, 2003; Valcour et al., 2004; Brown and 
Qaqish, 2006; Heaton et al., 2010). Secondly, there is accelerated physiological decline, 
such as an increase in the age-associated loss of aerobic capacity, and an increase in 
frailty, which is seen as a core phenotype of physiological ageing (Oursler et al., 2006; 
Desquilbet et al., 2007). Thirdly, and from a more pathophysiological standpoint, HIV-
infected patients show an acceleration of immune senescence, despite virally 
suppressive anti-retroviral therapy, and despite reconstitution of absolute numbers of 
CD4 T lymphocytes (Effros et al., 1996; Bestilny et al., 2000; Appay et al., 2007). 
However, an alternative approach to the consideration of the ageing is ‘bottom-up’, 
from the cellular level, a process often referred to as ‘intrinsic ageing’. Intrinsic ageing 
describes the notion that there is a fundamental ageing process within humans, which is 
not simply the sum total of increasing chronic diseases acquired during life. Such a 
process starts with molecular damage, thence leading to cell, tissue and organ 
dysfunction, as succinctly reviewed by Kirkwood (Kirkwood, 2005; Kirkwood, 2008). 
Intrinsic ageing is proposed as the ‘canvas’ upon which the diseases of older age (for 
example, neurodegeneration) may develop (Campisi and d'Adda di Fagagna, 2007).  
 
One of the best characterised tenants of intrinsic ageing in healthy persons is the 
phenomenon of acquired (somatic) mitochondrial DNA (mtDNA) mutation (Linnane et 
al., 1989; Corral-Debrinski et al., 1992a; Corral-Debrinski et al., 1992b; Simonetti et 
al., 1992; Brierley et al., 1998; Michikawa et al., 1999; Pesce et al., 2001; Wang et al., 
2001; Lin et al., 2002; Del Bo et al., 2003). Given a wealth of data linking HIV 
infection, anti-retroviral therapy and mitochondrial dysfunction (as outlined below), it is 
plausible that an acceleration of intrinsic ageing might therefore occur in anti-retroviral 
treated HIV-infected patients through a mitochondrial mechanism. 
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1.2 Mitochondrial DNA replication and maintenance 
Human mtDNA is a compact circular genome of 16.5kb, encoding 13 essential 
polyproteins of the respiratory chain, the principle intracellular source of energy (ATP) 
production (DiMauro and Schon, 2003). Unlike the nuclear genome which replicates 
only at cell division, mtDNA is continuously turned over throughout life, with a half-
life estimated to be 1-10 days in vivo (Gross et al., 1969). There is a sole mtDNA 
polymerase, pol γ, encoded by the nuclear gene, POLG (Kaguni, 2004; Hudson and 
Chinnery, 2006). Multiple additional nuclear genes encoding proteins with direct or 
indirect involvement in mtDNA replication and maintenance have recently been 
described (Copeland, 2008).  
 
1.2.1 Somatic mtDNA mutations, their character and formation 
It has been widely assumed that somatic mtDNA mutations arise largely as a 
consequence of oxidative damage to mtDNA. This notion arises from the fact that 
mitochondria are the principle source of intra-cellular energy production, and as such 
are also the principle source of ROS (reactive oxygen species), a natural by-product of 
oxphos (oxidative phosphorylation) reactions. Furthermore mtDNA is vulnerable to 
oxidative damage due to: its proximity to the inner mitochondrial membrane (the site of 
oxphos); a lack of protective histones; and more limited DNA repair mechanisms 
compared with nuclear DNA (nDNA). This has lead to the ‘vicious cycle hypothesis’ 
whereby mtDNA mutation causes a functional change in a respiratory chain subunit, 
leading to partial uncoupling of the respiratory chain, the result of which is increased 
ROS production, and further mtDNA mutation (Harman, 1956; Linnane et al., 1989; 
Richter, 1995; Mecocci et al., 1999).  
 
However, much recent work has focussed on the role of mtDNA replication error in the 
generation of somatic mtDNA mutations. Replication error is of course an obvious 
candidate mechanism of mtDNA mutation formation in many of the inherited disorders 
of mtDNA maintenance (such as POLG defects) where secondary mtDNA defects 
(somatic mutations) are the molecular hallmark. In contrast, oxidative damage has been 
assumed to be the key player in driving the mtDNA damage associated with ageing and 
neurodegeneration. It is however equally plausible that natural mtDNA replication error 
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occurs even in the absence of a defective polymerase or other abnormal regulatory 
protein, and this process may also contribute to age-associated mtDNA mutation 
formation (Krishnan et al., 2008). 
 
There are two main types of mtDNA mutations: large-scale deletion mutations and 
point mutations. Large-scale deletion mutations are the predominant mutation type 
leading to cellular defects of mitochondrial function within post-mitotic (non-dividing) 
tissues, such as muscle and neurons (Corral-Debrinski et al., 1992a; Bua et al., 2006). 
As the mitochondrial genome is comprised almost entirely of coding sequence, large-
scale deletion mutations typically delete several mitochondrial genes and thus have a 
high likelihood of a functional consequence within the cell. In contrast, large-scale 
deletion mutations are not readily observed in replicative tissues, a phenomenon which 
is assumed to arise because the resultant cellular oxphos defect would lead to a 
replicative disadvantage for the cell, and thus cells with such mutations would quickly 
be lost. This effect can be observed in primary cell culture, where myoblasts are derived 
from a muscle sample of a patient with an inherited single mtDNA deletion disorder. 
The deletion is detectable at significant levels in DNA extract from the biopsy itself, but 
disappears after only a few passages in vitro. In contrast in post-mitotic tissues, the non-
dividing cells cannot, by definition, be subject to a replicative disadvantage, and the 
mutations can therefore persist within cells, despite their functional consequences. The 
means by which deletion mutations appear in the first place remains to be fully 
explained (Krishnan et al., 2008). It is however increasingly clear that short 
homologous sequences within separate parts of the mitochondrial genome are almost 
certainly of key importance (Samuels et al., 2004). Virtually all deletion mutations are 
located within the ‘major arc’ of the mitochondrial genome, between the origins of 
replication (Bua et al., 2006). The prototype example of this is the 13bp repeat sequence 
found at each end of the 4977bp mtDNA ‘common deletion’ mutation (δmt.8483-
13446). The ‘common deletion’ is so-called because it is the single most commonly 
observed large-scale deletion mutation. However, in absolute terms it is not in fact very 
common, comprising perhaps no more than 5-10% of all deletion mutations detected in 
patient samples. It furthermore appears that the vast majority of deletions have 5’ and 3’ 
ends which fall within hot-spots near to the common deletion loci (Samuels et al., 
2004). Elegant chemical modelling has shown that molecules arising from deletion 
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origins in these regions have inherent stability, which may facilitate their formation 
(Guo et al., 2010).  
 
With respect to the initial event in deletion formation, the prevailing theory has been 
that the primary problem arises from the ‘strand asynchronous’ method of mtDNA 
replication, which inherently temporarily creates portions of single-stranded DNA 
(ssDNA). This view has recently been challenged by a new theory which proposed that 
a double-strand break (DSB) in the mtDNA is the initiating event (Krishnan et al., 
2008). The response to a DSB will be 3’ to 5’ exonuclease activity. This will 
temporarily create ssDNA, which may well contain repeats which are able to undergo 
homologous annealing, leading to a deleted molecule. The advantage of this theory is 
that it relies on a process (DSB) that is already known to occur, both in health and 
disease. It implies a role for replication stalling, but also accommodates ROS or 
irradiation damage as a direct cause of DSBs.   
 
1.2.2 MtDNA mutations, heteroplasmy and clonal expansion 
Cells contain hundreds to tens of thousands of copies of the mitochondrial genome. 
Therefore if a somatic mtDNA mutation arises de novo within a cell it will initially be 
far outnumbered by wild-type mtDNA. The proportion of mutant mtDNA within a cell 
or tissue is termed the heteroplasmy level. Typically mutant mtDNA has to exceed a 
heteroplasmy level of ~65% to cause a functional defect within a cell (Durham et al., 
2005). Furthermore a cell will typically attempt to compensate for the presence of high 
proportional levels of mutant mtDNA by increasing the total cellular mtDNA content, a 
process known as mtDNA proliferation (Durham et al., 2007). It is assumed that this 
process occurs as it is advantageous to increase the amount of wild-type mtDNA within 
the cell to try and restore normal oxphos function, but the cell is unable to discriminate 
between wild-type and mutant mtDNA and thus the only option is to proliferate total 
cellular mtDNA content. There is therefore some debate as to whether it is the 
percentage level of mutant mtDNA or the residual level of wild-type mtDNA within a 
cell that is important in determining whether there is a functional defect within that cell. 
Furthermore, the way in which cellular mtDNA copy number is regulated largely 
remains to be determined. 
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How do somatic mtDNA mutations therefore reach high levels within cells? Broadly 
there are two competing theories. Firstly, that mutant mtDNA has a competitive 
advantage over wild-type mtDNA and therefore preferentially expands within a cell. Or 
secondly, that there is no selective advantage to mutant mtDNA, but it can expand 
simply through the continued turnover of mtDNA throughout the human lifespan. The 
latter process arises from the consideration that mtDNA is constantly turned over, even 
in non-dividing cells, and has been termed ‘relaxed replication’. The process has been 
modelled in silico based on empirically derived parameters, such as the in vivo half-life 
of mtDNA (Chinnery and Samuels, 1999; Elson et al., 2001). Essentially the process 
leading to expansions of mutations within some cells is the chance play of random drift. 
Under this model, there are of course predicted to be far more cells where a mutation 
arises at a very low level and is rapidly lost. The additional factor acting within cells 
that do contain mutations is that of mtDNA proliferation as mentioned above, a process 
for which there is extensive empiric evidence. The net result of this compensatory 
response is that once a mutation reaches a high enough intracellular level to induce a 
proliferation response, the effect of this will be to also increase the copy number of 
mutant mtDNA within that cell, ultimately making it very difficult for the mutant 
mtDNA to ever then be lost from that cell by further natural drift. The relaxed 
replication model is attractive in that it relies only on parameters for which empirical 
evidence exists, and it can equally well explain the behaviour of all types of mtDNA 
mutations within cells: large-scale deletions, pathogenic point mutations, non-
pathogenic point mutations. Conversely, a model based on a selective replicative 
advantage of mutant mtDNA would require empiric evidence for that phenomenon. 
Such a process is easiest to envisage for large-scale deletion mutations, where the 
smaller mutant molecule may be able to replicate more quickly (or have a higher 
probability of successfully completing replication) than the larger wild-type molecule. 
There is now a small amount of in vitro evidence for this process from trans-
mitochondrial cybrid cell lines containing a heteroplasmic mix of wild-type mtDNA 
with a single large-scale deletion mutation (Moraes et al., 2001). When such cells lines 
are subjected to a profound but transient depletion in mtDNA content (by ethidium 
bromide treatment), the repopulation of the smaller mutant mtDNA is significantly 
faster than that of the wild-type mtDNA (Diaz et al., 2002). However, given time the 
repopulation of wild-type mtDNA does ‘catch up’ and the balance of wild-type to 
mutant mtDNA is then restored. Therefore the percentage heteroplasmy level eventually 
returns to baseline. Furthermore, upper estimates of the in vivo half-life of mtDNA are 
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in the range of 8-16 days, whereas the time taken to complete a single cycle of mtDNA 
replication is measured in tens of minutes. Thus it seems improbable that any slight 
differential in speed of replication of deleted vs. wild-type mtDNA during a single cycle 
of replication, would translate into a shift in the balance of heteroplasmy. Finally it is 
hard to envisage how a point mutation would have any replicative advantage. 
 
These contrasting models have potential implications for the relative timing of mutation 
formation with respect to the functional cellular defect that ultimately results, with 
consequence differences in inference of the speed of the clonal expansion process in 
between (Khrapko, 2011). This concept is discussed further below. 
 
1.2.3 The challenges of measuring mtDNA mutation 
In various studies of acquired mtDNA mutation, including ageing and 
neurodegeneration, a variety of measures of mtDNA mutation have been employed, 
some qualitative (for example ‘clamped’ PCR to detect the presence or absence of a 
specific mtDNA somatic point mutation of interest), and some quantitative. There is no 
accepted ‘gold standard’: all current methods have technical challenges and the 
approach depends in part on the tissue under study (Table 1).  
 
In post-mitotic tissue (such as muscle), as mutations will be physically constrained by 
lack of cell division, it is common to initially look for cells that are deficient in 
mitochondrial function, as such cells are likely to contain clonally expanded somatic 
mtDNA mutations. This is achieved through sequential COX/SDH (cytochrome c 
oxidase / succinate dehydrogenase) histochemistry (Muller-Hocker, 1989). The 
principle of this assay is that COX contains respiratory chain subunits which are 
encoded by mtDNA. Therefore mtDNA mutations (especially large-scale deletions) will 
usually cause loss of COX activity (loss of brown stain). In contrast, SDH is entirely 
encoded by nDNA, and therefore activity will be maintained in the face of an mtDNA 
defect, and the cell will counterstain blue. The specific mutation may then be identified 
by single cell laser micro-dissection of the COX-deficient cell, followed by single cell 
molecular analyses (Brierley et al., 1998; Taylor et al., 2001; He et al., 2002; Taylor et 
al., 2003; Bender et al., 2006). This method therefore has the advantage of helping to 
find the ‘needle in the haystack’, as somatic mtDNA mutations will vary from cell-to-
7 
 
cell, and thus will be individually rare in the tissue as a whole. Furthermore, although 
this method does not directly quantify the mutations themselves within the tissue, given 
that COX-deficient cells will contain clonally-expanded somatic mtDNA mutations, the 
percentage of cells showing a COX defect can be easily determined from examination 
of the histological images, and this count will give a surrogate for the ‘functionally 
relevant’ mutation burden.  
 
In replicative tissues (such as peripheral blood mononuclear cells, PBMCs) or 
homogenised tissues, alternative approaches must be employed. For example, in the 
first paper to consider somatic mtDNA mutations in the context of HIV, Mallal and 
colleagues used SSCP (single strand conformational polymorphism) analysis to screen 
for differences in DNA sequence between pairs of samples (pre-treatment / on treatment 
in this case) (Martin et al., 2003). Again this method helps to select for changes, but is 
not quantitative.  
 
Deletion mutation load may be relatively easily quantified by real-time PCR (He et al., 
2002). If mtDNA point mutational burden (sometimes, less accurately, referred to as 
‘mutation rate’) is to be formally quantified, three main methods have been compared: 
post-PCR cloning, single molecule PCR (smPCR) and random mutation capture (RMC) 
(Trifunovic et al., 2004; Kraytsberg et al., 2009). Their comparison has recently been 
evaluated by Greaves and colleagues (Greaves et al., 2009). All are technically 
challenging and give conflicting absolute measures of mtDNA mutation burden; 
however all have proven useful in the comparative analysis of patient / experimental 
groups.  
 
1.2.4 ‘Next-generation’ re-sequencing for mtDNA 
Most recently there has been great interest in the application of massively parallel (‘next 
generation’) re-sequencing (NGS) to the question of mtDNA mutations. Three main 
NGS platforms have been used to date: Illumina (previously Solexa) GA, Applied 
Biosystems SOLiD, and Roche 454 FLX GS. A small handful of studies (including two 
of my studies, presented herein) have now looked at the use of NGS to deep sequence 
mtDNA in search of low-frequency heteroplasmic variants (He et al., 2010; Payne et 
al., 2011; Payne et al., 2013b). A larger number of studies have used NGS technology 
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to simply obtain a consensus mtDNA sequence (Hudson et al., 2012). Although the 
practical approach is essentially the same in these two scenarios, the questions being 
asked are different, and the challenges, particularly in analysis, are far more substantial 
in the case of deep sequencing. Firstly the question is one of coverage per base position. 
In order to obtain a good consensus sequence, coverage of at least ~30-fold per base 
position is typically planned in the experimental design. Inevitably, with all NGS 
platforms, there may be considerable variation in coverage between base positions. The 
reasons for this are not fully defined, but are likely to relate, at least in part, to local 
sequence context (for example G-C content). Thus by extension, if one wishes to deep 
sequence then this degree of over-coverage ideally needs to be built in to the 
experimental design with respect to the ‘minor allele frequency’ of interest. For 
example, if one is interested in examining heteroplasmic variants at the 1% level, then 
30-50 fold coverage would ideally be designed for that variant, therefore a total of 
3000-5000 fold over-coverage per base position. The standard NGS approach for large 
genomes is fragment sequencing. Thus total DNA extract (for example from human 
blood, or from a bacterial culture), is fragmented (ultrasonically or enzymatically) into 
small fragments (typically ~200bp) to which ‘adapter’ DNA oligomers are then ligated. 
These fragments are typically then PCR enriched before sequencing. The issue of 
variable coverage presumably reflects the fact that fragments from some parts of a 
genome participate in these reactions less efficiently than others. NGS of mtDNA 
creates the additional challenge of isolating the mtDNA from nDNA. Although mtDNA 
is present at hundreds to tens of thousands of copies per cell, owing to the small size of 
the mitochondrial genome, mtDNA amounts to only 1-2% of the total DNA content 
(mass) within a cell. Thus if total cellular DNA extract is subjected to fragment NGS, 
the signal from mtDNA will be negligible. Furthermore, in this scenario there is a 
substantial potential for confounding by nuclear mitochondrial sequences (NumtS, or 
pseudogenes) (Simone et al., 2011). Currently, three potential solutions exist. All were 
compared in the original mtDNA deep sequencing by NGS paper (He et al., 2010). 
Firstly there is physical enrichment of mtDNA by methods based on ultracentrifugation, 
sometimes termed a ‘mito-prep’. Technically such methods are considered easiest to 
perform on cultured cells; however methods do exist for fresh muscle biopsy samples, 
and in diagnostic practice may be used to obtain mitochondrial fractions for biochemical 
analysis. Evidence suggests that these methods are very variable in the extent to which 
they enrich the mtDNA fraction. An optimal result of enrichment might be considered a 
DNA extract that comprises 75% mtDNA. This represents a ~40-fold enrichment. In 
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contrast however, a 10-fold enrichment, which might be considered adequate for other 
applications, would preclude the reliable deep-sequencing of mtDNA (as it achieves an 
mtDNA content of only ~10-20%). Furthermore, if there is any nDNA carry-over 
(which is essentially inevitable), then the issue of NumtS remains. However, the key 
theoretical advantage of a ‘mito-prep’ is that it is not PCR-dependent, which potentially 
reduces PCR error, and thus noise, as will be discussed further below. The second 
method of mtDNA enrichment is long-range PCR. Typically the mitochondrial genome 
is first PCR amplified by a small number of over-lapping long-range PCR amplicons. 
This is currently probably the preferred approach, as it is relatively quick to perform, 
and it may be possible to avoid NumtS, by designing long-PCR primer pairs to avoid 
their amplification. It will generally be easier to avoid amplification of NumtS with long 
rather than short amplicons. The long-PCR products are then purified, fragmented and 
sequenced in essentially the same way as total DNA. The disadvantage of this approach 
is the additional long-PCR step which has the potential to introduce PCR error. 
Polymerases with high fidelity and 3’-5’ exonuclease activity should be used in an 
attempt to reduce this issue. A harder to define issue is that of amplification bias, that is, 
the potential of some molecules to be preferentially amplified within the PCR reactions. 
Experience suggests that long-PCR may be particularly prone to this phenomenon, with 
the possibility that only a minority of DNA molecules actually participate in the 
amplification reaction. Finally, long-PCR enrichment will not significantly improve the 
issue of variable coverage, as fragmentation is still required. In fact the presence of 
long-PCR amplicon ends, and areas of overlap, may actually compound this issue. We 
have used long-PCR enrichment to perform NGS (using the Roche 454 FLX GS 
platform) of mtDNA where the aim was a consensus read (Hudson et al., 2012). I have 
also used this approach for the deep sequencing of mtDNA using the Applied 
Biosystems SOLiD platform (unpublished observations). The third approach to mtDNA 
enrichment is by making short PCR amplicons. The advantage of this approach is that it 
negates the need for fragmentation, as amplicons can be designed that are already of 
suitable size for sequencing (with the relevant adapter sequences incorporated into the 
amplicon generation primers). This approach is best suited to the 454 FLX platform, as 
this allows relatively long amplicons (typically 250-400bp, although even longer 
amplicon protocols are now available). This technique has been the method of choice 
for deep sequencing small genomes, such as regions of viral genomes. Over-coverage 
can be very accurately planned as variable coverage will not be an issue. Furthermore, 
bioinformatic alignment is usually technically easier as the locus of each amplicon is 
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pre-defined. Conversely, the disadvantage of short amplicon re-sequencing for mtDNA 
is that a large number of amplicons would need to be generated to cover the entire 
mtDNA genome, therefore the preparation would be time-consuming. Furthermore it 
will be impossible to avoid NumtS in many parts of the mitochondrial genome with 
short amplicons. I have extensively explored the use of short amplicon deep sequencing 
of mtDNA using the 454 FLX platform, as described in the work presented herein 
(Payne et al., 2011; Payne et al., 2013b). I elected to use two amplicons in areas of the 
mitochondrial genome predicted to have contrasting rates of base substitutions (based 
on population polymorphism data) (Pereira et al., 2009). Both these amplicons were 
specifically designed to avoid NumtS, and this was confirmed empirically by 
demonstrating failure to amplify a product from rho0 DNA (DNA that has been entirely 
depleted of mtDNA, as detailed in my papers).  
 
As discussed above, in order to use NGS for deep sequencing, a high degree of over-
coverage must be used to ensure adequate coverage of low level heteroplasmic variants. 
In general, sufficient coverage can be relatively easily achieved, in particular with 
Illumina GA where coverage of mtDNA typically attains tens or hundreds of thousands 
of fold. Thus the depth to which low level heteroplasmic variants can be resolved is not 
often limited in practical terms by coverage. However, coverage is not the only 
determinant of resolution. For example, 500,000-fold coverage could be achieved on the 
Illumina GA, thus theoretically giving 50-fold over-coverage of a heteroplasmy present 
at 0.01%. However, pragmatically such a variant could not be resolved owing to noise 
limiting the sensitivity of the assay. Noise is likely to be multi-factorial owing to the 
multi-step nature of the assay: primary PCR error (short amplicon or long-PCR), 
enrichment PCR (in the case of fragment sequencing), sequencing reaction PCR (e.g. 
cluster generation for Illumina GA, or emulsion PCR (emPCR) for 454), and base-
calling. Technically therefore, in comparison with other methods of mtDNA mutation 
detection, NGS is most akin to post-PCR cloning (as it involves a primary PCR step). 
However, it has the significant advantage of vastly higher throughput.  
 
The exact error rate of NGS for mtDNA, and thus the achievable lower limit of 
resolution is a subject of on-going debate. It seems likely that the reading of the 
sequence (base-calling) is the step (of the several outlined above) that contributes the 
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vast majority of error. In the case of the PCR-dependent steps, if suitably high fidelity 
polymerases with proof-reading activity are used (such as pfu or KOD), error rates as 
low as 10
-6
 per bp should be achievable for the PCR steps. In contrast the base-calling 
error rate has been estimated to lie in the range of ~0.1-2%. Unfortunately there have 
been no direct head-to-head studies between platforms, which would be a very welcome 
addition to the field. With the kind of base-calling error rates suggested above, 
combined with adequate coverage, a lower limit of heteroplasmy resolution of ~2% has 
been suggested from theoretical modelling (Li and Stoneking, 2012). Previous studies 
have generally chosen to adopt a heteroplasmy threshold above which variants are 
considered to be ‘real’. Thus the prototype study adopted a threshold of 1.5%, whereas 
the threshold in some subsequent studies has been as high as 10% (although coverage 
was rather inadequate in that paper) (He et al., 2010; Li et al., 2010).   
 
Although heteroplasmy resolution of ~2% represents a significant advance on Sanger 
sequencing (limit of heteroplasmy detection ~20%), from first principles we may expect 
that de novo mtDNA mutations will initially be present at extremely low levels, and 
thus would be below the limit of detection of such an NGS assay. Thus the assay is 
geared only to detect higher level heteroplasmic variants, which are expected to have 
either been transmitted (maternally inherited) at low levels, or represent hot-spots for 
recurrent mutations (for example some mtDNA non-coding control region loci). Ideally 
however we would like to develop ways to go below this relatively modest threshold in 
the hope of examining rarer variants, which are more likely to truly represent new 
somatic mutations. The solutions to this potentially lie in a combination of technical and 
bioinformatic advances. Firstly there are simple bioinformatics tools that can be used to 
remove substantial amounts of noise, for example by the use of bidirectional read data. 
Thus only a variant that is present in both read directions is accepted. I have used this 
method in one publication herein (Payne et al., 2013b) as well as in the analysis of 
SOLiD data (unpublished). The justification is that base-calling errors are likely to be 
unidirectional (or at last markedly asymmetric) as they will be sequence context 
specific. This argument probably applies most strongly to the 454 FLX platform, where 
pyro-sequencing error is well known to be very largely dependent on long 
homopolymeric tracts. We thus also arrive at the consideration that the base-calling 
error rate of a platform may in some cases (notably 454 FLX pyro-sequencing) be rather 
non-random, whereas in others (Illumina GA) it may be more truly random. 
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Paradoxically therefore, non-random error may actually be advantageous in attempting 
to improve depth of resolution as analytical approaches can be used which simply filter 
out positions known to be noisy, as I have demonstrated in the work presented herein. 
The disadvantage of this approach is that true variants within these positions will also 
not be called, and thus a complete sequence (including heteroplasmies) for the entire 
amplicon cannot be achieved. However, in my work I have favoured optimising 
specificity at the expense of sensitivity, especially when my concern was to determine 
whether such low level heteroplasmic variants were ‘universal’ (i.e. present in all 
individuals). Finally one can run suitable technical negative controls to empirically 
determine the validity of the bioinformatic approach and the putative lower limit of 
resolution. Usually this will involve running a cloned DNA sample, where it is assumed 
that all detected variants represent noise. (In fact, this will not be quite true as even the 
biological polymerase of the cloning vector will have a small error rate.) Not all studies 
have included such a control, and some have used the commercially available controls 
such as a DNA phage (Li et al., 2010). The disadvantage of this approach is that it is not 
sensitive to any context specific error rate changes, and I have thus used clones of the 
actual mtDNA amplicons. In this way I have shown that my approach has a lower limit 
of resolution of ~0.2%, a significant improvement on prior work. 
 
Finally, since my work, further technical advances have been published, based on the 
principle of unique molecular tagging. This was first applied with NGS (454 FLX) for 
HIV RNA deep resequencing, but related methods have now been published for 
mtDNA (Jabara et al., 2011). The essence of the method is that, at an additional initial 
step, individual molecules of nucleic acid are given unique molecular tags (through the 
use of oligomers with multiple degenerate base positions). Thus all duplicate molecular 
tags are excluded in the analysis (they are assumed to be PCR duplicates), and if 
multiple reads with the same molecular tag show different variants, then only the 
consensus of those reads is taken, on the assumption that the less frequent variants are 
PCR errors. In order to calculate the variant frequency, one adds up the number of 
unique molecular tags that carry the same variant.  
 
In conclusion, although deep sequencing of mtDNA by NGS does not offer the 
extremely high depths of resolution cited for smPCR or RMC, it has the great 
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advantages of massively higher throughput, and very broad coverage. The recent 
methodological advances should allow NGS to address some of the fundamental 
questions in mtDNA biology, for example to what extent low level variants are 
transmitted, and how variants accumulate with age. These questions have fundamental 
implications for our understanding of inheritance, population evolution, and ageing.   
 
1.3 Inherited disorders of mtDNA maintenance 
Primary mtDNA disorders arise due to primary mutations with the mitochondrial 
genome, as single base substitution mutations (for example MELAS, m.3243A>G) or 
single large-scale deletion mutations. In contrast, the disorders of mtDNA maintenance 
comprise mutations of nuclear genes which directly or indirectly affect mtDNA 
replication and maintenance. The prototype example is defects in POLG, encoding the 
mtDNA pol γ, and dozens of mutations have now been described within this gene 
(Hudson and Chinnery, 2006). More recently pathogenic mutations have been reported 
in other nuclear genes such as TWINKLE and ANT1 (Copeland, 2008). These disorders 
are both genotypically and phenotypically diverse, but in all cases the disease is felt to 
be caused by the secondary effects on mtDNA and consequent disruption of cellular 
oxphos function. In some cases they cause severe infantile onset disease. In these cases 
the principle secondary mtDNA defect is profound depletion of mtDNA (reduction of 
cellular mtDNA content), presumably due to profound difficulty in adequately 
synthesising mtDNA. However, in many cases, disease is typically late onset (in middle 
age). In these cases the secondary mtDNA defect takes the form of somatic (acquired) 
mutations in mtDNA. These disorders predominantly affect neuromuscular tissues, 
which have a high energy (ATP) requirement, and are comprised of post-mitotic (non-
dividing) cells. In these tissues the predominant mtDNA mutations are large-scale 
deletions, and in diagnostic practice, such disorders are often screened for by detecting 
the presence of multiple large-scale deletion mutations within DNA extracted from 
skeletal muscle biopsy.  
 
1.4 Acquired mtDNA mutations, neurodegeneration and ageing 
MtDNA has a mutation rate estimated to be ~5-15 times that of the nuclear genome, and 
somatic mtDNA mutations are well described in normal human ageing (Linnane et al., 
1989; Corral-Debrinski et al., 1992a; Richter, 1995; Michikawa et al., 1999; Fayet et 
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al., 2002; Taylor and Turnbull, 2005; Bua et al., 2006). Ageing individuals have been 
shown to have gradual accumulation of COX-deficient cells in multiple tissues 
(including skeletal muscle, cardiac muscle, neurons, and colonic crypts) (Muller-Hocker 
et al., 1992; Brierley et al., 1996; Brierley et al., 1998; Taylor et al., 2003; Bender et 
al., 2006). Such cells contain high proportional levels of somatic mtDNA mutations 
which are unique within each cell. The degree to which such mtDNA damage is causal 
in the ageing process remains a subject of much research, however recent supporting 
evidence has come from elegant mouse models, where a proof-reading deficient pol γ 
leads to accelerated accumulation of mtDNA mutations and a prematurely aged 
phenotype (Trifunovic et al., 2004; Kujoth et al., 2005). Finally somatic mtDNA 
mutations have been linked with a range of common neurodegenerative diseases of 
ageing. For example brain tissue shows accumulation of somatic mtDNA mutations 
with normal ageing, but these are further increased in Alzheimer Disease (Corral-
Debrinski et al., 1994; de la Monte et al., 2000; Lin et al., 2002; Coskun et al., 2004; 
Wang et al., 2005).  
 
1.4.1 The early mutation hypothesis and ageing 
Critical to our understanding of the role of somatic mtDNA mutations in ageing and in 
disease states is a consideration of the role of heteroplasmy. As described above, a 
pathogenic mtDNA mutation arising within a cell can only cause a functional defect 
within that cell if it manages to exceed a critical threshold. Given that such a mutation 
will arise as a single event among potentially thousands of wild-type mtDNA 
molecules, how does this occur? The ‘relaxed replication’ hypothesis of clonal 
expansion, as outlined above, predicts that although mtDNA mutation events may occur 
throughout life, the mutation events that ultimately lead to cellular COX defects 
probably need to occur very early in life (perhaps during childhood or adolescence). 
Modelling experiments suggest that, based on a non-selective process of clonal 
expansion, continuous mtDNA replication over a period of decades is required for some 
mutant mtDNA species by chance to achieve the required levels within cells to cause a 
functional (COX) defect (Elson et al., 2001). Thus a fundamental implication of this 
‘relaxed replication’ model is that it requires a great deal of time for these seeding 
mutations to clonally expand, and has thus been termed the ‘early mutation’ hypothesis 
(Khrapko, 2011). Support for this model comes from recent observations, including 
some I present herein, that although the proportion of COX deficient cells (which 
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contain these clonally amplified somatic mtDNA mutations) progressively increases 
throughout older age, the overall number of mutations (‘mutation burden’) in the tissue 
homogenate, does not significantly increase (Greaves et al., 2009; Payne et al., 2013b). 
This recent observation would be consistent with a notion that mutations are present 
from early in life and only a tiny proportion ever become clonally expanded.  
 
Finally, the ‘earliest point’ in childhood for a ‘somatic’ mtDNA mutation to appear, 
would be if it were in fact inherited. Very low level inherited variants could be present 
at birth, below the limit of detection, but over time these variants could occasionally 
clonally expand within cells. They would thus appear as ostensibly somatic mutations. 
If this were true, this would tend to give further weight to the ‘early mutation’ 
hypothesis, and would also suggest that strategies to target mitochondrial ageing may be 
better targeted at clonal expansion, rather than mutagenesis. I explore this very 
fundamental issue in mtDNA biology in a paper presented herein (Payne et al., 2013b).  
 
1.5 HIV infection and anti-retroviral therapy 
In many ways anti-retroviral therapy is one of the great success stories of modern 
medicine. Since 1996, the standard of care has been combination anti-retroviral therapy 
(cART, often also referred to as highly-active anti-retroviral therapy, HAART) (Collier 
et al., 1996). This therapy uses at least 3 drugs from at least two classes, and leads to 
durable suppression of viraemia without the emergence of viral resistance in most cases. 
This in turn allows the restoration of immune function, and prevents opportunistic 
infections.  
 
The earliest anti-retroviral drug class were the nucleoside analogue reverse transcriptase 
inhibitors (NRTIs). The first of these, zidovudine (AZT) has been used since 1987 
(Fischl et al., 1987). The clinical action of the drug arises as it lacks a 3’ hydroxyl group 
compared with the natural nucleoside (thymidine). It therefore causes chain termination 
if incorporated into an elongating HIV cDNA molecule. There are now more than 
twenty licenced anti-retroviral drugs spread across multiple classes. Most target viral 
enzymes: reverse transcriptase inhibitors, protease inhibitors (PIs), integrase inhibitors, 
and fusion inhibitors. One drug, maraviroc, an entry inhibitor, binds to a human target, 
the CCR5 co-receptor, which most HIV strains use. However, NRTIs still remain the 
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mainstay of HAART, and the vast majority of regimens comprise two NRTIs, combined 
with a third agent (usually a non-nucleoside reverse transcriptase inhibitor (NNRTI), or 
a PI). The initial NRTIs to be developed following AZT were didanosine (ddI), 
zalcitabine (ddC), stavudine (d4T), and lamivudine (3TC). More recently abacavir 
(ABC), tenofovir (TDF, a nucleotide RTI) and emtricitabine (FTC) have been licenced. 
Of these various options, in industrialised countries combinations of TDF/FTC, and 
ABC/3TC are overwhelmingly used. These choices are principally due to favourable 
toxicity profiles compared with older NRTIs. In contrast in the developing world, d4T 
and AZT remain in common use. ddC is no longer licenced. However, in industrialised 
country cohorts there are significant numbers of patients who have extensive prior 
exposure to the older NRTIs (AZT, ddI, ddC, d4T). The significance of this lifetime 
burden of NRTI exposure is central to the arguments outlined in my publications herein. 
 
1.6 Anti-retroviral therapy and the polymerase γ hypothesis 
Early in the anti-retroviral era it was recognised that a significant minority of patients 
experienced serious acute or sub-acute treatment toxicity such as symptomatic lactic 
acidosis and hepatic steatosis, which resembled severe inherited mitochondrial disease 
(Bissuel et al., 1994). Such acute effects were generally reversible with cessation of the 
causative drug (Helbert et al., 1988). Later it was proposed that more common and 
insidious treatment complications such as peripheral neuropathy and lipodystrophy may 
also be mitochondrially-mediated (Carr et al., 2000; Dalakas et al., 2001). 
Mechanistically, it became apparent from in vitro data that many of the older NRTIs 
cause inhibition of pol γ, and thus inhibition of mtDNA replication, manifesting in vitro 
and in vivo as a reduction in cellular mtDNA content (depletion) (Arnaudo et al., 1991; 
Casademont et al., 1996; Dalakas et al., 2001; Lewis et al., 2001; Lim and Copeland, 
2001; Cherry et al., 2002; Cote et al., 2002; Miro et al., 2003; Nolan et al., 2003; 
Walker et al., 2004; Buffet et al., 2005; Haugaard et al., 2005; Cherry et al., 2006). This 
biochemical effect arises in the same manner as the therapeutic effect of NRTIs on HIV 
reverse transcriptase (HIV-RT), namely chain termination during DNA synthesis. The 
affinity of NRTIs for mtDNA pol γ has been estimated to be ~500 fold less than that for 
HIV-RT; however this varies between specific drugs. The hierarchy of pol γ in vitro 
inhibition is described as: ddC>ddI>d4T>AZT=3TC>ABC, a notion which fits 
reasonably well with in vivo data on observed severity of mtDNA depletion, and with 
the frequency of observed treatment complications (Lim and Copeland, 2001). Of the 
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N(t)RTIs in current common clinical usage, both ABC and TDF are reported to have 
minimal effect on mtDNA replication (Johnson et al., 2001; Birkus et al., 2002; 
McComsey et al., 2005b; Venhoff et al., 2007).  
 
1.6.1 Mitochondrial DNA mutations and anti-retroviral therapy 
It follows from the polymerase γ hypothesis that if the causative NRTI is removed, then 
mtDNA levels will recover, and indeed there is in vivo data to support this (McComsey 
et al., 2005b). Although most patients in industrialised countries are now treated with 
ABC or TDF based HAART, there are large numbers of patients who have had many 
years of exposure to the pol γ inhibiting NRTIs (ddC, ddI, d4T, AZT) in the past. These 
patients will not be expected to show persistent mtDNA depletion, and indeed I have 
now demonstrated this (Payne et al., 2011). If there is any persistent effect on mtDNA 
in such patients it is therefore likely to be a qualitative defect: somatic mutations. Based 
upon our knowledge of the action of NRTIs, coupled with our understanding of mtDNA 
mutation formation, there are several hypothetical means by which NRTI therapy could 
promote mtDNA mutations (as discussed further below). The first evidence that NRTIs 
may indeed lead to somatic mtDNA mutation came from a longitudinal study of patients 
commencing d4T therapy. Surprisingly, 5 of 16 subjects developed new mtDNA 
mutations in PBMCs (peripheral blood mononuclear cells) after starting therapy (Martin 
et al., 2003). Shortly thereafter, another group described a similar phenomenon, again in 
blood (McComsey et al., 2005a). These observations have been revisited only recently 
when a small series of papers have sought to detect anti-retroviral associated acquired 
mtDNA mutations in a variety of settings (Ortiz et al., 2011; Jitratkosol et al., 2012). In 
my work I demonstrate that patients with a history of exposure to pol γ inhibiting 
NRTIs show an excess of skeletal muscle fibres containing high levels of somatic 
mtDNA mutations (both point mutations and large-scale deletion mutations) (Payne et 
al., 2011). Importantly the relevant drug exposures were often in the remote past, 
suggesting that the mutations are indeed irreversible. Studies examining mtDNA 
mutations in the setting of HIV / anti-retroviral therapy are presented in Table 2. 
 
1.6.2 What is driving NRTI induced mtDNA mutation? 
The intuitive deduction when considering mechanisms whereby anti-retroviral therapy 
may increase somatic mtDNA mutations is accelerated de novo mutagenesis. This is 
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essentially the correlate of an inherited POLG defect, whereby there will be continuous 
production of higher levels of mtDNA mutations throughout a treatment period. There 
are plausible biological mechanisms whereby this might occur, for example impairment 
of the limited exonuclease function of pol γ by NRTIs would lead to poor proof-reading. 
This biochemical effect has been reported at least for AZT (Lim and Copeland, 2001). 
Furthermore it is suggested that, in addition to any effects on pol γ, AZT may inhibit 
TK2 (mitochondrial thymidine kinase) plausibly leading to purine / pyrimidine 
imbalance and thus mtDNA mutations (Rylova et al., 2005; Akman et al., 2008). The 
difficulty with this de novo mutagenesis hypothesis however, is that such mutations will 
need to undergo clonal expansion before they achieve high enough levels within cells to 
cause a functional (COX) defect. Under a simple ‘relaxed replication’ model (as 
described above), these mutations will be predicted to take many years or decades to 
reach high levels within cells. It would therefore be predicted that a typical period of 
NRTI exposure during early adult life would lead to a COX defect only in late middle 
age, if ever (Figure 1). Furthermore modelling data suggests that the relative increase in 
mutation rate would need to be very substantial indeed to cause a significant increase in 
COX defects (Elson et al., 2001).  
 
Therefore, I have proposed an alternative hypothesis of accelerated clonal expansion 
(Payne et al., 2011). This hypothesis requires no additional de novo mutagenesis, as 
clonal expansion can act on the pre-existing somatic mtDNA mutations which arose 
early in life, as described previously. Modelling this scenario suggests that a finite 
period of mtDNA depletion associated with NRTI therapy, creates an intracellular 
‘bottle-neck’, leading to accelerated molecular segregation and thus accelerated clonal 
expansion of pre-existing (age-associated) mtDNA mutations. The severity of mtDNA 
depletion will predict the rapidity of clonal expansion, and this is in keeping with my 
empirical data whereby potent pol γ inhibitors (ddC, ddI) which cause profound mtDNA 
depletion, caused a much higher number of COX deficient fibres (i.e. more rapid clonal 
expansion) than weaker inhibitors (d4T, AZT). Importantly this model acts rapidly 
during a period of NRTI treatment (as the ‘seeding’ mutations are already present), and 
furthermore the mutations are ‘locked in’ at the end of the period of NRTI exposure as 
they have already reached high levels in some cells, a ‘point of no return’. In 
conclusion, the resultant COX defect is predicted to appear rapidly during the causative 
NRTI therapy, and be persistent thereafter.  
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Finally, a variation on a non-selective clonal expansion model is the idea that NRTI 
therapy may select for mutant mtDNA. This is certainly plausible in the case of large-
scale deletion mutations, where we may suggest that deleted (smaller) mtDNA 
molecules would replicate more readily in the face of NRTI-induced pol γ inhibition 
than full-size molecules. There is analogous data to support this notion from the non-
HIV setting, as previously described but NRTI-specific data is awaited (Diaz et al., 
2002). Such a process would ultimately serve to further accelerate clonal expansion. 
 
1.7 The functional consequences of somatic mtDNA damage 
The evidence that somatic mutation in mtDNA and associated COX defects are 
temporally related to the normal human ageing process is increasingly robust, however 
the key question remains to what extent they are causally related? The POLG ‘mutator’ 
mouse would seem to provide evidence for a causal relationship in that, as far as we 
know, the only difference between this mouse and the wild-type is that it accumulates 
mtDNA mutations at a significantly increased rate, leading to a progeroid phenotype 
(Trifunovic et al., 2004; Kujoth et al., 2005). However, in the case of human POLG 
defects, or other inherited disorders of mtDNA maintenance, there is also more rapid 
accumulation of secondary mtDNA defects, but the phenotype is usually one of late-
onset neurodegenerative disease, but not premature ageing. Clearly therefore, the 
situation is more complex. Khrapko has recently discussed important differences 
between the premature ageing in the POLG mouse and normal human ageing (Khrapko 
and Vijg, 2007). It turns out that levels of mtDNA mutations in the homozygous POLG 
mouse are vastly (several orders of magnitude) increased compared with the wild-type 
mouse, even in the case of a very elderly wild-type animal. Furthermore, the 
heterozygous POLG mouse shows an intermediate level of mtDNA mutation, but an 
apparently normal phenotype. It appears therefore that there must be a very large 
increase in mtDNA mutation rate in the mouse, above a rather high threshold, in order 
to cause a progeroid phenotype. If we then consider the mtDNA mutation rate in an 
elderly human, this appears to be greater than that in an elderly wild-type mouse, but 
less than that in the POLG heterozygous mouse. This observation has led some writers 
to suggest that, because the mtDNA mutation rate in the elderly human clearly falls well 
below the threshold for a functional effect in the mouse, then this implies that mtDNA 
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mutations are not causally related to normal ageing in humans. The flaw in this 
argument is potentially however the very great difference in normal lifespan in humans 
(>80 years) and mice (<3 years). It appears that the rate of mtDNA turnover (mtDNA 
‘half-life’) does not alter significantly between species. Therefore the elderly human has 
experienced far more cycles of mtDNA replication than the mouse. As described earlier, 
mtDNA turnover is thought to be the ‘engine’ driving clonal expansion of mtDNA 
mutations. Thus in a long-lived mammal such as the human, a low mutation rate may 
well still be entirely compatible with a functional role in ageing given the long period of 
time for those mutations to clonally expand within individual cells and lead to defects of 
oxidative function within those cells. 
 
Moving away from animal models, is there evidence that humans with healthy 
mitochondria are less ‘biologically aged’ than humans of equivalent chronological age 
who have greater somatic mitochondrial defects? Early work from Doug Turnbull’s 
group suggested that elderly patients with increased physiological performance (for 
example grip strength); tended to have lower proportional COX defects on lower limb 
skeletal muscle biopsy (Brierley et al., 1996). Of course, this observation could either 
be compatible with the notion that slower accumulation of mtDNA defects results in 
preserved function, or that preserved muscular function (for example through better 
general health, and higher levels of exertion), results in the preservation of 
mitochondrial function. Further longitudinal studies are desperately needed in this area 
to better address such questions. However, such studies are difficult to do owing to the 
vast timescales involved; as described earlier, a COX defect in an individual in their 
seventh decade might have resulted from a new mutation event several decades earlier. 
 
Is there other indirect evidence to support a causal role for mtDNA mutation in ageing? 
If certain mtDNA genotypes were more or less susceptible to somatic mtDNA mutation, 
then we might expect to see differences in the rate of ageing between such populations. 
Work by David Samuels suggests that this notion may hold true when comparing 
animal species. As described earlier, short mtDNA sequence repeats, are strongly 
associated with the formation of large-scale mtDNA deletion mutations. Samuels 
demonstrated that species with lower numbers of such homologous repeats in their 
mtDNA genome show increased longevity (Samuels, 2004). Within the human species, 
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mtDNA is also highly polymorphic, and one mtDNA haplogroup (D4a) contains SNPs 
(single nucleotide polymorphisms) that disrupt that 13bp repeat associated with the 
δ4977bp ‘common deletion’. The D4a haplogroup contains unexpectedly large numbers 
of centenarians (Bilal et al., 2008). Finally another polymorphism in the non-coding 
mtDNA control region, results in a change in the origin of mtDNA replication, with 
predicted consequences for mtDNA turnover. This group also shows increased 
longevity (Zhang et al., 2003).  
 
1.7.1 Clinical implications of mitochondrial ageing in HIV-infected patients 
The increasing evidence for accelerated mtDNA somatic mutation accumulation in the 
setting of certain NRTI therapy may currently be considered principally as ‘accelerated 
intrinsic ageing’. The field of biogerontology, although rapidly evolving, is still in its 
relative infancy, and the downstream effects of intrinsic ageing at the tissue and 
organism level are becoming increasingly well defined. Of particular note are the recent 
links made between mitochondrial and telomere function in ageing, thus bringing 
together two fundamental tenants of biogerontology (Sahin et al., 2011). On this note, it 
is interesting to observe that certain NRTIs (including TDF) are suggested to have some 
affinity for TERT (telomerase reverse transcriptase), suggesting links between anti-
retovirals and telomere biology (Hukezalie et al., 2012). Further research is warranted.  
 
The downstream consequences of mtDNA somatic mutations at the tissue level are 
shown in Figure 2. It seems likely that ‘mitochondrial ageing’ in NRTI-treated HIV-
infected patients might have a role in driving frailty and perhaps sarcopenia in this 
patient group. Both these gerontological markers have been shown to be prevalent in 
HIV-infected patients and in the non-HIV setting are predictive of adverse clinical 
outcomes (Chabi et al., 2008; Waters et al., 2009; Cruz-Jentoft et al., 2010; Erlandson 
et al., 2013). Simple clinical measures of ‘ageing’ are lacking, and extensive long-term 
follow-up may be required to establish a clear causal link between markers of intrinsic 
ageing in HIV and clinical outcomes. These findings are likely to be of most relevance 
to those patients with extensive past exposure to pol γ inhibiting NRTIs who are 
entering older age. This specific subgroup of patients should be considered for 
particular close study within clinical cohorts for evidence of accelerated frailty, and 
appropriate multi-disciplinary measures implemented. Finally, millions of patients in 
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the developing world have been exposed to AZT and d4T in recent years as part of anti-
retroviral roll-out programmes and these data are likely to reinforce the WHO position 
that such patients should be switched to TDF based therapy as soon as is feasible 
(WHO, 2006).  
 
Finally, we may turn the question on its head and ask, ‘what can the NRTI story tell us 
about the role of mtDNA in normal human ageing?’ It has been argued that although 
there are animal models causally linking mtDNA mutations and ageing the association 
in humans is less clear cut (Trifunovic et al., 2004; Kujoth et al., 2005; Trifunovic et 
al., 2005; Khrapko and Vijg, 2007). Progeroid diseases in humans may be considered 
‘extremes’ in which the ageing process is qualitatively as well as quantitatively altered. 
In contrast, in the setting of NRTI exposure, crudely we may have acceleration of one 
aspect of ageing at the molecular level in genetically normal persons, and a patient 
group in whom we have possible clinical evidence of premature ageing. 
 
1.8 The need for biomarkers of mitochondrial dysfunction 
In the study of mitochondrial dysfunction in inherited mitochondrial disorders and in 
normal ageing, skeletal muscle biopsy remains the ‘gold standard’ investigation. This 
arises from the fact that it is a relatively accessible tissue, contains large numbers of 
mitochondria, and the natural history of mtDNA mutations in this tissue is relatively 
well understood. However in studies related to ageing or when a therapeutic 
intervention is planned (which might include an anti-retroviral switch), methods more 
amenable to serial measurement would be required.  
 
A possible candidate as a non-invasive measure is phosphorus magnetic resonance 
spectroscopy (
31
P-MRS) of skeletal muscle. This technique uses MR imaging to obtain 
spectra from ATP metabolites. The subject performs a repeated exercise paradigm in the 
scanner, and metabolites are then tracked during recovery. Of principle interest is the 
rate of re-synthesis of ATP following its depletion during the exercise. Patients with 
mitochondrial dysfunction will be expected to show delayed ATP re-synthesis. In 
contrast a highly trained athlete may show more rapid ATP re-synthesis. Such 
abnormalities have previously been shown in a variety of inherited mitochondrial 
disorders, and the technique has been used in serial monitoring studies (Penn et al., 
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1992; Chinnery et al., 2001). In the context of HIV, a study from early in the epidemic 
used 
31
P-MRS to evaluate patients with myopathy due to high-dose AZT monotherapy, 
but did not show clear differences compared to controls (Miller et al., 1991). More 
recently, d4T has been studied in healthy controls, and acute defects on 
31
P-MRS were 
observed (Fleischman et al., 2007). The relevant question in the modern era though is 
whether patients hypothesised to have mitochondrial damage consequent on prior 
mitochondrially-toxic NRTI therapy, will have persistent defects of oxidative function 
detectable on 
31
P-MRS which we address herein.  
 
At one time measurement of mtDNA depletion in PBMCs (peripheral blood 
mononuclear cells) was proposed as a biomarker of clinical NRTI-induced 
mitochondrial toxicity. Although some studies have demonstrated significant 
correlations between mtDNA depletion and clinical abnormalities, such as lactic 
acidosis, a number of limitations to the use of PBMC mtDNA content have been 
described (Cote et al., 2002; Montaner et al., 2003). Firstly, PBMCs are not a tissue that 
demonstrates meaningful clinical mitochondrial toxicity, and in many studies mtDNA 
levels in PBMCs show poor correlation with those in the clinically relevant tissues (e.g. 
muscle, fat) (Cherry et al., 2006; Maagaard et al., 2006). Secondly, untreated HIV 
infection itself may also be associated with mtDNA depletion in PBMCs compared with 
healthy, HIV-uninfected, individuals (Miura et al., 2003; Miro et al., 2004). Although 
not conclusively proven, the most likely explanation for this observation is that cellular 
mtDNA depletion is a consequence of HIV-induced T-cell dysfunction. The 
significance of these observations is uncertain and there is no good data to suggest that 
cellular mtDNA content in other tissues is low in untreated HIV infection. Furthermore, 
with respect to the scenario in current developed world practice, the vast majority of 
patients are no longer taking the pol γ inhibiting NRTIs (ddC, ddI, d4T, AZT). Data 
suggests that mtDNA copy number in blood recovers on switching away from these 
agents (McComsey et al., 2005b). This effect has been shown for switch to ABC, and 
would be predicted to also apply to TDF, where in vitro data suggests a lack of mtDNA 
depletion. Thus mtDNA copy number blood is predicted to reflect only current NRTI 
exposure and not mitochondrial damage from prior exposures.  
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Recently serum FGF-21 (fibroblast growth factor 21) levels have been proposed as a 
promising biomarker for inherited mitochondrial disease (Suomalainen et al., 2011). 
FGF-21 is thought to increase mitochondrial oxidative function in a PGC-1α 
(peroxisome proliferator-activated receptor gamma coactivator 1-alpha) dependent 
manner. Levels showed a very high predictive value for biopsy COX defect (area under 
ROC (receiver operated curve) = 0.95). Correlation was highest in children with early 
onset (therefore clinically severe) mitochondrial disorders. Such children may have very 
high level COX defects on biopsy (up to 60% of fibres). In contrast in adults with late-
onset disease, which is more typical of the inherited disorders of mtDNA maintenance, 
phenotypes are less severe, and COX defects are less pronounced (typically <10%). 
Furthermore elevated serum FGF-21 levels have been reported in other metabolic 
disorders, including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes 
mellitus, and obesity (Moyers et al., 2007; Chen et al., 2008; Zhang et al., 2008; 
Dushay et al., 2010). This is likely to be because a major target for FGF-21 and PGC-1α 
activity is adipose tissue. Many patients with longstanding HAART-treated HIV 
infection will be expected to have increased frequency of the metabolic syndrome and 
insulin resistance (Carr et al., 1998; Gan et al., 2002). Although the aetiology of some 
of this pathology may overlap with that of acquired mitochondrial damage (for example 
d4T may cause both insulin resistance and pol γ inhibition), in many cases it will not 
(for example PIs may promote central obesity but not pol γ mediated mtDNA injury). 
Thus there may theoretically be heterogeneous reasons why FGF-21 levels may be 
expected to be elevated in HIV infection. My paper presented herein explores the 
determinants of elevated serum FGF-21 levels in HIV-infected patients on 
contemporary HAART (Payne et al., 2013c).   
  
1.9 Preventing somatic mtDNA mutation: therapeutic avenues 
A rational approach to ameliorate the effects of age-associated mtDNA mutations 
depends to a large extent on how and when those mutations arise, and what their natural 
history may be in terms of the progression from a new mutation to a clonally expanded 
mutation within a single cell, leading to a functional defect. As described above, many 
of these fundamental aspects of mtDNA biology remain the subject of on-going 
research, and as such, discussion of how best to prevent these changes is currently 
largely a matter of speculation.  
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If one takes the view that de novo mtDNA mutations arise at significant levels 
throughout the normal human lifespan, and that these may clonally expand relatively 
rapidly (perhaps through positive selection), then prevention of new mutation formation 
may be of therapeutic benefit. In the case of mutations arising from ROS damage, anti-
oxidant treatment might be proposed. Anti-oxidant compounds frequently show 
beneficial effects in vitro but almost none of these benefits have so far been translated in 
vivo. There are a few animal models which have suggested a beneficial effect. For 
example a mouse model has been developed which expresses a mitochondrially targeted 
antioxidant. These mice show reduced levels of ROS, reduced mtDNA mutations, and 
increased life span (Schriner et al., 2005). Furthermore, a recent study in LHON 
(Leber’s hereditary optic neuropathy) has shown benefit of idebenone in improving 
visual function in the setting of a randomised controlled trial (Klopstock et al., 2011). 
The cause of visual failure in LHON is thought to be mitochondrial dysfunction, and 
idebenone is thought to act as an anti-oxidant. This may therefore represent the first 
beneficial effect of an anti-oxidant compound in a mitochondrial disorder. Clearly, more 
work needs to be done to elucidate the precise pathophysiological mechanisms affected, 
but these observations at the least suggest that this approach may be worthy of further 
study, including in related mtDNA disorders.  
 
Alternatively it may be that natural replication errors are of primary importance. Thus 
one would wish to either increase the fidelity of pol γ, or increase mtDNA repair 
mechanisms. Currently there are no clear means to achieve either of these aims. 
 
Conversely, we may take the view that clonal expansion is the more important process. 
As discussed above, there is some recent evidence to suggest the relative importance of 
clonal expansion in normal human ageing, and this is borne out in my own work in 
ageing, and NRTI therapy. If de novo mutations are therefore very early events, and 
clonal expansion is a slow process, as proposed in the ‘relaxed replication’ model, then 
targeting clonal expansion would seem attractive. Indeed, clonal expansion is a 
necessary step, no matter how slowly or rapidly it occurs. Currently, the key putative 
means to change the rate of clonal expansion is to modify mitochondrial biomass or 
mtDNA copy number (the two appear to be intrinsically linked). How may we therefore 
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increase cellular mtDNA content? In the case of in vitro studies this effect has 
principally been achieved by uridine supplementation (Walker et al., 2006). However 
there is no good data to suggest that uridine supplementation is beneficial in vivo, at 
least in otherwise healthy animals or humans (McComsey et al., 2010). It is likely that 
in vitro uridine prevents mtDNA content in cells from being constrained by the rigorous 
demands of continuous cellular replication. In a rodent model, uridine supplementation 
has however prevented the detrimental effects of NRTI treatment on the brain, 
presumably by preventing profound mtDNA depletion (Venhoff et al., 2010). Another 
technique that has proved successful in vitro is supplementation with dNMPs. As we 
have shown, interestingly these supplements increase mtDNA content even in control 
cell lines, but have a greater effect in cell lines that have an mtDNA replication defect 
or are NRTI treated (Bulst et al., 2012). However, the best evidence for such an 
approach probably comes from exercise studies. It has long been established that 
endurance exercise increases cellular mtDNA content. Frail elderly subjects show 
reduced cellular mtDNA content compared with active elderly and younger subjects. 
This reduction in copy number may plausibly accelerate the clonal expansion of 
mtDNA mutations within cells in these subjects, leading to a more rapid increase in 
COX defects. Exercise studies have been attempted in patients with inherited mtDNA 
defects (Murphy et al., 2008). On serial biopsy, subjects with single deletion mtDNA 
disorders, showed a decrease in the proportion of COX deficient fibres, and an increase 
in COX intermediate fibres following a period of endurance exercise training. COX 
intermediate cells are suggestive of cells where wild-type mtDNA content is just about 
sufficient to maintain cellular oxphos function (Murphy et al., 2012). The exercise-
treated patients also have increased cellular mtDNA content. Finally, the most 
compelling evidence perhaps comes from a recent elegant paper using the pol γ 
‘mutator’ mouse as described previously. When subjected to endurance exercise the 
homozygous mutant mouse appears phenotypically as the wild-type mouse, rather than 
developing the progeroid state. MtDNA content is significantly increased in the mouse 
subjected to endurance exercise. However, the mutant mtDNA proportion remains 
comparable with that observed in the homozygous mutant mouse that did not undergo 
endurance exercise (Safdar et al., 2011). This suggests that by increasing mitochondrial 
biomass, endurance exercise cannot shift the proportional balance of wild-type and 
mutant mtDNA, but it can prevent the functional consequences of mutant mtDNA on 
the cell. These theoretical concepts, as applied to HIV infection and anti-retroviral 
therapy are shown in Table 3. 
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1.10 Fatigue and dysautomia 
Fatigue is a highly prevalent symptom but its physiological basis remains poorly 
understood. By definition, patients with Chronic Fatigue Syndrome (CFS, also known 
as Myalgic Encephalitis / Encephalomyelitis, ME) have disabling fatigue in the absence 
of a known physical or psychiatric illness (Fukuda et al., 1994). This case definition 
might imply that the aetiology of fatigue found in association with physical and 
psychiatric diseases is therefore different to that in CFS. In fact however, recent work 
suggests that symptomatology is very similar (Jones et al., 2009). Furthermore, fatigue 
in chronic physical illness tends to correlate poorly, if at all, with traditional markers of 
disease severity, at least until that disease is very severe. For example in Primary Biliary 
Cirrhosis (PBC) which has been well studied as a prototype disease where fatigue is 
highly prevalent, fatigue does not associate with liver function (Newton et al., 2006b; 
Pells et al., 2013).  
 
The extent to which physiological, as opposed to psychological factors contribute to the 
aetiology of CFS is a subject of on-going debate. Recently there has been increased 
interest in physiological factors. Orthostatic intolerance (dysautonomia) is highly 
prevalent in CFS as well as fatigue-associated chronic diseases (including PBC, and 
multiple sclerosis, MS), but not in chronic diseases in which fatigue is uncommon (for 
example primary sclerosing cholangitis, PSC) (Freeman and Komaroff, 1997; Rowe and 
Calkins, 1998; Schondorf et al., 1999; Schondorf and Freeman, 1999; Flachenecker et 
al., 2003; Chaudhuri and Behan, 2004; Newton et al., 2006a; Newton et al., 2007a; 
Newton et al., 2007b; Newton et al., 2007c). Furthermore the prevalence of fatigue has 
been shown to be high in patients with vasovagal syncope (VVS), a form of primary 
orthostatic intolerance (Legge et al., 2008). The association between fatigue and 
orthostatic intolerance is co-linear in terms of the severity of both symptoms, and this 
observation holds equally well for CFS as for other chronic diseases. This is therefore 
further evidence that common physiological pathways may underpin fatigue in diverse 
chronic diseases as well as CFS. The therapeutic approaches that have been developed 
for CFS may therefore also be of some benefit to patients experiencing fatigue in 
association with chronic illnesses (NICE, 2007). 
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What may be the pathophysiological mechanism linking dysautonomia and fatigue? 
Preliminary observations have suggested that oxygen delivery to muscles and the brain 
may be dysregulated in patients with fatigue and dysautonomia, but much further work 
is needed to fully explore this hypothesis (Jones et al., 2010). This observation does not 
tell us about the nature of the relationship in terms of whether or not it is causal, and in 
which direction the causality may lie. In the case of CFS, it perhaps seems more 
plausible that fatigue predates dysautonomia, perhaps initially as a response to an illness 
(for example viral infection). During a period of significant rest, and perhaps under the 
influence of neuroendocrine factors, autonomic function may become dysregulated. 
This may then drive further fatigue (for example through the pathways suggested 
above), and a vicious cycle may ensue. In the case of various fatigue-associated chronic 
illnesses, it seems equally plausible that either fatigue or dysautonomia came first, but 
in either case the end result is similar.  
 
Should therapeutic approaches to CFS or fatigue in the context of chronic illness 
therefore target dysautonomia? It is possible to gain objective improvement in 
autonomic function through either physical measures (such as compression stockings), 
or pharmacological measures (such as fludrocortisone which will increase retention of 
salt and water, or midrodrine which increases vascular tone). To date no high-quality 
studies have suggested any benefit of these approaches on fatigue itself. This may be 
because studies did not stratify CFS patients into those with and without dysautonomia 
at enrolment. Alternatively, it may be that although peripheral vascular tone can be 
improved, there is not a corresponding beneficial effect on the important ‘target tissues’, 
for example brain and muscle.  
 
What do we know about the role of mitochondria in fatigue? Preliminary magnetic 
resonance spectroscopy studies have suggested that muscle mitochondrial function is 
abnormal in the context of CFS and PBC. The principle abnormality seems to be 
delayed acid clearance following repeated exercise (Jones et al., 2010). There may be a 
number of potential explanations for this observation. Firstly it may be that fatigue-
induced deconditioning has caused a reduction in the oxidative capacity of the muscle. 
Secondly it may be that dysautonomia associated with the fatigue has adversely affected 
vascular supply, and thus oxygen delivery to the muscle, or the ability to appropriately 
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adapt this supply to the exercise challenge. Finally, in the case of PBC, it may be that 
the mitochondrion is a direct pathological target as the auto-antibodies seen in PBC 
(AMA, anti-mitochondrial antibody) are directed against a component of the respiratory 
chain.   
     
1.10.1 Fatigue and HIV 
Fatigue was a highly prevalent symptom in the pre-HAART era (Darko et al., 1992). At 
this time, there was a correlation between fatigue and clinical disease state (i.e. the CDC 
stage, AIDS-defining illnesses etc.). Many such patients were profoundly 
immunosuppressed and had high levels of HIV replication, both in the periphery, and in 
the brain. It is therefore unclear to what extent fatigue should be expected to remain an 
issue in the current era where patients are generally well treated on HAART, with fully 
suppressed plasma HIV viral loads, and good immune reconstitution.  
 
My work on fatigue in HIV presented herein, shows some interesting novel insights 
(Payne et al., 2013a). Firstly fatigue was very common (affecting ~50% of patients) 
despite good immune function, and near universal HAART treatment. In keeping with 
CFS and other fatigue-associated medical disorders, there was a strong correlation of 
fatigue with dysautonomia symptoms. Again, the direction of a potential causal 
relationship is a subject for debate, but it seems at least likely that dysautonomia is an 
aggravating or perpetuating factor in this patient group. What may have been the initial 
precipitant of fatigue or dysautonomia? This may be heterogeneous between patients, as 
clearly not all are affected, despite seemingly similar courses of HIV infection. We may 
speculate that in some subjects the initial untreated HIV infection may have adversely 
affected the immune or neuroendocrine response, as has been hypothesised for CFS 
following a viral infection. Furthermore in the case of HIV infection, we know that in 
most cases, immune function remains qualitatively abnormal, with increased immune 
activation even in ‘successfully’ treated HIV (Jiang et al., 2009). Alternatively, or 
additionally, some HIV infected patients may experience an adverse psychological 
reaction to their diagnosis which may contribute to the onset of fatigue.  
 
In addition, I identified a sub-group of HIV-infected patients where fatigue was near 
universal. This group was characterised by longstanding HIV infection, long history of 
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anti-retroviral treatment, previous exposure to mitochondrially toxic anti-retroviral 
drugs (pol γ inhibiting NRTIs), and the presence of clinical side effects of such drugs, 
such as the lipodystrophy syndrome. It is certainly plausible that residual mitochondrial 
dysfunction contributes to on-going fatigue in this group.  
 
1.11 Concluding remarks  
There are numerous ways in which the older NRTI anti-retroviral drugs may increase 
somatic mutations in mtDNA, and I show empiric evidence of this herein. It is plausible 
that the mechanism is via an acceleration of the clonal expansion of pre-existing (age-
associated) mtDNA mutations. Fuller understanding of the exact mechanism involved 
has potential implications for predicting the natural history of such mutations as patients 
continue to age.  
 
Conversely, NRTI exposure arguably presents a rather unique scenario in which aspects 
of normal mtDNA maintenance are iatrogenically altered. Observations from NRTI 
treatment may further the debate on the fundamental biology of mtDNA mutations in 
normal human ageing.  
 
Through my work I have defined a sub-group of mainly highly treatment experienced 
HIV-infected patients, with prior exposure to pol γ inhibiting NRTIs who show 
evidence of increased somatic mtDNA mutation and residual cellular mitochondrial 
dysfunction, long after such drugs have been switched to cleaner agents. This group 
should be the focus of close attention as they continue to age in order to determine the 
extent to which they will demonstrate accelerated frailty or increased comorbidity. I 
have already shown that increased fatigue may be one clinical consequence of this 
damage. Finally, given that many millions of patients in sub-Saharan Africa have been 
exposed to d4T in recent years as part of HAART rollout programmes, it remains to be 
seen what the extent of complications will be in this group in the future. 
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Figure 1. Early mutation hypothesis, clonal expansion, and putative role of 
nucleoside analogue reverse trancriptase inhibitors.  
Diagrams show an individual COX (cyctochrome c oxidase) positive cell (brown) in a 
young individual eventually becoming COX deficient (blue) in later life, over a 
representative timescale. Multiple copies of wild-type mitochondrial DNA (mtDNA) 
are initially present within the cell, shown as green circular molecules (in reality ‘00’s 
to ‘0,000’s per cell). A mutation occurs (red molecule) which is initially at a low 
percentage heteroplasmy level within the cell, but over time may clonally expand to 
reach a high heteroplasmy level causing the COX defect. (a) Under an ‘early mutation’ 
hypothesis, new mtDNA somatic mutations that lead to COX deficient cells late in life, 
arise in early life and clonally expand very slowly, by a non-selective process of drift 
(‘relaxed replication’). (b) Under an alternative model, mutant mtDNA clonally expands 
relatively rapidly within cells, and therefore the observed COX defect in late life is due 
to a relatively recent mutation. Such a process of rapid clonal expansion is likely to 
require a selective replicative advantage for mutant mtDNA. A hypothesis of 
accelerated clonal expansion of mtDNA mutations due to NRTI (nucleoside analogue 
reverse transcriptase inhibitor) exposure is most coherent with an ‘early mutation’ 
hypothesis (a) where the somatic mutations have already occurred  by early adult life, 
and therefore expand to result in COX deficient cells many years earlier than expected. 
  
32 
 
  
    
    
 AGE:  0    20    55    60 
 NRTI 
a. 
b. 
33 
 
Figure 2. Hypothesised model of how age-associated somatic mitochondrial DNA 
mutations may lead to a functional defect at the tissue level.  
Somatic mutations may arise either through oxidative damage to mitochondrial DNA 
(mtDNA), for example, due to reactive oxygen species (ROS), or through natural 
replication errors. MtDNA mutations may cause synthesis of abnormal respiratory chain 
proteins, leading to partial uncoupling of the mitochondrial respiratory chain. This may 
lead to a vicious cycle of increased ROS. In order for somatic mtDNA mutations to 
cause a functional mitochondrial (COX, cytochrome c oxidase) defect at the cellular 
level, the mutation must clonally expand to reach a high percentage level within the cell. 
Frequent COX deficient cells will decrease function of the tissue, and may also undergo 
apoptosis. Boxes shown in red may plausibly be adversely affected by HIV or NRTI 
(nucleoside analogue reverse transcriptase inhibitor) anti-retroviral therapy (ART) 
exposure.   
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Table 1. Overview of current methods for detecting or quantifying mitochondrial DNA mutations.  
Method 
Point mutations or 
deletions 
Detection or 
quantification 
Advantages Limitations 
Post-PCR cloning Point mutations 
Detection and 
quantification 
Well-established method 
Resolution limited by PCR-induced noise 
and achievable depth of coverage 
Single molecule PCR 
(smPCR) 
Point and deletion 
mutations 
Detection and 
quantification 
Low rate of noise. Ability to amplify 
whole mtDNA genome 
Time-consuming and relatively technically 
demanding method; low depth of coverage, 
therefore samples only a tiny fraction of all 
mtDNA molecules 
Random mutation capture 
(RMC) 
Point mutations Quantification Very low rate of noise 
Detects only one specific mutation type, 
therefore mutation rate may not reflect that 
of other mutation types 
Next-generation 
resequencing (NGS) 
Point mutations 
Detection and 
quantification 
Very high throughput, very high depth of 
coverage, can quantify each mutation 
detected 
Resolution good, but limited by noise 
(mainly base-calling error rate) 
Real-time PCR (generic 
major arc assay, e.g. 
ND1:ND4) 
Deletion mutations Quantification 
Quick method of quantifying deletion 
burden 
Can only accurately quantify relatively high 
heteroplasmy levels of mutations (>~25%), 
therefore better suited to single cell analyses 
Real-time PCR (specific 
assay, e.g. ‘common 
deletion’) 
Deletion mutations 
Detection and 
quantification 
Quick method of detecting and quantifying 
very low heteroplasmy levels (e.g. <0.1%) 
of a specific deletion mutation 
Limited to quantifying a single deletion 
mutation, therefore may not reflect total 
mutation burden 
Allele-specific PCR (e.g. 
clamped PCR) 
Point mutations Detection 
Quick method of detecting relatively low 
levels of a specific point mutation (e.g. 
mt.414T>G) 
Limited to detecting a single point mutation. 
Not quantitative 
COX histochemistry, 
single cell analysis 
Point and deletion 
mutations 
Quantification (COX 
histochemistry), and 
detection (single cell) 
COX histochemistry quantifies 
functionally abnormal cells, and localises 
somatic mutations 
Will not routinely detect low level mutations 
that have not become clonally amplified 
within cells 
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Table 2. Summary of papers examining mitochondrial DNA mutations in the setting of HIV or anti-retroviral therapy. mtDNA, mitochondrial 
DNA; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism analysis; TA, thymidine analogue; SSCP, single-strand 
conformation polymorphism analysis; NRTI, nucleoside analogue reverse transcriptase inhibitor; TTGE, temporal temperature gradient gel 
electrophoresis; AZT, zidovudine; DGGE, denaturing gradient gel electrophoresis; HIV-SN, HIV-associated sensory neuropathy; ddC, zalcitabine; 
d4T, stavudine; BER, base excision repair; DRG, dorsal root ganglion. 
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Citation Species / Subjects Tissue Findings Methods Comments 
Bartley et al. (2001). 
AIDS 15(3):419-420 
Human (single case report 
of fatal lactic acidosis) 
Blood, skeletal 
muscle, liver 
Large-scale deletion mutations in 
hepatic mtDNA 
PCR, RFLP, 
Sanger 
sequencing 
Possibility this was unmasking of 
underlying mitochondrial disease 
Martin et al. (2003). Am 
J Hum Genet 72(3):549-
560 
Human (subjects starting 
TA based therapy) 
Blood 
5 of 16 patients at one year 
developed new heteroplasmic 
mtDNA point mutations 
SSCP, cloning, 
Sanger 
sequencing 
Mutations seen in mtDNA non-coding 
and protein coding regions 
Walker et al. (2004). 
Cardiovasc Toxicol 
4(2):133-153 
Mouse (adult females, 
exposed in utero to NRTIs) 
Cardiac muscle 
Increased mutations in mtDNA 
tRNA genes following in utero 
AZT exposure 
PCR, DGGE, 
Sanger 
sequencing 
No increase in mtDNA deletion 
mutations seen. Some lesions may have 
been strain-specific rather than acquired. 
McComsey et al. (2005). 
J Acquir Immune Defic 
Syndr 39(2):181-188 
Human (serial samples from 
NRTI treated patients) 
Blood 
2 of 54 NRTI treated patients 
developed mtDNA point 
mutations whilst on therapy 
PCR, TTGE, 
Sanger 
sequencing 
Mutations were in mtDNA non-coding 
region only.  
Chan et al. (2007). 
Environ Mol Mutag 
48(3-4):190-200 
Mouse (young adult mice, 
exposed in utero and in 
early post-natal period to 
NRTIs) 
Cardiac muscle 
Increased mutations in mtDNA 
tRNA genes following in utero 
and early post-natal AZT 
exposure 
PCR, DGGE, 
Sanger 
sequencing 
No increase in mtDNA deletion 
mutations seen. Some lesions may have 
been strain-specific rather than acquired. 
Torres et al. (2009). 
Environ Mol Mutag 
50(1):10-26 
Human (infants exposed in 
utero) 
Umbilical cord 
(vascular endothelium 
and smooth muscle) 
Increased mutations in mtDNA 
tRNA genes following in utero 
AZT exposure. 
PCR, DGGE, 
Sanger 
sequencing 
Many mutations were at known 
polymorphic sites, some were novel. No 
comparison was made with maternal 
mtDNA sequence. 
Wu et al. (2009). Mutat 
Res 664(1-2):28-38 
HuH-7 human hepatoblast 
cell line 
In vitro 
Increased frequency of mtDNA 
d-loop mutations with d4T 
exposure 
PCR, Sanger 
sequencing 
Hypothesised to be due to decreased 
mtDNA BER 
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Balcarek et al. 
(2010). J Acquir 
Immune Defic Syndr 
55(5):550-557 
Mouse (young adult 
mice exposed to 
NRTIs) 
Cardiac 
muscle 
AZT and ddC treated mice showed mtDNA 
common deletion mutation which was absent 
or at very low levels in controls 
PCR, semi-quantitative  
Uridine supplementation somewhat 
lessened the increase in the mtDNA 
common deletion mutation levels 
seen with NRTI treatment 
Lehmann et al. 
(2011). Ann Neurol 
69(1):100-110 
Human (post-mortem 
frozen tissue) 
Peripheral 
nerves 
Increased levels of mtDNA common deletion 
mutation in HIV-SN 
Real-time PCR 
Common deletion more common in 
distal nerves than DRG (these are 
‘older’ mitochondria) 
Ortiz et al. (2011). J 
Infect Dis  
203(5):620-624 
Human (patients 
starting TA based 
therapy) 
Blood 
None of 29 patients developed new mtDNA 
mutations on therapy 
PCR, Sanger sequencing 
Could have missed low-level 
heteroplasmic mtDNA mutations 
Payne et al. (2011). 
Nat Genet 
43(8):726-727 
Human (cross 
sectional analysis of 
currently and 
previously NRTI 
treated subjects) 
Skeletal 
muscle 
NRTI treated subjects showed mtDNA 
mutations which were clonally expanded 
within single cells. Also increase in common 
deletion mutation. Pattern of mutations similar 
to that seen later in life due to normal ageing 
Single cell real-time PCR 
and Sanger sequencing; 
next-generation 
sequencing; in silico 
modelling 
Data consistent with accelerated 
expansion of pre-existing (ageing-
associated) mtDNA mutations, 
without increased de novo 
mutagenesis 
Jitratkosol et al. 
(2012). AIDS 
26(6):675-683 
Human (NRTI treated 
mothers and infants 
exposed in utero) 
Blood 
AC/TG mutations only were increased in 
mothers and trend towards increase in infants 
Post-PCR cloning and 
Sanger sequencing of 
mtDNA d-loop 
Reported significant issues with 
assay noise 
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Table 3. Putative strategies to slow mitochondrial ageing in HIV infection or anti-retroviral therapy. 
 
Strategy Process targeted Comments 
Reduce oxidative stress 
Mutagenesis – oxidative 
damage 
Identify and use anti-retrovirals with minimal effect on oxidative stress, identify 
and treat disease-associated oxidative stress 
Mitochondrially targeted 
anti-oxidant  
Mutagenesis – oxidative 
damage 
In general, human studies of anti-oxidant supplements in other diseases have been 
disappointing 
Increase polymerase fidelity 
Mutagenesis – replication 
errors 
Use anti-retrovirals with minimal effect on pol γ base misincorporation 
Increase excision repair 
Mutagenesis – replication 
errors 
Use anti-retrovirals with minimal effect on pol γ exonuclease function 
Increase mitochondrial 
biomass 
Clonal expansion 
Identify treatments or processes (such as endurance exercise) which may increase 
mitochondrial biomass, and therefore total and wild-type mtDNA content within 
cells, reducing the effect of clonally-amplified mutant mtDNA  
Reduce amplification of 
mutant mtDNA 
Clonal expansion 
Avoid the use of anti-retrovirals which inhibit pol γ polymerase function, and thus 
potentially confer replicative advantage to deleted mtDNA 
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Abstract 
There is emerging evidence that people with successfully treated HIV infection age 
prematurely, leading to progressive multi-organ disease (Effros et al., 2008), but the 
reasons for this are not known. Here we show that patients treated with commonly used 
nucleoside analog anti-retroviral drugs progressively accumulate somatic mitochondrial 
DNA (mtDNA) mutations, mirroring those seen much later in life caused by normal 
aging (Trifunovic et al., 2004; Bua et al., 2006). Ultra-deep re-sequencing by synthesis, 
combined with single-cell analyses, suggests that the increase in somatic mutation is not 
caused by increased mutagenesis but might instead be caused by accelerated mtDNA 
turnover. This leads to the clonal expansion of preexisting age-related somatic mtDNA 
mutations and a biochemical defect that can affect up to 10% of cells. These 
observations add weight to the role of somatic mtDNA mutations in the aging process 
and raise the specter of progressive iatrogenic mitochondrial genetic disease emerging 
over the next decade. 
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Main Text 
Somatic mtDNA mutations accumulate in individual cells during normal human aging, 
leading to cellular bio-energetic defects of oxidative phosphorylation (Brierley et al., 
1996; Bua et al., 2006). Transgenic mice with a defective mtDNA polymerase (pol γ) 
accumulate secondary mtDNA mutations and a prematurely aged phenotype (Trifunovic 
et al., 2004), but it is still not clear whether the mtDNA mutations are a cause or a 
consequence of aging in humans. Accelerated senescence has recently been described in 
humans with successfully treated HIV infection (Effros et al., 2008). These patients 
become frail at an early age, decline physiologically (Oursler et al., 2006; Desquilbet et 
al., 2007) and acquire age-associated degenerative disorders affecting the 
cardiovascular system and the brain leading to dementia (Valcour et al., 2004; Guaraldi 
et al., 2009). Several nucleoside analog reverse transcriptase inhibitor anti-retroviral 
drugs (NRTIs) used in the treatment of HIV inhibit the function of pol γ (Lim and 
Copeland, 2001), raising the possibility that drug treatment contributes to the 
accelerated aging phenotype through mtDNA damage. NRTIs are well known to cause 
an acute, temporary and reversible reduction in the amount of mtDNA (mtDNA 
depletion), and one previous study detected mtDNA deletions in patients being actively 
treated with NRTIs (Cote et al., 2002; McComsey et al., 2005; Maagaard et al., 2006). 
However, no previous studies have looked at the possibility of irreversible long-term 
effects of the drugs on mtDNA mutations after NRTI treatment has ceased. 
 
We studied skeletal muscle from 33 HIV-infected adults, all aged 50 years or under, 
stratified by lifetime exposure to NRTIs previously shown to affect pol γ in vitro (Lim 
and Copeland, 2001) (Online Methods and Supplementary Table 1), and 10 HIV-
uninfected healthy controls (HIV−) of comparable age. We initially looked for a defect 
of mitochondrial oxidative phosphorylation within individual cells using 
cytochrome c oxidase–succinate dehydrogenase (COX-SDH) histochemistry. Cellular 
COX defects would not be expected in this younger subject group (<0.5%) (Brierley et 
al., 1996). The frequency of COX-deficient muscle fibers in HIV-infected non-treated 
(treatment-naïve, HIV+/NRTI−) subjects (n = 12) was indistinguishable from that 
observed in HIV− controls, with the majority having no COX-deficient fibers. By 
contrast, NRTI-exposed (HIV+/NRTI+) subjects (n = 21) had an increased frequency of 
COX-deficient muscle fibers (maximum 9.8%, P = 0.047), reaching or exceeding levels 
expected in healthy elderly individuals (Brierley et al., 1996) (Fig. 1). The severity of 
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the COX defect was strongly predicted by cumulative lifetime NRTI exposure, rather 
than therapy at the time of study, implicating a persistent and cumulative mitochondrial 
defect (r
2
 = 87%, P < 0.001; Supplementary Fig. 1). 
 
We then defined the molecular basis for the COX deficiency observed in NRTI-exposed 
subjects. We first excluded persistent mtDNA depletion. The mtDNA content in 
homogenized skeletal muscle did not differ between HIV+/NRTI+ and HIV+/NRTI− 
patients (Supplementary Fig. 2). In keeping with this, the analysis of individual laser-
captured single muscle fibers (n = 128) showed that only a small minority of COX-
deficient fibers (6 out of 70, or 9%) from NRTI-treated patients had mtDNA depletion 
compared to adjacent fibers with normal COX activity. By contrast, the vast majority of 
the isolated COX-deficient fibers contained markedly increased amounts of mtDNA 
(geometric mean of 2.1-fold proliferation, maximum 21.3-fold; P < 0.001 for difference 
in mean mtDNA content between COX-deficient and normal fibers) (Fig. 2a). Focal 
mtDNA proliferation is often seen in association with pathogenic mtDNA mutations. In 
keeping with this, the majority of the COX-deficient fibers analyzed (40 out of 70 fibers 
from 12 HIV+/NRTI+ patients) showed high percentage levels of mtDNA molecules 
containing large-scale deletion mutations, exceeding the percentage level of mutation 
required to cause a COX defect (~60% (Hayashi et al., 1991)). We detected no deletion 
mutations in adjacent skeletal muscle fibers (n = 58) with normal COX activity. 
Analysis of the mtDNA deletion break points (n = 15 fibers from four HIV+/NRTI+ 
patients) revealed different deletions in different fibers, all of which were clonal within 
individual fibers. Most of the clonally expanded deletions were unique; the only 
deletion observed more than once was the mt.δ4977 'common deletion', the commonest 
age-associated somatic mtDNA mutation (Corral-Debrinski et al., 1992; Brierley et al., 
1998) (Fig. 2b,c and Supplementary Table 2). 
 
Although less common than large-scale deletion mutations, mtDNA point mutations are 
also found in COX-deficient fibers from healthy aged subjects (Fayet et al., 2002). In 
keeping with this, in the NRTI-treated patients, we found COX-deficient fibers not 
containing a deletion to harbor non-synonymous somatic mtDNA point mutations (5 out 
of 29 fibers). These mutations are predicted to alter a highly conserved amino acid and 
have not previously been described as inherited polymorphic variants in 5,140 humans 
(Table 1) (one variant, 12797T>C, had been observed as a somatic variant in a single 
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human sequence) (Pereira et al., 2009) and thus provide an explanation for the 
associated cellular COX defect. Other fibers contained high levels of noncoding control-
region (nt 16,024 to nt 576) variants, which were previously described in healthy aged 
humans. 
 
We then estimated the total burden of mtDNA deletion mutations at the whole-tissue 
level. The proportion of mtDNA molecules containing the mt.δ4977 'common deletion' 
was significantly higher in NRTI-treated patients compared with untreated patients 
(HIV+/NRTI+ (mean ± s.e.m.), −3.45 ± 0.25 log10(/mtDNA); HIV+/NRTI−, −4.56 ± 
0.31 log10(/mtDNA); P = 0.012) (Fig. 3) and were comparable with those previously 
reported in very elderly healthy subjects (Lee et al., 1994). Furthermore, the proportion 
of COX-deficient muscle fibers from NRTI-treated subjects which contained mt.δ4977 
was very similar to that reported in healthy aged individuals (Brierley et al., 1998). 
Pathogenic mutations within single fibers (of which the majority were deletions) were 
accompanied by proliferation of mtDNA, which occurs in an attempt to maintain 
adequate levels of wild-type mtDNA, as shown previously (Chinnery and Samuels, 
1999). As a result, mutated mtDNA also proliferates within the fiber. Over time, this 
will lead to a detectable increase in the level of deletions at the whole-tissue level. 
 
To estimate the relative burden of mtDNA point mutations between treatment groups in 
homogenized skeletal muscle, we designed an ultra-deep re-sequencing by synthesis 
(UDS) assay using FLX GS technology (Roche 454). First, we carried out a series of 
control experiments to show the sensitivity of UDS to detect mtDNA point variants. We 
initially established that UDS of an mtDNA template did not generate an intrinsically 
different signal when compared to a nuclear DNA template by sequencing amplicons of 
cloned autosomal and mitochondrial DNA fragments as well as an autosomal DNA 
amplicon from genomic DNA (Supplementary Table 3). By this approach, we 
confirmed a very low background noise level for the UDS assay (Online Methods and 
Supplementary Fig. 3). As a positive control, we then compared two mtDNA amplicons 
from skeletal muscle DNA of POLG patients (n = 4), individuals known to harbor high 
levels of somatic mtDNA point mutations (Del Bo et al., 2003; Wanrooij et al., 2004). 
One mtDNA amplicon was in the hypervariable noncoding control region (MT-HV2) 
predicted from 5,140 population-level sequences (Pereira et al., 2009) to have a high 
mutation rate, and one was in a highly conserved mtDNA coding region (MT-CO3). 
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Mean coverage was 5,892 sequence reads per amplicon in each direction. Consistent 
with an error-prone pol γ, these subjects showed an increase in mtDNA point variants 
detectable at >0.2% frequency in the MT-HV2 amplicon (OR = 2.33, P = 0.002) (Fig. 4) 
when compared to healthy controls (n = 4). We detected no increase in variants in 
the MT-CO3 amplicon. These findings were confirmed on replicate samples 
(Supplementary Fig. 4). When we studied skeletal muscle mtDNA from the 
HIV+/NRTI+ subjects (n = 8), the overall burden of point variants within each amplicon 
was indistinguishable from HIV+/NRTI− subjects (n = 4) and healthy HIV− controls 
(n = 4), all of comparable age (OR = 1.08, P = 0.79 for comparison of HIV+/NRTI+ 
and HIV− for MT-HV2). Furthermore, there was no correlation between COX defect in 
HIV+/NRTI+ subjects (range up to 10%) and mutation burden on the UDS assay. 
 
Given that NRTI-treated subjects showed high-level COX defects (up to 10% of fibers) 
which contained clonal mutated mtDNA species, one explanation for our findings is 
accelerated segregation of pre-existing (age-associated) mtDNA mutations caused by 
NRTI treatment rather than de novo somatic mutation. In contrast, the POLG subjects 
showed a significant increase in point mutation burden in the UDS assay (although only 
in MT-HV2, P = 0.002) but a low proportion of COX-deficient fibers. Although the 
UDS data does not exclude the possibility of a slight increase in mutagenesis in NRTI-
exposed subjects, it would not be of the level predicted to be required (>100-fold 
increase (Elson et al., 2001)) to cause the observed COX defects. 
 
To determine whether accelerated clonal expansion was a plausible explanation for our 
findings, we used an established computational model based solely on experimentally 
derived parameters (Elson et al., 2001) and simulated the effects of NRTI-induced 
chain-termination during mtDNA replication (Lim and Copeland, 2001). The de novo 
mutation rate was not altered from the original model of aging muscle. A finite NRTI 
exposure predicted a period of temporary mtDNA depletion which was concordant with 
reported mtDNA levels (Cherry et al., 2006; Maagaard et al., 2006) and the COX 
defects observed (Maagaard et al., 2006) in acutely treated HIV patients. This resulted 
in accelerated clonal expansion of pre-existing mtDNA mutations and led to an 
irreversible increase in the frequency of COX-deficient muscle fibers (Fig. 5a,b). The 
severity of predicted COX defect was dependent on the degree of replication failure and 
the duration of exposure (Fig. 5b,c), which is in keeping with our observations in patient 
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muscle that had suggested a strong dependence on these factors (Supplementary Fig. 
1). In silico modeling is thus consistent with the hypothesis that accelerated clonal 
expansion of pre-existing (age-associated) mtDNA somatic mutations is sufficient to 
explain our observations in NRTI-treated subjects. Having established the model, we 
explored the effect of timing of NRTI exposure and showed that later periods of therapy 
predicted a higher frequency of COX deficiency (Fig. 5d). This is because of older 
subjects harboring a greater number of age-related somatic mtDNA mutations than 
younger subjects, which rapidly clonally segregate during NRTI therapy. This is in 
keeping with the observation that mitochondrially mediated clinical complications of 
NRTI therapy appear to be more common in older individuals (Smyth et al., 2007). 
Finally we modeled the longer-term effects of treatment. Using this approach, an HIV-
infected individual treated with NRTIs during their third decade is predicted to develop 
~5% COX-deficient cells by age 60 (Fig. 5b–d). This is similar to or exceeds that seen 
in the healthy very old (Brierley et al., 1996). 
 
Although the UDS data for mtDNA point mutations support the hypothesis of 
accelerated clonal expansion of pre-existing age-related mutations rather than increased 
mutagenesis, it is possible that additional mechanisms may be involved for mtDNA 
large-scale deletions, including a replicative advantage favoring deleted molecules 
(Diaz et al., 2002). Furthermore, although UDS provides great depth of mutational 
analysis, it is analogous to the PCR-cloning method of mutation rate determination and 
as such will tend to exaggerate an estimate of the mutation rate (Kollberg et al., 2005; 
Greaves et al., 2009). 
 
The rapid clonal expansion of somatic mtDNA mutations we observed in NRTI-treated 
HIV-infected patients provides a plausible mechanism for accelerated aging in treated 
HIV infection. This is potentially of great importance for the millions of HIV-infected 
patients in the developing world where these drugs remain the mainstay of therapy 
(WHO, 2006) and adds weight to a causal role for somatic mtDNA mutations in human 
aging. 
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Methods 
Ethics 
This study was approved by the Newcastle and North Tyneside Local Research Ethics 
Committee. Informed consent was obtained from all subjects. 
 
Clinical details 
Clinical details are described in the Supplementary Note. 
 
Histochemistry 
We obtained 20 μm frozen sections from fresh-frozen lower limb skeletal muscle 
biopsies and placed them on polyethylene naphthalate (PEN) membrane slides (Leica) 
for subsequent laser microdissection. COX (cytochrome c oxidase) contains subunits 
encoded by the mitochondrial genome and stains brown (positive) in the presence of 
preserved respiratory chain activity. SDH (succinate dehydrogenase) provides an 
effective counter stain (blue), as this respiratory chain complex is entirely encoded by 
the nuclear genome and will be preserved in the presence of an mtDNA defect. Thus, 
COX-deficient fibers are predicted to contain somatic mtDNA mutations. ATPase 
histochemistry was performed on adjacent frozen sections in order to determine fiber 
type (oxidative or glycolytic). 
 
Molecular analyses 
All primers used are listed (Supplementary Table 4). All nucleotide positions refer to 
the revised Cambridge Reference Sequence (rCRS, NC_012920).  
 
Individual skeletal muscle fibers were captured by laser microdissection (Leica) and 
digested in 30 μl of lysis buffer (50 mM Tris-HCl pH 8.5, 0.5% Tween-20 and 200 
μg/ml proteinase K). Real-time PCR was performed as previously described (Durham et 
al., 2007). Briefly, mtDNA content was determined using a target template in MT-ND1. 
When comparing COX-deficient and normal fibers, these were matched for fiber type 
and adjusted for fiber size. We estimated the proportion of mtDNA molecules 
containing large-scale deletions using a target template in MT-ND4. For determination 
65 
 
of relative mtDNA content at the whole-tissue level, we performed real-time PCR as 
above with the inclusion of the nuclear template, B2M. The proportion of mtDNA 
molecules in muscle homogenate containing the mt.δ4977 'common deletion' were 
estimated by real-time PCR comparing MT-ND1 and a product (CD) specifically 
amplified only in the presence of the common deletion. CD-ND1 real-time PCR was 
performed in a 20 μl reaction comprising 1× Evagreen supermix (Bio-Rad), 0.625 μM 
primers and 50 ng DNA. PCR protocol comprised 98 °C for 2 min, followed by 40 
cycles of 98 °C for 5 s and 60 °C for 20 s. In addition to a PCR negative, DNA 
extracted from whole blood of a 25-year-old healthy control subject was used to define 
the lower limit of sensitivity for this assay, as negligible mt.δ4977 is expected to be 
detectable in blood by these methods (Lee et al., 1994; Shieh et al., 2007). 
 
Long-range PCR to detect mtDNA deletions in individual fibers was performed using 
nested PCR as previously described (Bender et al., 2006). Deletion break points were 
then characterized by amplification of a ~500-bp fragment across the deletion break 
point. Break-point PCR reactions were performed in a 25 μl reaction containing 1× 
ImmoBuffer (Bioline), 2 mM MgCl2, 0.2 mM dNTPs, 1 U Immolase (Bioline) and 1 μl 
of long-range PCR product, diluted 1:50 with PCR-grade water. PCR conditions were 
95 °C for 10 min and 25 cycles of 95 °C for 15 s, 58 °C for 15 s and 72 °C for 30 s. 
Cycle sequencing was performed using BigDye Terminator v3.1 kit (Applied 
Biosystems) and visualized through a 3130× Genetic Analyzer (Applied Biosystems). 
 
Whole-genome sequencing from individual fibers was performed based on our previous 
methods (Durham et al., 2006). A nested PCR comprising a primary PCR with nine 
overlapping primer pairs was followed by 36 overlapping secondary PCR primer pairs. 
Primary PCR was performed in a 50 μl volume containing 1× PCR buffer (10 mM Tris-
HCl pH 8.3, 1.5 mM MgCl2, 50 mM KCl and 0.001% w/v gelatin), 1 mM MgCl2, 0.2 
mM dNTPs, 0.6 μM primers, 1.75 U AmpliTaq Gold (Applied Biosystems) and 1 μl 
lysate. PCR conditions were 94 °C for 10 min and 38 cycles of 94 °C for 45 s, 58 °C for 
45 s and 72 °C for 2 min. Final extension was 8 min. Secondary PCR was performed in 
a 25 μl volume containing 1× PCR buffer (as above), 0.2 mM dNTPs, 0.8 μM primers, 
0.65 U AmpliTaq Gold and 1 μl of primary PCR product. PCR conditions were as 
above except for 1 min extension and 30 cycles. Cycle sequencing was performed as 
above. 
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Ultra-deep re-sequencing by synthesis (UDS; Roche 454 GS FLX) was performed by 
PCR amplification of two mtDNA amplicons: one in the noncoding (control region) 
hypervariable segment 2 (MT-HV2) (amplicon position, nt 162 to nt 455, 294 bp) and 
one in the coding region, COX subunit 3 (MT-CO3) (amplicon position, nt 9,307 to nt 
9,591, 285 bp). Primer specificity and lack of amplification of nuclear pseudogenes was 
predicted by BLAST (Altschul et al., 1990) and confirmed by failure of amplification of 
any product from rho0 cellular DNA. In addition we generated a nuclear DNA amplicon 
(BRCA2, NC_000013.10, 32,907,099–32,907,295). Amplicon generation was 
performed in a 50 μl volume containing 1× buffer for KOD Hot Start DNA Polymerase 
(Novagen), 1.5 mM MgSO4, 0.2 mM dNTPs, 0.3 μM primers, 1 U KOD Hot Start DNA 
Polymerase (Novagen) and 100 ng DNA. Cycling conditions were 95 °C for 2 min 
followed by 30 cycles of 95 °C for 20 s, 60 °C for 10 s and 70 °C for 4 s. Emulsion PCR 
and sequencing were performed according to manufacturer's instructions (Roche 454). 
Confirmatory experiments were performed by amplicon sequencing a larger amplicon in 
the same regions using Roche 454 GS FLX Titanium system. Amplicon positions for 
Titanium assay were: MT-HV2, nt 109 to nt 483; MT-CO3, nt 9,304–9,653; BRCA2, 
32,907,060–32,907,350. Amplicon generation PCR was as for the initial FLX assay 
with the exception of a 5 s extension per cycle. Repeat assays were performed for 
HIV−, HIV+/NRTI+ and POLG subjects (n = 4 each). Amplicons were additionally 
generated from cloned DNA fragments (MT-HV2 clone, nt 16,548 to nt 771; MT-
CO3 clone, nt 9,127 to nt 9,661; BRCA2 clone, 32,906,828–32,907,480; cloned in 
pGEM-T-Easy vector, Promega). An analysis pipeline of PyroBayes and Mosaik 
(Quinlan et al., 2008) was used to call and align bases from the 454 flowgram output. 
Subsequent analysis of variants was done in R using the custom made R library 
flowgram (available from the authors I.W. and M.S.K.). For comparison of samples 
with varying coverage depths, 5,000 sub-sampled sequences were used for all samples 
in all analyses. Recent studies of low-level variance in mtDNA using next-generation 
sequencing by synthesis technology have employed the Illumina GA platforms (He et 
al., 2010). Experience to date suggests that this approach appears limited to a resolution 
of ~1–1.5% variant frequency or higher, below which true variance cannot be 
distinguished from noise, despite very high theoretical read depths. In order to improve 
on this depth of resolution, we filtered the raw FLX flowgram output for sites predicted 
to give poor resolution. As FLX resequencing employs pyrosequencing technology, it is 
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prone to sequencing errors associated with mononucleotide tracts. Analysis of our 
outputs from cloned DNA confirmed this observation, and such sites were excluded 
from further analysis. Such an approach enabled resolution to variants with measured 
frequency ≥0.2%, whereby there was negligible variance detected in any cloned DNA 
amplicon or the nuclear (BRCA2) amplicon from genomic DNA at this level (~0.5% of 
base positions). Comparison with mtDNA amplicon sequence variants from patient 
samples thus indicated that almost all low frequency variants (>0.2%) reflect true 
sequence variation rather than noise. Power calculations indicate that this assay will 
have 80% power to detect an absolute increase in mutation burden of 2.7% at P < 0.05. 
 
Modeling of NRTI effects on mtDNA replication 
Modeling was performed by development of a validated simulation model of mtDNA 
replication and age-associated clonal expansion of mtDNA mutations based solely on 
experimentally derived parameters (Elson et al., 2001). The effect of NRTIs on mtDNA 
replication was modeled by including a probability of failure for each replication event. 
In the case of a replication failure, the mtDNA molecule being copied was assumed to 
be destroyed. With this assumption, any failure rate of 50% or greater results in the 
complete loss of the mtDNA from the simulation. De novo mutations were modeled by 
including a probability of mutation formation at each replication event, with a 
probability of 5 × 10
−5 
per replication, which was kept constant across all simulated 
exposure groups. The de novo mutation rate was set at this value in order to keep the 
probability of forming clonal expansions below 1% before age 70 in the control case. 
Other relevant parameter values were the optimal mtDNA copy number (Nopt = 5,000), 
the mtDNA half life (10 days) and the maximum proliferation factor (α = 15). Two-
thousand cells were simulated to measure the probability of developing clonal 
expansions of mtDNA mutations. Simulated cells which fixed on the mutant (a very 
rare occurrence) were removed from the model. The simulation was written in 
FORTRAN and is available from the author (DCS). 
 
Statistical analyses 
Percentage levels of COX defect were compared between groups (≥500 fibers per 
subject) by Mann-Whitney test. Comparison of proportions of COX-deficient and 
normal fibers showing mtDNA deletions was made by χ2 test. Comparison of mean 
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log10(mtDNA) content and log10(CD/mtDNA) levels in skeletal muscle homogenates 
was made using a t test. Statistical comparisons were performed using R. The multiple 
regression models were run in Origin 7 (OriginLab). 
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Figure 1: COX (cytochrome c oxidase) deficiency in single skeletal muscle fibers. 
(a) COX histochemistry from a representative healthy control subject (HIV−) showing 
normal COX activity, whereas a nucleoside analog treated HIV-infected patient 
(HIV+/NRTI+) shows multiple COX-deficient fibers (counterstained blue by residual 
SDH (succinate dehydrogenase) activity). Scale bars, 100 μm. (b) COX defects 
observed in each subject group (HIV+/NRTI−, HIV-infected treatment-naïve subjects; 
each dot represents an individual patient biopsy; ≥500 fibers sampled per biopsy). 
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Figure 2: Mitochondrial DNA analysis of single skeletal muscle fibers. 
(a) Mitochondrial DNA (mtDNA) content in individual COX (cytochrome c oxidase)-
deficient muscle fibers from nucleoside analog treated HIV-infected (HIV+/NRTI+) 
subjects, expressed relative to mtDNA content in adjacent fibers of normal COX 
activity from the same subject. A few fibers show reduced mtDNA content, whereas the 
majority show increased content (geometric mean of 2.1-fold proliferation, maximum 
21.3-fold; P < 0.001 for difference in mean mtDNA content between COX-deficient 
and normal fibers). (b) The majority of COX-deficient fibers (COX−) contained high 
percentage levels of mtDNA containing a large-scale deletion of the major arc, causing 
the COX defect; whereas no deleted mtDNA was detected in adjacent COX positive 
fibers (COX+) (P < 0.001). (c) Schematic representation of mtDNA large-scale deletion 
breakpoints in COX-deficient fibers from HIV+/NRTI+ patients relative to the mtDNA 
gene positions (transfer RNA and ribosomal RNA not shown). Each line represents an 
individual deleted region. OL, origin of light chain replication; OH, origin of heavy chain 
replication. (n = 15 fibers from four patients). 
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Figure 3: Proportional level of mt.δ4977 'common deletion' (CD) in homogenized 
skeletal muscle from HIV-infected subjects. 
HIV+/NRTI+, HIV-infected, nucleoside analog exposed; HIV+/NRTI−, HIV-infected, 
treatment-naïve. The dashed line represents the lower threshold of the assay. NRTI-
treated subjects showed significantly higher mean levels of common deletion than 
untreated subjects (HIV+/NRTI+ (mean ± s.e.m.), −3.45 ± 0.25 log10(/mtDNA); 
HIV+/NRTI−, −4.56 ± 0.31 log10(/mtDNA); P = 0.012). Box and whisker plot. 
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Figure 4: Ultra-deep re-sequencing by synthesis (UDS) of skeletal muscle mtDNA. 
UDS (Roche 454 FLX GS) shows no difference in burden of low-level mtDNA point 
variants (exceeding 0.2% frequency) between HIV-infected nucleoside analog treated 
(HIV+/NRTI+, n = 8), HIV-infected treatment-naïve (HIV+/NRTI−, n = 4) and control 
(HIV−, n = 4) subjects in two amplicons located in mtDNA hypervariable segment 2 
(MT-HV2) and mtDNA COX subunit 3 (MT-CO3). In contrast, positive control subjects 
with inherited POLG defects (POLG, n = 4) show an increased burden of low-level 
mutations compared with healthy controls in MT-HV2 (OR = 2.33, P = 0.002). 
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Figure 5: Simulations of the effects of partial mitochondrial DNA (mtDNA) 
replication failure caused by nucleoside analog (NRTI) exposure. 
Using a validated computer model of mtDNA replication based solely on 
experimentally derived parameters
22
, we incorporated a finite period of partial 
replication failure caused by the mtDNA chain-terminating effects of NRTI exposure
9
, 
assigning a probability of failure per mtDNA replication event. All other parameters 
remained constant, including the de novo mutation rate
22
. We simulated 2,000 cells for 
80 years. (a) The amount of mtDNA depletion during the NRTI exposure period caused 
by 25% and 45% probability of replication failure between 20 and 30 years of age. 
(>50% failure led to the complete loss of mtDNA.) The range of mtDNA depletion 
predicted is in keeping with published in vivo data
12, 23
. (b) This led to a persistent 
increase in the frequency of COX (cytochrome c oxidase)-deficient cells through the 
accelerated clonal expansion of preexisting somatic mtDNA mutations. (c) Direct 
simulation of the effects of NRTI exposure within our study population (two different 
periods, 10 and 3 years, starting at age 20, of replication failure with 45% probability). 
The range of COX defects predicted closely fits our empiric data. (d) Late exposure 
(40–50 years) had a more pronounced effect than early exposure (20–30 years) (with 
45% probability of replication failure) caused by the higher number of preexisting (age-
related) somatic mtDNA mutations at the time of exposure. 
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Supplementary Information 
Supplementary Figure 1. Predicted COX defect according to cumulative NRTI 
exposure. Multivariate linear regression model of predicted percentage COX 
(cytochrome c oxidase) defects in skeletal muscle fibers from HIV-infected subjects, 
according to cumulative exposure to specific nucleoside analog anti-retroviral drugs 
(NRTIs). The inclusion in the model of cumulative (lifetime) exposure to those NRTIs 
implicated in perturbation of mtDNA replication (ddI, didanosine; ddC, zalcitabine; 
AZT, zidovudine; d4T, stavudine) was sufficient to explain 87% of the observed 
variation in COX defects (R = 0.93). Equation of regression line = A + TddI BddI + TddC 
BddC + TAZT BAZT + Td4T Bd4T. T, duration of exposure (months). Coefficients: constant 
(A) = -0.459 ± 0.530; BddI = 0.107 ± 0.017; BddC = 0.093 ± 0.023; BAZT = 0.011 ± 0.007; 
Bd4T = 0.017 ± 0.013. ddI (p < 0.001) and ddC (p = 0.001) were independently 
significantly associated with the proportion of COX deficient fibers. The p value for the 
model fit to the data is < 0.001. 
 
 
  
79 
 
Supplementary Figure 2. MtDNA content in homogenized skeletal muscle. Relative 
mitochondrial DNA (mean log10 (mt/nDNA) ±SEM) content in homogenized skeletal 
muscle. HIV-, uninfected controls (n=10; 3.17 ±0.06); HIV+/NRTI-, treatment-naïve 
(n=11; 3.15 ±0.05); HIV+/NRTIc, currently treated with relevant nucleoside analog 
drug (n=14, all with AZT (zidovudine) exposure only; 3.22 ±0.05); HIV+/NRTIp, prior 
(but not current) exposure to relevant NRTIs (n=6, with prior AZT, d4T (stavudine), ddI 
(didanosine) and / or ddC (zalcitabine) exposure; 3.31 ±0.07). There was therefore no 
evidence of persistent mtDNA depletion in HIV+/NRTIp subjects, in fact previously 
treated patients showed a trend towards higher mean mtDNA content compared with 
HIV+/NRTI- (p = 0.079). 
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Supplementary Figure 3. Determination of experimental noise in UDS assay. 
Demonstration of low level of background noise in ultra-deep re-sequencing-by-
synthesis (UDS, Roche 454 GS FLX) assay by study of autosomal genomic DNA 
(BRCA2 amplicon) and cloned DNA (mtDNA hypervariable segment 2, MT-HV2; 
mtDNA COX subunit 3, MT-CO3; and BRCA2). Very few base positions (0.5% of 
total) demonstrate >0.2% variance frequency on UDS assay, confirming low intrinsic 
background noise, as well as no systematic difference in noise between autosomal and 
mtDNA amplicons. 
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Supplementary Figure 4. UDS replication experiment. Ultra-deep re-sequencing-by-
synthesis (UDS) replication experiment (Roche 454 GS FLX Titanium). Comparison of 
point mutation burden (>0.2% variant frequency) in skeletal muscle DNA extract from 
HIV-uninfected controls (HIV-), NRTI-treated HIV-infected (HIV+/NRTI+) subjects 
and patients with inherited defects of POLG (n=4 each) as well as cloned DNA. Two 
amplicons were located in mtDNA hypervariable segment 2 (MT-HV2) and mtDNA 
COX subunit 3 (MT-CO3). Subjects with inherited POLG defects show increased 
burden of low-level mutations compared with healthy controls in MT-HV2 (OR 2.00, p 
=0.001), whereas HIV+/NRTI+ subjects do not.
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Supplementary Table 1. Subject demographic and treatment details.  
NRTI, history of nucleoside analogue reverse transcriptase inhibitor exposure; ART, 
anti-retroviral therapy; LDS, anti-retroviral-associated lipodystrophy syndrome. 
Polymerase γ inhibiting NRTIs: AZT, zidovudine; d4T, stavudine; ddI, didanosine; 
ddC, zalcitabine. Other ART: 3TC, lamivudine; FTC, emtricitabine; ABC, abacavir; 
TDF, tenofovir; NVP, nevirapine; EFV, efavirenz; SQV, saquinavir; IDV, indinavir; 
NFV, nelfinavir; RTV, ritonavir (therapeutic dosing); /r, ritonavir (pharmacokinetic 
boosting dosing); ATV, atazanavir; LPV, lopinavir; RAL, raltegravir. COX defect, 
proportion of cytochrome c oxidase deficient skeletal muscle fibers. 
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Supplementary Table 2. MtDNA deletion break-points in single muscle fibers 
Sequence break-points for large scale mitochondrial DNA (mtDNA) deletions identified in individual COX (cytochrome c oxidase) deficient skeletal 
muscle fibers from nucleoside analog (NRTI) treated, HIV-infected subjects. Deletion shown as nucleotide positions (rCRS) and size of sequence 
overlap (where present). Bracketed nucleotides, sequence overlap (where repeat appears once only in the deleted molecule); bold italic nucleotides, 
partial mismatch in overlap sequences. 
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Subject Deletion Size Flanking sequence 
18 8145-8-14379 6243bp AAACCACTTT(CACCGCTA)-(CATCGCTA)ACCCCACTAAAA 
18 8246---14603 6358bp AAAAATCTTTGA-AGGCTTAGAAGAAAA 
18 9924-2-16070 6149bp CGAAGCCGCCG(CC)-(CC)CATCAACAACCG 
18 8718---14298 5581bp TACACAACACTAA-TATTCAGCTTCCTA 
18 8483-13-13446 4977bp AAACTACCACCT(ACCTCCCTCACCA)-(ACCTCCCTCACCA)TTGGCAGCCTAGCA 
18 9011-12-14931 5933bp AGCCCTGGCCGT(ACGCCTAACCGC)-(ACGCCTCAACCGC)CTTTTCATCAATC 
18 7376---13406 6031bp AACCCTCCATAAA-AAAAATAGGAGGACT 
20 7106-11-12082 4988bp ATTCACTGATT(TCCCCTATTCT)-(TCCCCCATTCT)CCTCCTATCCC 
20 7960-12-14481 6534bp TTCAACTCCTA(CATACTTCCCCC)-(CATCATTCCCCC)TAAATAAATTAAAAAAA 
15 7129-14-13991 6877bp TCAGGCTACAC(CCTAGACCAAACCT)-(CCTAGACCTAACCT)GACTAGAAAA 
15 8035-11-11422 3399bp TACTCCCGATT(GAAGCCCCCAT)-(GAAGCCCCCAT)CGCTGGGTCAATA 
12 8483-13-13446 4977bp AAACTACCACCT(ACCTCCCTCACCA)-(ACCTCCCTCACCA)TTGGCAGCCTAGCA 
12 6942---14816 7875bp AGGATTCATCTTTC-CATCCAACATCTCC 
12 6071---12499 6429bp CCACATCTACAACGTT-TGTGCCTAGACCAAGAA 
12 8936---16070 7135bp CACCTACACCCC-CCCATCAACAACC 
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Supplementary Table 3. UDS (Roche 454 FLX GS) outputs.  
Variance and read depth detected at individual base positions in mtDNA hypervariable 
segment 2 (MT-HV2), COX subunit 3 (MT-CO3) and autosomal (BRCA2) amplicons, 
for skeletal muscle DNA extracts from HIV-infected NRTI-treated subjects 
(HIV+/NRTI+, n=8), HIV-infected untreated subjects (HIV+/NRTI-, n=4), HIV-
uninfected healthy controls (HIV-, n=4), subjects with POLG defects (POLG, n=4) and 
cloned DNA.  
 
Raw 454 Flowgram output is available from the authors. 
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Supplementary Table 4. Primers. 
All mitochondrial nucleotide positions refer to revised Cambridge Reference Sequence 
(rCRS, NC_012920). 
 
Long-range PCR from single skeletal muscle fibers 
Primary PCR: forward primer, nt5855-5875 (AGATTTACAGTCCAATGCTTC);  
reverse primer, nt129-110 (AGATACTGCGACATAGGGTG). 
Secondary PCR: forward primer, nt6358-6377 (TAGCAGGTGTCTCCTCTATC);  
reverse primer, nt20-1 (AGGGTGATAGACCTGTGATC). 
 
Real-time PCR from skeletal muscle homogenate and single fibers 
B2M (nuclear):forward primer, nt9145-9166 (CACTGAAAAAGATGAGTATGCC);  
reverse primer, nt9375-9357 (AACATTCCCTGACAATCCC). 
MT-ND1:  forward primer, nt3458-3481 (ACGCCATAAAACTCTTCACCAAAG);  
reverse primer, nt3569-3546 (GGGTTCATAGTAGAAGAGCGATGG). 
MT-ND4:  forward primer, nt11144-11165 (ACCTTGGCTATCATCACCCGAT);  
reverse primer, nt11250-11230 (AGTGCGATGAGTAGGGGAAGG). 
CD:  forward primer, nt8393-8414 (CCCACCATAATTACCCCCATAC) 
  rev. primer, nt13509-13486 (GGAGTAGAAACCTGTGAGGAAAGG) 
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Whole mtDNA genome sequencing from single skeletal muscle fibers 
Primary PCR     nt 
AF GCTCACATCACCCCATAAAC           627-646 
AR  CTCGTCTTGCTGTGTTATGC        2721-2702 
BF ACCAACAAGTCATTATTACCC         2395-2415 
BR  ATACTTGATGGCAGCTTCTG        4646-4627 
CF  GTCAGCTAAATAAGCTATCGG     4408-4428 
CR GGACGGATCAGACGAAGAG            6468-6450 
DF AATACCCATCATAATCGGAGG         6113-6133 
DR GGTGATGAGGAATAGTGTAAG       8437-8417 
EF TCAATGCTCTGAAATCTGTGG          8167-8187 
ER TCGAAGCCGCACTCGTAAG            10183-10165 
FF  CTATTGATGAGGGTCTTACTC       9974-9994 
FR  GAGCTTTCTCGGTAAATAAGG    12216-12196  
GF  CTGTGCTAGTAACCACGTTC     11898-11917 
GR GGTAGAATCCGAGTATGTTGG        13924-13904 
HF TATTCGCAGGATTTCTCATTAC        13721-13742 
HR GTGCTAATGGTGGAGTTAAAG        15989-15969 
IF CCCATCCTCCATATATCCAAAC         15659-15680 
IR   TCACTGCTGTTTCCCGTGG           823 -805 
 
  
94 
 
Secondary PCR 
Forward primers with M13 tag for cycle sequencing (TGTAAAACGACGGCCAGT) 
1F TGTAAAACGACGGCCAGTTCACCCTCTAAATCACCACG           721-740 
2F TGTAAAACGACGGCCAGTTTAAAACTCAAAGGACCTGGC      1157-1177 
3F TGTAAAACGACGGCCAGTAACTTAACTTGACCGCTCTGAG    1650-1671 
4F TGTAAAACGACGGCCAGTACTGTTAGTCCAAAGAGGAAC       2091-2111 
5F TGTAAAACGACGGCCAGTCAGTGACACATGTTTAACGGC       2549-2569 
6F TGTAAAACGACGGCCAGTCAGCCGCTATTAAAGGTTCG         3017-3036 
7F TGTAAAACGACGGCCAGTACCATCACCCTCTACATCAC          3505-3524 
8F TGTAAAACGACGGCCAGTTCGCCCTATTCTTCATAGCC          3965-3984 
9F TGTAAAACGACGGCCAGTACACTCATCACAGCGCTAAG         4518-4537 
10F TGTAAAACGACGGCCAGTCTCACTCTCTCAATCTTATCC      4932-4952 
11F TGTAAAACGACGGCCAGTACCTCAATCACACTACTCCC        5367-5386 
12F TGTAAAACGACGGCCAGTAGATTTACAGTCCAATGCTTC      5855-5875 
13F TGTAAAACGACGGCCAGTTAGCAGGTGTCTCCTCTATC        6358-6377 
14F TGTAAAACGACGGCCAGTATTTAGCTGACTCGCCACAC        6863-6882 
15F TGTAAAACGACGGCCAGTGGCTCATTCATTTCTCTAACAG    7272-7293 
16F TGTAAAACGACGGCCAGTTCCTAACACTCACAACAAAAC      7713-7723 
17F TGTAAAACGACGGCCAGTACAGTTTCATGCCCATCGTC        8196-8215 
18F TGTAAAACGACGGCCAGTACCACCCAACAATGACTAATC      8656-8676 
19F TGTAAAACGACGGCCAGTATCCTAGAAATCGCTGTCGC        9127-9146 
20F TGTAAAACGACGGCCAGTCATCCGTATTACTCGCATCAG      9607-9627 
21F TGTAAAACGACGGCCAGTCAACACCCTCCTAGCCTTAC       10085-10104 
22F TGTAAAACGACGGCCAGTATCGCTCACACCTCATATCC        10534-10553 
23F TGTAAAACGACGGCCAGTTATCCAGTGAACCACTATCAC     11010-11030 
24F TGTAAAACGACGGCCAGTTCCTTGTACTATCCCTATGAG      11541-11561 
25F TGTAAAACGACGGCCAGTCTCCCTCTACATATTTACCAC       11977-11997 
95 
 
26F TGTAAAACGACGGCCAGTCTCTTCCCCACAACAATATTC      12478-12498 
27F TGTAAAACGACGGCCAGTGCCCTTCTAAACGCTAATCC        12940-12959 
28F TGTAAAACGACGGCCAGTCGGGTCCATCATCCACAAC          13365-13383 
29F TGTAAAACGACGGCCAGTACCTAAAACTCACAGCCCTC        13790-13809 
30F TGTAAAACGACGGCCAGTATTAAAGTTTACCACAACCACC    14317-14341 
31F TGTAAAACGACGGCCAGTATTCATCGACCTCCCCACC          14797-14815 
32F TGTAAAACGACGGCCAGTCATCTTGCCCTTCATTATTGC       15295-15315 
D1F TGTAAAACGACGGCCAGTATCGGAGGACAACCAGTAAG       15758-15777 
D2F TGTAAAACGACGGCCAGTCTCAACTATCACACATCAACTG  16223-16244 
D3F TGTAAAACGACGGCCAGTCCTTAAATAAGACATCACGATG  16548-16569 
D4F TGTAAAACGACGGCCAGTGCCACAGCACTTAAACACATC      323-343 
 
Reverse primers with M13 tag (CAGGAAACAGCTATGACC)   
1R CAGGAAACAGCTATGACCGATGGCGGTATATAGGCTGAG        1268-1248 
2R CAGGAAACAGCTATGACCCTGGTAGTAAGGTGGAGTGGG        1709-1689 
3R CAGGAAACAGCTATGACCATTGGTGGCTGCTTTTAGG               2193-2175 
4R CAGGAAACAGCTATGACCTCGTGGAGCCATTCATACAG            2644-2625 
5R CAGGAAACAGCTATGACCGATTACTCCGGTCTGAACTC             3087-3068 
6R CAGGAAACAGCTATGACCGGAGGGGGGTTCATAGTAG              3374- 3356 
7R CAGGAAACAGCTATGACCAGAGTGCGTCATATGTTGTTC           4057-4037 
8R CAGGAAACAGCTATGACCGTTTATTTCTAGGCCTACTCAG         4577-4556 
9R CAGGAAACAGCTATGACCGATTTTGCGTAGCTGGGTTTG           5003-4983 
10R CAGGAAACAGCTATGACCTGTAGGAGTAGCGTGGTAAGG       5481-5462 
11R CAGGAAACAGCTATGACCTAGTCAACGGTCGGCGAAC             5924-5906 
12R CAGGAAACAGCTATGACCATGGCAGGGGGTTTTATATTG         6430-6410 
13R CAGGAAACAGCTATGACCAAGAAAGATGAATCCTAGGGC       6944-6924 
14R CAGGAAACAGCTATGACCCATCCATATAGTCACTCCAGG         7396-7376 
96 
 
15R CAGGAAACAGCTATGACCGGCAGGATAGTTCAGACGG            7791-7773 
16R CAGGAAACAGCTATGACCTACAGTGGGCTCTAGAGGG             8301-8283 
17R CAGGAAACAGCTATGACCGTATAAGAGATCAGGTTCGTC        8740-8720 
18R CAGGAAACAGCTATGACCGTTGTCGTGCAGGTAGAGG             9201-9183 
19R CAGGAAACAGCTATGACCATTAGACTATGGTGAGCTCAG        9661-9641 
20R CAGGAAACAGCTATGACCTAGCCGTTGAGTTGTGGTAG        10147-10128 
21R CAGGAAACAGCTATGACCAGGCACAATATTGGCTAAGAG    10649-10629 
22R CAGGAAACAGCTATGACCATGATTAGTTCTGTGGCTGTG      11109-11089 
23R CAGGAAACAGCTATGACCTAGGTCTGTTTGTCGTAGGC         11605-11586 
24R CAGGAAACAGCTATGACCCGTGTGAATGAGGGTTTTATG     12054-12034 
25R CAGGAAACAGCTATGACCGTGGCTCAGTGTCAGTTCG           12545-12527 
26R CAGGAAACAGCTATGACCCTGATTTGCCTGCTGCTGC            13009-12991 
27R CAGGAAACAGCTATGACCGGGAGGTTGAAGTGAGAGG         13453-13435 
28R CAGGAAACAGCTATGACCGTTAGGTAGTTGAGGTCTAGG     13859-13839 
29R CAGGAAACAGCTATGACCAGGATTGGTGCTGTGGGTG          14374-14356 
30R CAGGAAACAGCTATGACCAAGGAGTGAGCCGAAGTTTC       14857-14838 
31R CAGGAAACAGCTATGACCGGTTGTTTGATCCCGTTTCG         15368-15349 
32R CAGGAAACAGCTATGACCTACAAGGACAGGCCCATTTG       15896-15877 
D1R CAGGAAACAGCTATGACCAGGGTGATAGACCTGTGATC           19-1 
D2R CAGGAAACAGCTATGACCAGATACTGCGACATAGGGTG          129-110 
D3R CAGGAAACAGCTATGACCCTGGTTAGGCTGGTGTTAGG            389-370 
D4R CAGGAAACAGCTATGACCTGCTGCGTGCTTGATGCTTG             771-752 
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Amplicon generation for ultra-deep sequencing-by-synthesis (454 GS FLX) 
Primers comprised a sequence-specific segment, a barcode, and a fusion primer 
segment. 
Sequence-specific segments 
MT-HV2: forward, nt162-184 (CGCACCTACGTTCAATATTACAG) 
reverse, nt455-434 (AAAATAATGTGTTAGTTGGGGG) 
MT-CO3: forward, nt9307-9329 (GATTTCACTTCCACTCCATAACG) 
reverse, nt9591-9572 (CTTCTAGGGGATTTAGCGGG)  
Fusion primer segments 
Forward:  GCCTCCCTCGCGCCATCAG 
Reverse:  GCCTTGCCAGCCCGCTCAG 
Barcode segments 
1  AAGGAAGGT 
2  TTAAGGACT 
3  TAAGGCCGT 
4  TTAAGTAAT 
5  TAAGTACGT 
6  AAGTCCGGT 
7  TAATTAAGT 
8  AATTACGGT 
9  TTAATTACT 
10  TTACGGAAT 
11  TACGGACGT 
12  ACGGCCGGT 
13  TACGTAAGT 
14  ACGTACGGT 
15  TTACGTCCT 
 
16  ACTTAAGGT 
17  TTACTTACT 
18  TACTTCCGT 
19  TCCGGAAGT 
20  CCGGACGGT 
21  TTCCGGCCT 
22  CCGTAAGGT 
23  TTCCGTACT 
24  TCCGTCCGT 
25  TTCCTTAAT 
26  TCCTTACGT 
27  CCTTCCGGT 
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Amplicon generation for ultra-deep sequencing-by-synthesis (454 GS FLX Titanium) 
Primers comprised a sequence-specific segment, a barcode, and a fusion primer 
segment. 
 
Sequence-specific segments 
HVS2:  forward, nt.109-130 (GCACCCTATGTCGCAGTATCTG) 
reverse, nt.483-458 (GAGATTAGTAGTATGGGAGTGGGAGG) 
CO3:  forward, nt.9304-9329 (TGTGATTTCACTTCCACTCCATAACG) 
reverse, nt.9653-9629 (ATGGTGAGCTCAGGTGATTGATACT) 
 
Barcode segments 
1  ACGAGTGCGT 
2  ACGCTCGACA 
3  AGACGCACTC 
4  AGCACTGTAG 
 
Fusion primer segments 
Forward:  CGTATCGCCTCCCTCGCGCCATCAG 
Reverse:  CTATGCGCCTTGCCAGCCCGCTCAG 
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Supplementary Note.  
Clinical Data 
All subjects were aged 50 years or below as no COX defect would be expected in 
skeletal muscle of healthy individuals in this age group (Brierley et al., 1996). All 
subjects gave informed consent to participation in the study. HIV-infected subjects were 
classified based on cumulative (lifetime) anti-retroviral drug exposure as HIV-infected, 
treatment naïve (HIV+/NRTI-) or as nucleoside analogue exposed (HIV+/NRTI+). We 
predicted that those NRTIs documented to disrupt mtDNA replication through pol γ 
inhibition may affect somatic mtDNA mutation  (Lim and Copeland, 2001; Martin et 
al., 2003). Therefore all HIV+/NRTI+ subjects studied had history of exposure to at 
least one of the following NRTIs: zidovudine (AZT), stavudine (d4T), didanosine (ddI) 
and / or zalcitabine (ddC). Full subject treatment histories are presented in 
Supplementary Table 1. HIV-infected subjects were unselected with respect to the 
presence or absence of clinical complications of anti-retroviral therapy. Subjects with 
history of (non-HIV-related) neuromuscular disease, diabetes mellitus or chronic viral 
hepatitis were specifically excluded.  
 
Lower limb skeletal muscle biopsies from HIV-infected subjects were obtained under 
local anesthesia. Open biopsies were obtained from HIV-uninfected control subjects 
(HIV-) at the time of elective orthopedic surgery. Samples were snap-frozen in the 
liquid phase of isopentane, cooled by liquid nitrogen, within 20 minutes of sampling.  
 
Four patients with inherited defects of POLG were used as positive controls for UDS 
assay. Two of these patients (both 56 year old females) carried a compound 
heterozygous mutation, R627Q / W748S; one patient (17 year old male) carried 
compound heterozygous mutation, R627Q / R1096H; and one patient (45 year old 
female) carried homozygous A467T. All POLG patients showed minimal histochemical 
COX defects. 
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CO3 coverage
POLG1 POLG1 POLG1 POLG1 HIV+/NRTI- HIV+/NRTI- HIV+/NRTI- HIV+/NRTI- HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV- HIV- HIV- HIV- clone
Subject P1 P2 P3 P4 29 23 32 25 17 20 18 16 7 12 15 5 35 38 37 39
CO3 seq CO3 pos
C 9330 20803 17644 18604 14397 15644 18614 15798 18509 10821 13209 15351 14770 15913 16186 14094 16544 17523 15913 15166 18460 12278
T 9331 20803 17644 18604 14397 15645 18614 15799 18509 10821 13209 15351 14770 15913 16187 14094 16544 17525 15913 15166 18460 12278
C 9332 20803 17644 18604 14397 15646 18614 15799 18509 10821 13209 15351 14770 15913 16187 14094 16544 17525 15913 15166 18460 12278
C 9333 20803 17644 18604 14397 15646 18614 15799 18509 10821 13209 15351 14770 15913 16187 14094 16544 17525 15913 15166 18460 12278
T 9334 20803 17644 18604 14397 15646 18614 15799 18509 10821 13209 15351 14770 15913 16187 14094 16544 17525 15913 15166 18461 12278
C 9335 20803 17644 18604 14397 15646 18614 15799 18509 10822 13209 15351 14770 15913 16187 14094 16544 17525 15913 15166 18461 12278
A 9336 20804 17644 18605 14397 15646 18614 15799 18511 10822 13209 15351 14770 15913 16187 14094 16544 17525 15913 15166 18461 12278
T 9337 20805 17644 18605 14397 15646 18614 15799 18511 10822 13209 15351 14770 15913 16187 14094 16544 17525 15913 15166 18461 12278
A 9338 20805 17644 18606 14397 15646 18614 15799 18511 10822 13209 15351 14770 15913 16187 14094 16544 17525 15913 15167 18461 12278
C 9339 20805 17644 18606 14397 15647 18614 15799 18511 10822 13209 15351 14770 15913 16187 14094 16544 17525 15913 15167 18461 12278
T 9340 20805 17644 18606 14397 15647 18614 15799 18511 10822 13209 15351 14770 15913 16187 14094 16544 17525 15913 15167 18461 12278
A 9341 20805 17644 18607 14397 15647 18614 15799 18511 10822 13209 15351 14770 15913 16187 14094 16544 17525 15913 15167 18461 12278
G 9342 20805 17644 18607 14398 15647 18614 15799 18511 10823 13209 15351 14770 15913 16188 14094 16544 17526 15913 15167 18461 12278
G 9343 20805 17644 18608 14398 15647 18614 15799 18511 10824 13209 15351 14770 15913 16188 14094 16544 17526 15913 15168 18461 12278
C 9344 20805 17644 18608 14398 15648 18615 15799 18511 10824 13210 15351 14770 15913 16188 14094 16544 17526 15914 15168 18461 12278
C 9345 20805 17644 18608 14398 15648 18615 15799 18511 10824 13210 15351 14770 15913 16188 14094 16544 17526 15914 15168 18461 12278
T 9346 20805 17644 18608 14398 15648 18615 15800 18511 10824 13210 15352 14770 15913 16188 14094 16544 17526 15914 15168 18461 12278
A 9347 20805 17644 18608 14398 15648 18615 15800 18511 10824 13210 15352 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
C 9348 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15352 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
T 9349 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15352 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
A 9350 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
A 9351 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
C 9352 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
C 9353 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
A 9354 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
A 9355 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
C 9356 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
A 9357 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
C 9358 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
A 9359 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
C 9360 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
T 9361 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
A 9362 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
A 9363 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
C 9364 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16188 14094 16544 17526 15915 15168 18461 12278
C 9365 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17526 15915 15168 18461 12278
A 9366 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18461 12278
T 9367 20805 17644 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18461 12278
A 9368 20805 17645 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18461 12278
T 9369 20805 17645 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18461 12278
A 9370 20805 17645 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18461 12278
C 9371 20805 17645 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18461 12278
C 9372 20805 17645 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18461 12278
A 9373 20805 17645 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18461 12278
A 9374 20805 17645 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18461 12278
T 9375 20805 17645 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18462 12278
G 9376 20805 17645 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18462 12278
A 9377 20805 17645 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18462 12278
T 9378 20805 17645 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18462 12278
G 9379 20805 17645 18608 14398 15648 18615 15800 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18462 12278
G 9380 20805 17645 18608 14398 15648 18615 15801 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18462 12278
C 9381 20805 17645 18608 14398 15648 18615 15801 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18462 12278
G 9382 20805 17645 18608 14398 15648 18615 15801 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18462 12278
C 9383 20805 17645 18608 14398 15648 18615 15801 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18462 12278
G 9384 20805 17645 18608 14398 15648 18615 15801 18511 10824 13211 15354 14770 15913 16189 14094 16544 17527 15915 15168 18462 12278
A 9385 20805 17645 18608 14398 15648 18615 15801 18512 10824 13211 15354 14770 15913 16189 14094 16545 17527 15915 15168 18462 12278
T 9386 20805 17645 18608 14398 15648 18615 15801 18513 10824 13211 15354 14770 15913 16191 14094 16545 17527 15917 15168 18462 12278
G 9387 20805 17645 18608 14398 15648 18615 15801 18513 10824 13211 15354 14770 15913 16191 14094 16545 17527 15917 15168 18462 12278
T 9388 20805 17645 18608 14398 15648 18615 15802 18513 10826 13211 15354 14772 15913 16191 14094 16545 17528 15918 15168 18462 12278
A 9389 20806 17645 18608 14398 15648 18615 15803 18514 10826 13212 15357 14772 15913 16192 14094 16545 17529 15919 15169 18462 12278
A 9390 20806 17645 18608 14398 15648 18615 15803 18514 10826 13212 15357 14772 15913 16193 14094 16545 17529 15919 15169 18462 12278
C 9391 20806 17645 18608 14398 15648 18615 15804 18514 10826 13212 15358 14772 15913 16193 14094 16545 17530 15920 15169 18462 12278
A 9392 20806 17645 18608 14398 15648 18615 15804 18514 10826 13212 15358 14772 15913 16193 14094 16545 17530 15920 15169 18462 12278
C 9393 20806 17645 18608 14398 15648 18615 15804 18515 10826 13212 15358 14773 15913 16193 14094 16545 17530 15920 15169 18462 12278
G 9394 20806 17646 18608 14398 15648 18615 15807 18515 10827 13212 15359 14773 15913 16193 14094 16545 17530 15921 15169 18462 12278
A 9395 20808 17646 18608 14398 15648 18615 15807 18515 10827 13212 15359 14773 15913 16193 14094 16547 17530 15921 15169 18462 12278
G 9396 20808 17646 18608 14398 15648 18615 15807 18515 10827 13212 15359 14773 15913 16193 14094 16547 17530 15922 15169 18462 12278
A 9397 20808 17646 18608 14398 15649 18615 15807 18515 10827 13212 15359 14773 15913 16193 14094 16547 17530 15922 15169 18462 12278
A 9398 20809 17646 18608 14398 15649 18615 15807 18515 10827 13213 15359 14773 15913 16193 14094 16547 17530 15922 15169 18462 12278
A 9399 20809 17646 18608 14398 15649 18615 15808 18515 10827 13213 15359 14773 15913 16194 14094 16547 17530 15922 15169 18462 12278
G 9400 20809 17646 18609 14398 15649 18615 15808 18515 10827 13213 15359 14774 15913 16194 14094 16547 17530 15922 15169 18462 12278
C 9401 20809 17646 18610 14398 15649 18615 15808 18516 10828 13213 15359 14774 15913 16194 14095 16547 17530 15922 15169 18462 12278
A 9402 20809 17646 18610 14398 15649 18615 15808 18516 10828 13213 15359 14774 15913 16194 14095 16548 17530 15922 15169 18462 12278
C 9403 20809 17646 18610 14398 15649 18615 15809 18516 10828 13213 15359 14774 15913 16195 14096 16548 17530 15922 15169 18462 12278
A 9404 20810 17646 18610 14398 15649 18615 15809 18516 10828 13213 15359 14774 15913 16195 14096 16548 17530 15922 15169 18462 12278
T 9405 20810 17646 18610 14398 15649 18615 15809 18516 10829 13213 15359 14774 15913 16195 14096 16548 17530 15922 15169 18462 12278
A 9406 20810 17646 18610 14398 15649 18616 15809 18516 10829 13213 15359 14774 15913 16195 14096 16548 17530 15922 15169 18462 12278
C 9407 20811 17646 18610 14398 15649 18616 15809 18516 10829 13213 15359 14774 15913 16195 14096 16548 17530 15922 15169 18462 12278
C 9408 20811 17646 18610 14398 15649 18616 15809 18516 10829 13213 15359 14774 15913 16195 14096 16548 17530 15922 15169 18463 12278
A 9409 20811 17646 18610 14398 15649 18616 15809 18516 10829 13213 15359 14774 15913 16195 14096 16548 17530 15922 15169 18463 12278
A 9410 20811 17646 18610 14398 15649 18616 15809 18516 10829 13213 15359 14774 15913 16195 14096 16548 17530 15922 15169 18463 12278
G 9411 20811 17646 18610 14398 15649 18616 15809 18516 10829 13213 15359 14774 15913 16195 14096 16548 17530 15922 15169 18463 12278
G 9412 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16195 14096 16548 17530 15922 15169 18463 12278
C 9413 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18463 12278
C 9414 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18463 12278
A 9415 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18463 12278
C 9416 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18463 12278
C 9417 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18463 12278
A 9418 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18463 12278
C 9419 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18463 12278
A 9420 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18463 12278
C 9421 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
A 9422 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
C 9423 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
C 9424 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
A 9425 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
C 9426 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
C 9427 20811 17646 18610 14398 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
T 9428 20811 17646 18610 14399 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
G 9429 20811 17646 18610 14399 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
T 9430 20811 17646 18610 14399 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
C 9431 20811 17646 18610 14399 15649 18617 15809 18516 10829 13213 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
G 9439 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
C 9440 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
C 9441 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
T 9442 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
T 9443 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
C 9444 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
G 9445 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15913 16196 14096 16549 17530 15922 15169 18464 12278
A 9446 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
T 9447 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
A 9448 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
C 9449 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
G 9450 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
G 9451 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
G 9452 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
A 9453 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
T 9454 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
A 9455 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
A 9456 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
T 9457 20811 17646 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
C 9458 20811 17645 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
C 9459 20811 17645 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
T 9460 20811 17645 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
A 9461 20811 17645 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
T 9462 20811 17645 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
T 9463 20811 17645 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
T 9464 20811 17645 18610 14399 15649 18617 15809 18516 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
A 9465 20811 17645 18610 14399 15649 18617 15809 18515 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
T 9466 20811 17645 18610 14399 15649 18617 15809 18515 10829 13214 15359 14774 15914 16196 14096 16549 17530 15922 15169 18464 12278
T 9467 20811 17645 18610 14398 15649 18617 15809 18515 10829 13214 15359 14774 15914 16196 14096 16549 17529 15922 15169 18464 12278
A 9468 20811 17645 18610 14398 15649 18617 15809 18515 10829 13214 15359 14774 15914 16196 14096 16549 17529 15922 15169 18464 12278
C 9469 20811 17645 18610 14398 15649 18617 15809 18515 10829 13214 15359 14774 15914 16196 14096 16549 17529 15922 15169 18464 12278
C 9470 20811 17645 18609 14398 15649 18616 15809 18515 10827 13214 15359 14774 15914 16196 14094 16549 17529 15922 15169 18464 12278
T 9471 20811 17645 18609 14398 15649 18616 15809 18515 10827 13214 15359 14774 15914 16196 14094 16549 17529 15922 15169 18464 12278
C 9472 20811 17645 18609 14398 15649 18616 15809 18515 10827 13214 15359 14774 15914 16196 14094 16549 17529 15922 15169 18464 12278
A 9473 20811 17645 18609 14398 15649 18616 15809 18515 10827 13214 15359 14774 15914 16196 14094 16549 17529 15922 15169 18464 12278
G 9474 20811 17645 18609 14398 15649 18616 15809 18515 10827 13214 15359 14774 15914 16196 14094 16549 17529 15922 15169 18464 12278
A 9476 20811 17645 18609 14398 15649 18616 15809 18515 10827 13214 15359 14774 15914 16196 14094 16549 17529 15922 15169 18464 12278
T 9486 20810 17645 18609 14397 15649 18615 15809 18513 10827 13214 15359 14773 15914 16196 14094 16549 17528 15922 15169 18464 12278
T 9487 20810 17645 18609 14397 15649 18615 15809 18513 10827 13214 15359 14773 15914 16196 14094 16549 17528 15922 15169 18464 12278
C 9488 20810 17645 18609 14397 15649 18615 15809 18513 10827 13214 15359 14773 15914 16196 14094 16548 17528 15921 15169 18464 12278
G 9489 20810 17645 18609 14397 15648 18615 15809 18513 10827 13214 15359 14773 15914 16196 14094 16548 17528 15920 15169 18464 12278
C 9490 20810 17645 18609 14397 15648 18615 15808 18513 10827 13214 15359 14773 15914 16196 14094 16548 17528 15920 15169 18464 12278
A 9491 20810 17645 18609 14397 15648 18615 15808 18513 10827 13214 15359 14773 15914 16196 14094 16548 17528 15920 15169 18464 12278
G 9492 20810 17645 18608 14397 15647 18615 15808 18513 10827 13214 15359 14773 15914 16196 14094 16548 17528 15920 15169 18464 12278
G 9493 20810 17645 18608 14397 15647 18615 15808 18513 10827 13214 15359 14773 15914 16196 14094 16548 17528 15920 15169 18464 12278
T 9501 20809 17645 18608 14397 15646 18614 15807 18513 10827 13214 15358 14773 15912 16193 14094 16548 17527 15920 15168 18464 12278
G 9502 20809 17645 18608 14397 15646 18614 15807 18513 10827 13214 15358 14773 15912 16193 14094 16548 17527 15920 15168 18464 12278
A 9503 20809 17645 18608 14397 15646 18614 15807 18513 10827 13214 15358 14773 15912 16193 14094 16548 17527 15920 15168 18464 12278
G 9504 20809 17645 18608 14397 15646 18614 15807 18513 10827 13214 15358 14773 15912 16193 14094 16548 17527 15920 15168 18464 12278
C 9505 20809 17645 18608 14397 15646 18614 15807 18513 10827 13214 15358 14773 15912 16193 14094 16548 17527 15920 15168 18464 12278
C 9512 20809 17645 18608 14397 15646 18614 15807 18513 10827 13214 15358 14773 15912 16193 14094 16548 17527 15919 15168 18464 12278
C 9513 20808 17645 18608 14397 15646 18614 15807 18513 10827 13214 15358 14773 15912 16191 14094 16548 17527 15919 15167 18464 12278
A 9514 20808 17645 18608 14397 15646 18614 15807 18513 10827 13214 15358 14773 15912 16191 14094 16548 17527 15919 15167 18464 12278
C 9515 20808 17645 18608 14397 15646 18614 15807 18513 10827 13214 15358 14773 15912 16190 14092 16548 17527 15919 15167 18464 12278
T 9516 20808 17645 18608 14397 15646 18614 15807 18513 10827 13214 15358 14773 15912 16190 14092 16548 17527 15919 15167 18464 12278
C 9517 20808 17645 18608 14397 15646 18614 15806 18513 10827 13214 15358 14773 15912 16190 14092 16548 17527 15919 15167 18464 12278
C 9518 20808 17645 18608 14397 15646 18614 15806 18512 10827 13214 15358 14773 15912 16189 14092 16548 17526 15919 15167 18464 12278
A 9519 20808 17645 18608 14397 15646 18614 15806 18512 10827 13214 15358 14773 15912 16189 14092 16548 17526 15919 15167 18464 12278
G 9520 20808 17645 18608 14397 15646 18614 15806 18512 10827 13214 15358 14773 15912 16189 14092 16548 17526 15919 15167 18464 12278
C 9521 20808 17645 18608 14397 15646 18614 15806 18512 10827 13214 15358 14773 15912 16189 14092 16548 17526 15919 15167 18464 12278
C 9522 20808 17645 18608 14397 15646 18614 15806 18512 10827 13214 15358 14773 15912 16189 14092 16548 17526 15919 15167 18464 12278
T 9523 20808 17645 18608 14397 15646 18614 15806 18512 10827 13214 15358 14773 15912 16189 14092 16548 17526 15919 15167 18464 12278
A 9524 20808 17645 18608 14397 15646 18614 15806 18512 10827 13214 15358 14773 15912 16189 14092 16548 17526 15919 15167 18464 12278
T 9540 20808 17645 18608 14397 15646 18614 15806 18510 10827 13214 15357 14773 15912 16189 14092 16548 17526 15918 15167 18464 12278
T 9541 20808 17645 18608 14397 15646 18614 15806 18510 10827 13214 15357 14773 15912 16189 14092 16548 17526 15918 15167 18464 12278
A 9542 20808 17645 18608 14397 15646 18614 15806 18510 10827 13214 15357 14773 15912 16189 14092 16548 17526 15918 15167 18464 12278
G 9543 20808 17645 18608 14397 15646 18614 15806 18510 10827 13214 15357 14773 15912 16189 14092 16548 17526 15918 15167 18464 12278
G 9544 20808 17645 18608 14397 15646 18614 15806 18509 10827 13214 15357 14773 15912 16189 14091 16548 17526 15918 15167 18464 12278
A 9545 20808 17645 18608 14397 15646 18614 15806 18509 10827 13214 15357 14773 15912 16189 14091 16548 17526 15918 15167 18463 12278
G 9546 20808 17645 18608 14397 15646 18614 15806 18509 10827 13214 15357 14773 15912 16189 14091 16548 17526 15917 15167 18463 12278
G 9547 20808 17645 18608 14397 15646 18614 15806 18509 10826 13214 15357 14773 15912 16189 14091 16548 17526 15916 15167 18463 12278
G 9548 20808 17645 18607 14397 15646 18614 15806 18509 10826 13214 15357 14773 15912 16189 14091 16547 17526 15916 15167 18463 12278
C 9549 20808 17643 18606 14396 15646 18614 15806 18509 10826 13214 15357 14773 15912 16189 14091 16547 17525 15916 15167 18463 12278
A 9550 20808 17643 18606 14396 15646 18614 15806 18509 10826 13214 15357 14773 15912 16189 14091 16547 17525 15916 15167 18463 12278
C 9551 20808 17642 18606 14396 15646 18614 15806 18509 10826 13214 15357 14773 15912 16189 14091 16546 17525 15916 15167 18463 12278
T 9552 20808 17642 18606 14396 15646 18614 15806 18509 10826 13214 15357 14773 15912 16189 14091 16546 17525 15916 15167 18463 12278
G 9553 20808 17642 18606 14396 15646 18614 15806 18509 10826 13214 15357 14773 15912 16189 14091 16546 17525 15916 15167 18463 12278
A 9561 20806 17640 18603 14396 15640 18613 15804 18508 10826 13212 15355 14773 15911 16184 14091 16544 17523 15915 15166 18461 12278
C 9562 20806 17640 18601 14396 15640 18613 15803 18508 10825 13211 15355 14771 15911 16182 14090 16541 17523 15915 15166 18460 12278
A 9563 20806 17639 18601 14396 15640 18613 15802 18507 10825 13211 15355 14771 15911 16182 14090 16540 17522 15914 15165 18460 12278
G 9564 20806 17639 18600 14396 15640 18613 15802 18507 10825 13211 15355 14769 15911 16180 14090 16539 17522 15914 15165 18460 12278
G 9565 20806 17639 18599 14396 15639 18613 15801 18504 10825 13211 15355 14769 15909 16180 14089 16539 17521 15913 15165 18460 12278
C 9566 20806 17639 18599 14396 15639 18612 15801 18504 10823 13211 15355 14769 15909 16180 14088 16539 17521 15913 15165 18459 12278
A 9567 20806 17639 18598 14395 15638 18612 15801 18504 10823 13211 15354 14769 15909 16179 14088 16539 17521 15913 15165 18458 12278
T 9568 20803 17636 18596 14390 15637 18610 15801 18501 10823 13211 15354 14769 15906 16179 14088 16539 17518 15912 15165 18456 12278
C 9569 20790 17622 18569 14377 15632 18604 15799 18493 10820 13208 15351 14767 15898 16172 14083 16535 17506 15902 15164 18442 12278
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CO3 variants
POLG1 POLG1 POLG1 POLG1 HIV+/NRTI- HIV+/NRTI- HIV+/NRTI- HIV+/NRTI- HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV- HIV- HIV- HIV- clone
Subject P1 P2 P3 P4 29 23 32 25 17 20 18 16 7 12 15 5 35 38 37 39
CO3 seq CO3 pos
C 9330 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.02% 0.01% 0.01% 0.01% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01%
T 9331 0.02% 0.03% 0.01% 0.00% 0.02% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.02% 0.00% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.02%
C 9332 0.05% 0.03% 0.08% 0.04% 0.10% 0.12% 0.06% 0.01% 0.09% 0.06% 0.03% 0.03% 0.09% 0.10% 0.11% 0.04% 0.11% 0.08% 0.07% 0.03% 0.00%
C 9333 0.01% 0.01% 0.02% 0.00% 0.00% 0.01% 0.01% 0.02% 0.00% 0.04% 0.05% 0.01% 0.02% 0.01% 0.01% 0.02% 0.00% 0.01% 0.01% 0.01% 0.11%
T 9334 0.01% 0.01% 0.00% 0.01% 0.01% 0.02% 0.01% 0.01% 0.04% 0.01% 0.01% 0.00% 0.00% 0.01% 0.02% 0.01% 0.02% 0.03% 0.00% 0.01% 0.03%
C 9335 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00%
A 9336 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.02% 0.00% 0.01% 0.00% 0.00%
T 9337 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00%
A 9338 0.02% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.02% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.02% 0.02% 0.00% 0.01% 0.00% 0.01% 0.00%
C 9339 0.01% 0.05% 0.03% 0.01% 0.01% 0.01% 0.01% 0.03% 0.00% 0.02% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00%
T 9340 0.01% 0.01% 0.03% 0.01% 0.01% 0.01% 0.02% 0.00% 0.00% 0.00% 0.02% 0.00% 0.01% 0.02% 0.03% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
A 9341 0.02% 0.03% 0.05% 0.02% 0.07% 0.11% 0.06% 0.04% 0.14% 0.08% 0.04% 0.07% 0.06% 0.06% 0.09% 0.05% 0.07% 0.06% 0.08% 0.08% 0.01%
G 9342 0.35% 0.26% 0.55% 0.18% 0.40% 0.80% 0.56% 0.15% 0.87% 0.11% 0.29% 0.23% 0.62% 0.41% 0.77% 0.47% 0.86% 0.27% 0.57% 0.12% 0.01%
G 9343 0.03% 0.01% 0.03% 0.03% 0.03% 0.01% 0.01% 0.01% 0.02% 0.02% 0.01% 0.00% 0.01% 0.04% 0.01% 0.01% 0.02% 0.01% 0.05% 0.01% 0.06%
C 9344 0.00% 0.03% 0.04% 0.03% 0.01% 0.01% 0.03% 0.02% 0.02% 0.02% 0.02% 0.05% 0.02% 0.02% 0.01% 0.01% 0.02% 0.01% 0.01% 0.03% 0.02%
C 9345 0.01% 0.03% 0.01% 0.01% 0.04% 0.01% 0.01% 0.01% 0.01% 0.03% 0.01% 0.01% 0.02% 0.01% 0.04% 0.02% 0.01% 0.02% 0.00% 0.00% 0.01%
T 9346 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02%
A 9347 0.03% 0.03% 0.02% 0.01% 0.02% 0.01% 0.01% 0.01% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.05% 0.01% 0.00%
C 9348 0.01% 0.00% 0.02% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01% 0.00% 0.00% 0.03% 0.03%
T 9349 0.00% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.02%
A 9350 0.00% 0.01% 0.01% 0.01% 0.03% 0.01% 0.02% 0.01% 0.01% 0.02% 0.00% 0.00% 0.01% 0.02% 0.04% 0.01% 0.01% 0.03% 0.02% 0.04% 0.00%
A 9351 0.02% 0.00% 0.01% 0.00% 0.01% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.02% 0.02% 0.02% 0.00% 0.01% 0.01% 0.03% 0.00% 0.01% 0.02%
C 9352 0.01% 0.02% 0.03% 0.01% 0.02% 0.04% 0.03% 0.00% 0.01% 0.00% 0.02% 0.00% 0.01% 0.02% 0.03% 0.01% 0.03% 0.00% 0.02% 0.00% 0.02%
C 9353 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.05%
A 9354 0.01% 0.01% 0.01% 0.00% 0.00% 0.02% 0.01% 0.00% 0.01% 0.01% 0.02% 0.00% 0.01% 0.00% 0.03% 0.00% 0.01% 0.00% 0.00% 0.02% 0.00%
A 9355 0.00% 0.01% 0.01% 0.01% 0.00% 0.02% 0.01% 0.04% 0.00% 0.02% 0.01% 0.01% 0.01% 0.01% 0.02% 0.01% 0.03% 0.02% 0.00% 0.03% 0.00%
C 9356 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.02% 0.00% 0.02%
A 9357 0.01% 0.01% 0.03% 0.02% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.02% 0.01% 0.01% 0.00% 0.01%
C 9358 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00%
A 9359 0.00% 0.01% 0.03% 0.01% 0.04% 0.01% 0.03% 0.00% 0.00% 0.01% 0.03% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.01%
C 9360 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.03%
T 9361 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
A 9362 0.00% 0.00% 0.01% 0.01% 0.00% 0.02% 0.00% 0.01% 0.02% 0.01% 0.01% 0.00% 0.01% 0.02% 0.01% 0.02% 0.02% 0.01% 0.00% 0.01% 0.00%
A 9363 0.00% 0.00% 0.01% 0.01% 0.01% 0.02% 0.02% 0.01% 0.02% 0.01% 0.01% 0.00% 0.02% 0.01% 0.06% 0.01% 0.02% 0.01% 0.01% 0.02% 0.01%
C 9364 0.28% 0.22% 0.62% 0.16% 0.35% 0.82% 0.53% 0.16% 0.72% 0.18% 0.35% 0.28% 1.24% 0.43% 0.94% 0.44% 0.89% 0.35% 0.59% 0.19% 0.00%
C 9365 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.03%
A 9366 0.00% 0.01% 0.00% 0.05% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00%
T 9367 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00%
A 9368 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.01% 0.00% 0.01%
T 9369 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01%
A 9370 0.00% 0.00% 0.02% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.02% 0.03% 0.01% 0.01% 0.02% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01%
C 9371 0.14% 0.11% 0.37% 0.13% 0.22% 0.45% 0.30% 0.08% 0.50% 0.05% 0.16% 0.11% 0.31% 0.22% 0.47% 0.16% 0.52% 0.18% 0.34% 0.10% 0.00%
C 9372 0.09% 0.10% 0.29% 0.07% 0.17% 0.38% 0.26% 0.05% 0.38% 0.03% 0.15% 0.10% 0.23% 0.18% 0.43% 0.13% 0.43% 0.13% 0.30% 0.07% 0.02%
A 9373 0.18% 0.15% 0.29% 0.14% 0.17% 0.90% 0.31% 0.12% 0.50% 0.15% 0.17% 0.20% 0.51% 0.32% 0.82% 0.26% 0.74% 0.27% 0.35% 0.11% 0.00%
A 9374 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.08%
T 9375 0.00% 0.03% 0.02% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00%
G 9376 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00%
A 9377 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00%
T 9378 0.01% 0.01% 0.02% 0.03% 0.01% 0.01% 0.01% 0.00% 0.01% 0.02% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00%
G 9379 0.41% 0.36% 0.87% 0.31% 0.57% 3.17% 0.97% 0.24% 1.31% 0.18% 0.55% 0.51% 1.18% 0.81% 2.75% 0.64% 2.40% 0.56% 1.23% 0.20% 0.00%
G 9380 0.01% 0.02% 0.04% 0.01% 0.04% 0.03% 0.06% 0.02% 0.08% 0.05% 0.02% 0.01% 0.04% 0.04% 0.02% 0.02% 0.02% 0.02% 0.01% 0.03% 0.01%
C 9381 0.02% 0.01% 0.02% 0.01% 0.01% 0.00% 0.00% 0.05% 0.00% 0.00% 0.02% 0.00% 0.01% 0.01% 0.00% 0.02% 0.01% 0.01% 0.01% 0.01% 0.01%
G 9382 0.02% 0.03% 0.09% 0.03% 0.01% 0.00% 0.01% 0.02% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.01% 0.02% 0.02% 0.02% 0.01% 0.02%
C 9383 0.05% 0.02% 0.03% 0.04% 0.01% 0.01% 0.01% 0.01% 0.02% 0.04% 0.01% 0.00% 0.01% 0.04% 0.02% 0.04% 0.02% 0.01% 0.04% 0.01% 0.03%
G 9384 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02%
A 9385 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 9386 0.01% 0.03% 0.02% 0.01% 0.00% 0.00% 0.04% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.04% 0.00%
G 9387 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00%
T 9388 0.02% 0.02% 0.01% 0.00% 0.01% 0.03% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.02% 0.00% 0.01% 0.01% 0.00%
A 9389 0.02% 0.01% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
A 9390 0.01% 0.02% 0.03% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.02% 0.02% 0.01% 0.01% 0.00% 0.02% 0.01%
C 9391 0.00% 0.01% 0.00% 0.03% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.03% 0.01% 0.00% 0.00% 0.01% 0.02%
A 9392 0.01% 0.01% 0.01% 0.01% 0.01% 0.03% 0.01% 0.02% 0.02% 0.01% 0.03% 0.02% 0.01% 0.00% 0.00% 0.01% 0.02% 0.01% 0.00% 0.01% 0.00%
C 9393 0.01% 0.02% 0.04% 0.00% 0.00% 0.00% 0.01% 0.00% 0.05% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.02% 0.00% 0.00% 0.03%
G 9394 0.04% 0.06% 0.07% 0.08% 0.04% 0.04% 0.04% 0.04% 0.03% 0.04% 0.05% 0.03% 0.06% 0.06% 0.06% 0.06% 0.02% 0.08% 0.07% 0.03% 0.01%
A 9395 0.02% 0.01% 0.00% 0.00% 0.01% 0.01% 0.01% 0.02% 0.01% 0.00% 0.03% 0.03% 0.00% 0.01% 0.00% 0.01% 0.01% 0.02% 0.01% 0.00% 0.00%
G 9396 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01%
A 9397 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01%
A 9398 0.00% 0.01% 0.01% 0.00% 0.01% 0.00% 0.03% 0.00% 0.04% 0.00% 0.02% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.00%
A 9399 0.00% 0.01% 0.02% 0.00% 0.00% 0.01% 0.04% 0.00% 0.03% 0.01% 0.02% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.05% 0.00% 0.01% 0.02%
G 9400 0.00% 0.01% 0.04% 0.00% 0.01% 0.03% 0.00% 0.02% 0.00% 0.00% 0.01% 0.01% 0.04% 0.01% 0.01% 0.02% 0.01% 0.00% 0.01% 0.01% 0.02%
C 9401 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.02%
A 9402 0.02% 0.01% 0.02% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.02% 0.00% 0.03% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
C 9403 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01%
A 9404 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00%
T 9405 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01%
A 9406 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.01% 0.02% 0.01% 0.03% 0.02% 0.00% 0.02% 0.03% 0.01% 0.01% 0.00%
C 9407 0.02% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.02% 0.01% 0.01% 0.00% 0.00% 0.03% 0.02% 0.01% 0.00% 0.02% 0.01% 0.01% 0.01% 0.00%
C 9408 0.03% 0.02% 0.01% 0.01% 0.01% 0.02% 0.01% 0.01% 0.00% 0.01% 0.02% 0.01% 0.02% 0.01% 0.01% 0.01% 0.01% 0.00% 0.01% 0.04% 0.01%
A 9409 0.03% 0.03% 0.01% 0.00% 0.01% 0.03% 0.03% 0.02% 0.04% 0.02% 0.01% 0.05% 0.01% 0.02% 0.01% 0.02% 0.02% 0.00% 0.02% 0.03% 0.02%
A 9410 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.02% 0.02% 0.01% 0.04% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.06%
G 9411 0.00% 0.02% 0.01% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01% 0.02% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00%
G 9412 0.02% 0.02% 0.02% 0.10% 0.00% 0.01% 0.03% 0.01% 0.02% 0.02% 0.01% 0.03% 0.01% 0.01% 0.01% 0.01% 0.02% 0.01% 0.03% 0.00% 0.01%
C 9413 0.00% 0.01% 0.00% 0.00% 0.00% 0.03% 0.00% 0.01% 0.01% 0.00% 0.01% 0.02% 0.04% 0.02% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00%
C 9414 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.04%
A 9415 0.01% 0.01% 0.01% 0.03% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.01% 0.02% 0.01% 0.03% 0.00% 0.02% 0.00%
C 9416 0.01% 0.02% 0.02% 0.00% 0.03% 0.02% 0.07% 0.01% 0.00% 0.01% 0.00% 0.01% 0.03% 0.01% 0.00% 0.02% 0.02% 0.01% 0.03% 0.00% 0.01%
C 9417 0.00% 0.00% 0.02% 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.02% 0.01% 0.01% 0.01% 0.00% 0.00% 0.02% 0.01%
A 9418 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.02% 0.00% 0.01% 0.00% 0.01% 0.01% 0.00% 0.02% 0.02% 0.02% 0.00% 0.01% 0.01%
C 9419 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.02% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01%
A 9420 0.01% 0.02% 0.01% 0.01% 0.00% 0.02% 0.01% 0.01% 0.02% 0.02% 0.02% 0.01% 0.00% 0.03% 0.03% 0.01% 0.02% 0.02% 0.01% 0.01% 0.02%
C 9421 0.00% 0.00% 0.03% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01%
A 9422 0.01% 0.02% 0.01% 0.02% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.03% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01%
C 9423 0.02% 0.03% 0.08% 0.01% 0.01% 0.00% 0.01% 0.01% 0.02% 0.02% 0.01% 0.03% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.03% 0.01% 0.02%
C 9424 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.03%
A 9425 0.01% 0.01% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.06% 0.01% 0.01% 0.01% 0.00% 0.01% 0.00%
C 9426 0.01% 0.00% 0.05% 0.00% 0.00% 0.02% 0.00% 0.01% 0.01% 0.02% 0.02% 0.00% 0.01% 0.01% 0.01% 0.03% 0.02% 0.01% 0.02% 0.01% 0.00%
C 9427 0.05% 0.03% 0.00% 0.00% 0.00% 0.02% 0.03% 0.01% 0.01% 0.02% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.03% 0.01% 0.00% 0.01% 0.01%
T 9428 0.01% 0.02% 0.02% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.02% 0.01% 0.02% 0.01% 0.01% 0.04% 0.03% 0.00% 0.01% 0.01% 0.01% 0.02%
G 9429 0.01% 0.07% 0.02% 0.04% 0.01% 0.08% 0.03% 0.04% 0.03% 0.04% 0.03% 0.07% 0.03% 0.03% 0.04% 0.05% 0.02% 0.02% 0.05% 0.04% 0.01%
T 9430 0.02% 0.03% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.02% 0.00% 0.01% 0.00% 0.01% 0.01% 0.02% 0.00% 0.00% 0.01% 0.04%
C 9431 0.00% 0.02% 0.05% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.02% 0.04% 0.00% 0.03% 0.03% 0.02% 0.02% 0.01% 0.00% 0.01% 0.03% 0.03%
G 9439 0.01% 0.03% 0.02% 0.00% 0.00% 0.03% 0.01% 0.01% 0.03% 0.05% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.02% 0.02%
C 9440 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.01% 0.02% 0.01% 0.02% 0.01% 0.01% 0.01% 0.01% 0.01% 0.02% 0.02% 0.01% 0.02% 0.02%
C 9441 0.00% 0.01% 0.01% 0.00% 0.01% 0.02% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.01% 0.02% 0.01% 0.01% 0.00% 0.00% 0.04%
T 9442 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.03% 0.02% 0.00% 0.02% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.03% 0.01% 0.02% 0.02%
T 9443 0.05% 0.08% 0.08% 0.03% 0.08% 0.07% 0.08% 0.05% 0.02% 0.03% 0.04% 0.05% 0.08% 0.04% 0.09% 0.05% 0.05% 0.04% 0.07% 0.04% 0.01%
C 9444 0.02% 0.01% 0.04% 0.05% 0.00% 0.00% 0.01% 0.01% 0.02% 0.01% 0.01% 0.01% 0.01% 0.04% 0.01% 0.00% 0.01% 0.01% 0.02% 0.02% 0.00%
G 9445 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00%
A 9446 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00%
T 9447 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.03% 0.00%
A 9448 0.00% 0.02% 0.04% 0.01% 0.02% 0.04% 0.02% 0.04% 0.01% 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.02% 0.01% 0.00% 0.05% 0.01%
C 9449 0.01% 0.01% 0.04% 0.00% 0.02% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.02% 0.01% 0.00% 0.02% 0.01% 0.03%
G 9450 0.01% 0.02% 0.02% 0.00% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.02% 0.02% 0.01% 0.01% 0.01% 0.00% 0.02% 0.01% 0.00% 0.00%
G 9451 0.00% 0.01% 0.07% 0.01% 0.01% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.04% 0.01% 0.02% 0.01% 0.00% 0.01%
G 9452 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.11%
A 9453 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00%
T 9454 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
A 9455 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01% 0.02% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
A 9456 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02%
T 9457 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.03% 0.00% 0.02% 0.01%
C 9458 0.01% 0.01% 0.03% 0.01% 0.02% 0.00% 0.00% 0.02% 0.02% 0.01% 0.01% 0.02% 0.00% 0.02% 0.00% 0.01% 0.03% 0.03% 0.01% 0.00% 0.01%
C 9459 0.02% 0.01% 0.03% 0.01% 0.01% 0.00% 0.01% 0.02% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.02% 0.00%
T 9460 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03%
A 9461 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 9462 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 9463 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 9464 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00%
A 9465 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 9466 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00%
T 9467 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.01%
A 9468 0.00% 0.01% 0.01% 0.01% 0.03% 0.00% 0.02% 0.01% 0.00% 0.01% 0.02% 0.01% 0.01% 0.02% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00%
C 9469 0.02% 0.04% 0.03% 0.02% 0.01% 0.02% 0.01% 0.03% 0.00% 0.01% 0.03% 0.01% 0.02% 0.06% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00%
C 9470 0.01% 0.03% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.02% 0.00% 0.01% 0.00% 0.01% 0.00%
T 9471 0.01% 0.01% 0.00% 0.02% 0.01% 0.01% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.02%
C 9472 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.02% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00%
A 9473 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00%
G 9474 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
A 9476 0.01% 0.02% 0.01% 0.03% 0.01% 0.01% 0.01% 0.01% 0.03% 0.00% 0.01% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00%
T 9486 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01%
T 9487 0.01% 0.04% 0.02% 0.03% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01% 0.00% 0.01% 0.02% 0.04% 0.01% 0.02% 0.00% 0.03% 0.01% 0.03% 0.01%
C 9488 0.01% 0.02% 0.03% 0.02% 0.00% 0.02% 0.04% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.02% 0.01% 0.03% 0.01% 0.01% 0.02%
G 9489 0.00% 0.01% 0.05% 0.00% 0.01% 0.01% 0.00% 0.00% 0.02% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.02% 0.01% 0.00% 0.01% 0.02% 0.00%
C 9490 0.00% 0.00% 0.01% 0.01% 0.03% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.03% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00%
A 9491 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.03% 0.00% 0.01% 0.02% 0.00% 0.00% 0.01% 0.02% 0.00% 0.01% 0.01%
G 9492 0.01% 0.01% 0.02% 0.00% 0.01% 0.01% 0.00% 0.03% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.02% 0.01% 0.00% 0.01% 0.00% 0.00%
G 9493 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00%
T 9501 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00%
G 9502 0.00% 0.02% 0.01% 0.00% 0.01% 0.01% 0.03% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.00%
A 9503 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.02% 0.01% 0.02% 0.00% 0.01% 0.01%
G 9504 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.02% 0.02% 0.01% 0.01% 0.01%
C 9505 0.01% 0.00% 0.02% 0.01% 0.00% 0.02% 0.00% 0.01% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.02% 0.01% 0.00% 0.01% 0.01%
C 9512 0.01% 0.03% 0.02% 0.02% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.03% 0.02% 0.02% 0.01% 0.03% 0.04% 0.00% 0.01% 0.02%
C 9513 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.04%
A 9514 0.00% 0.01% 0.02% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.01% 0.01%
C 9515 0.01% 0.03% 0.02% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.03% 0.01% 0.01% 0.03% 0.01% 0.00% 0.01%
T 9516 0.00% 0.00% 0.03% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.01% 0.01% 0.02% 0.02%
C 9517 0.01% 0.02% 0.05% 0.04% 0.01% 0.02% 0.01% 0.02% 0.01% 0.03% 0.02% 0.01% 0.03% 0.01% 0.00% 0.01% 0.01% 0.03% 0.03% 0.02% 0.01%
C 9518 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01% 0.00% 0.02% 0.01%
A 9519 0.00% 0.03% 0.02% 0.01% 0.00% 0.04% 0.01% 0.02% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00%
G 9520 0.01% 0.01% 0.03% 0.02% 0.00% 0.00% 0.01% 0.01% 0.01% 0.02% 0.01% 0.04% 0.01% 0.00% 0.01% 0.02% 0.01% 0.00% 0.00% 0.00% 0.00%
C 9521 0.01% 0.01% 0.03% 0.02% 0.01% 0.01% 0.06% 0.02% 0.05% 0.01% 0.02% 0.01% 0.01% 0.00% 0.01% 0.00% 0.05% 0.01% 0.01% 0.00% 0.02%
C 9522 0.00% 0.01% 0.01% 0.02% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.01% 0.01% 0.01%
T 9523 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.02% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01%
A 9524 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.02% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.02% 0.01%
T 9540 0.02% 0.03% 0.02% 0.01% 0.03% 0.02% 0.08% 0.49% 0.02% 0.05% 0.65% 0.00% 0.21% 0.03% 0.01% 0.01% 0.01% 0.72% 0.01% 0.09% 0.01%
T 9541 0.00% 0.02% 0.01% 0.02% 0.00% 0.00% 0.01% 0.02% 0.03% 0.01% 0.02% 0.01% 0.01% 0.02% 0.04% 0.02% 0.00% 0.01% 0.00% 0.02% 0.00%
A 9542 0.00% 0.02% 0.01% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.01%
G 9543 0.03% 0.03% 0.03% 0.05% 0.04% 0.03% 0.06% 0.03% 0.01% 0.05% 0.01% 0.04% 0.06% 0.03% 0.03% 0.04% 0.06% 0.01% 0.03% 0.04% 0.01%
G 9544 0.04% 0.03% 0.02% 0.06% 0.03% 0.02% 0.03% 0.03% 0.04% 0.02% 0.01% 0.03% 0.04% 0.02% 0.04% 0.04% 0.01% 0.02% 0.01% 0.03% 0.12%
A 9545 0.01% 0.01% 0.03% 0.02% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01% 0.02% 0.01% 0.03% 0.01% 0.01% 0.01% 0.02% 0.02%
G 9546 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01% 0.02%
G 9547 0.04% 0.02% 0.06% 0.02% 0.01% 0.02% 0.04% 0.02% 0.02% 0.01% 0.02% 0.01% 0.06% 0.02% 0.03% 0.02% 0.04% 0.01% 0.01% 0.03% 0.00%
G 9548 0.00% 0.01% 0.03% 0.01% 0.01% 0.01% 0.04% 0.02% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.01% 0.02% 0.15%
C 9549 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.03% 0.01%
A 9550 0.01% 0.01% 0.03% 0.03% 0.01% 0.01% 0.06% 0.02% 0.02% 0.02% 0.01% 0.02% 0.02% 0.01% 0.02% 0.03% 0.01% 0.03% 0.01% 0.01% 0.00%
C 9551 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01% 0.04% 0.01% 0.00% 0.01% 0.00% 0.00% 0.02%
T 9552 0.02% 0.04% 0.03% 0.01% 0.01% 0.01% 0.03% 0.05% 0.00% 0.02% 0.02% 0.01% 0.01% 0.02% 0.01% 0.02% 0.01% 0.00% 0.01% 0.02% 0.00%
G 9553 0.05% 0.09% 0.06% 0.07% 0.03% 0.08% 0.06% 5.51% 0.06% 0.08% 0.08% 0.09% 0.16% 0.11% 0.09% 0.06% 0.03% 0.14% 0.03% 0.05% 0.02%
A 9561 0.01% 0.03% 0.01% 0.03% 0.01% 0.02% 0.03% 0.04% 0.03% 0.01% 0.07% 0.01% 0.02% 0.02% 0.04% 0.02% 0.01% 0.08% 0.01% 0.01% 0.07%
C 9562 0.01% 0.00% 0.02% 0.01% 0.02% 0.00% 0.01% 0.02% 0.00% 0.00% 0.01% 0.00% 0.02% 0.03% 0.01% 0.03% 0.02% 0.01% 0.01% 0.01% 0.00%
A 9563 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.02% 0.02%
G 9564 0.01% 0.02% 0.02% 0.03% 0.00% 0.02% 0.01% 0.01% 0.02% 0.02% 0.01% 0.01% 0.04% 0.01% 0.08% 0.01% 0.01% 0.02% 0.02% 0.01% 0.00%
G 9565 0.00% 0.02% 0.04% 0.03% 0.01% 0.01% 0.01% 0.01% 0.01% 0.02% 0.01% 0.01% 0.02% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.02% 0.00%
C 9566 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.01%
A 9567 0.00% 0.00% 0.01% 0.02% 0.01% 0.00% 0.00% 0.03% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01%
T 9568 0.00% 0.01% 0.01% 0.04% 0.00% 0.01% 0.02% 0.02% 0.00% 0.03% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.02% 0.00%
C 9569 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01% 0.01% 0.00% 0.01% 0.01% 0.00% 0.01% 0.01%
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HVS2 coverage
POLG1 POLG1 POLG1 POLG1 HIV+/NRTI- HIV+/NRTI- HIV+/NRTI- HIV+/NRTI- HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV- HIV- HIV- HIV- clone
Subject P1 P2 P3 P4 29 23 32 25 17 20 18 16 7 12 15 5 35 38 37 39
HVS2 seq HVS2 pos
G 185 8774 8936 9450 9354 8489 6414 9148 8816 9242 9385 9257 9679 9732 9750 10369 8229 9144 8488 8100 10077 8733
C 186 8778 8936 9450 9355 8489 6419 9149 8819 9246 9387 9259 9679 9732 9751 10370 8229 9144 8488 8100 10078 8733
G 187 8778 8936 9450 9356 8489 6425 9149 8819 9246 9387 9259 9679 9732 9751 10370 8229 9144 8488 8100 10078 8733
A 188 8812 8970 9450 9358 8489 6542 9153 8848 9273 9453 9273 9683 9733 9756 10387 8229 9155 8492 8101 10123 8733
A 189 8814 8971 9450 9358 8489 6542 9153 8849 9274 9454 9273 9683 9733 9756 10387 8229 9156 8492 8101 10124 8733
C 190 8814 8971 9450 9358 8489 6546 9153 8849 9274 9455 9273 9683 9733 9756 10387 8229 9156 8492 8101 10124 8733
A 191 8814 8971 9450 9359 8489 6584 9153 8849 9274 9455 9273 9684 9733 9756 10387 8229 9156 8492 8101 10124 8733
T 192 8815 8971 9450 9359 8489 6600 9153 8849 9274 9455 9273 9684 9733 9756 10387 8229 9156 8492 8101 10124 8733
A 193 8815 8971 9450 9359 8489 6600 9153 8849 9274 9455 9273 9684 9733 9756 10387 8229 9156 8492 8101 10124 8733
C 194 8815 8971 9450 9359 8489 6600 9153 8849 9274 9455 9273 9684 9733 9756 10387 8229 9156 8492 8101 10124 8733
T 195 8815 8971 9450 9359 8489 6600 9153 8849 9274 9455 9273 9684 9733 9756 10387 8229 9156 8492 8101 10124 8733
T 196 8815 8971 9450 9359 8489 6600 9153 8849 9274 9455 9273 9684 9733 9756 10387 8229 9156 8492 8101 10124 8733
A 197 8815 8971 9450 9359 8489 6600 9153 8849 9274 9455 9273 9684 9733 9756 10387 8229 9156 8492 8101 10124 8733
C 198 8815 8971 9450 9359 8489 6608 9153 8849 9274 9455 9273 9684 9733 9756 10387 8229 9156 8492 8101 10124 8733
T 199 8815 8971 9450 9359 8489 6632 9153 8849 9274 9455 9273 9684 9733 9756 10387 8230 9156 8492 8101 10124 8733
A 200 8815 8972 9450 9359 8489 6640 9153 8849 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
A 201 8815 8972 9450 9361 8489 6641 9153 8849 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
A 202 8815 8972 9450 9361 8489 6641 9153 8849 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
G 203 8815 8973 9450 9361 8489 6641 9153 8849 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
T 204 8815 8973 9450 9361 8489 6641 9153 8849 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
G 205 8815 8973 9450 9361 8489 6641 9153 8849 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
T 206 8815 8973 9450 9361 8489 6641 9153 8849 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
G 207 8817 8973 9450 9361 8489 6641 9153 8849 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
T 208 8817 8973 9450 9361 8489 6641 9153 8849 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
T 209 8817 8973 9450 9361 8489 6641 9153 8849 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
A 210 8818 8973 9450 9361 8489 6641 9153 8850 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
A 211 8818 8973 9450 9361 8489 6641 9153 8850 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
T 212 8819 8973 9450 9362 8489 6641 9153 8850 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
T 213 8819 8973 9450 9362 8489 6641 9153 8850 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
A 214 8819 8973 9450 9362 8489 6641 9153 8850 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
A 215 8819 8973 9450 9362 8489 6641 9153 8850 9274 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
T 216 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
T 217 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
A 218 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
A 219 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
T 220 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
G 221 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
C 222 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
T 223 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
T 224 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
G 225 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
T 226 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
A 227 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
G 228 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
G 229 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
A 230 8819 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8492 8101 10124 8733
C 231 8820 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8493 8101 10124 8733
A 232 8821 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8493 8101 10124 8733
T 233 8822 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9685 9733 9756 10387 8230 9156 8493 8101 10124 8733
A 234 8825 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8493 8101 10124 8733
A 235 8825 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8493 8101 10124 8733
T 236 8825 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8493 8101 10124 8733
A 237 8825 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
A 238 8825 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
T 239 8825 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
A 240 8825 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
A 241 8825 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
C 242 8825 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
A 243 8825 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
A 244 8825 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
T 245 8825 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
T 246 8826 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
G 247 8826 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
A 248 8826 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
A 249 8826 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
T 250 8826 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
G 251 8826 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
T 252 8826 8973 9450 9362 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
C 253 8828 8973 9450 9363 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
T 254 8828 8973 9450 9363 8489 6641 9153 8850 9275 9455 9273 9686 9733 9756 10387 8230 9156 8494 8101 10124 8733
G 255 8828 8973 9450 9363 8489 6641 9153 8851 9275 9456 9273 9686 9733 9757 10388 8230 9156 8494 8101 10124 8733
C 256 8828 8973 9452 9363 8489 6642 9153 8851 9275 9456 9273 9687 9735 9759 10388 8230 9156 8494 8101 10124 8733
A 257 8829 8973 9452 9363 8490 6642 9153 8851 9275 9457 9273 9687 9735 9759 10388 8230 9156 8496 8101 10124 8733
C 258 8829 8973 9452 9364 8490 6642 9153 8851 9275 9457 9273 9687 9737 9759 10388 8230 9156 8496 8101 10124 8733
A 259 8829 8973 9452 9364 8490 6642 9153 8851 9275 9457 9273 9687 9737 9759 10388 8230 9156 8496 8101 10124 8733
G 260 8829 8974 9452 9364 8490 6642 9153 8851 9275 9457 9273 9687 9737 9759 10388 8230 9156 8496 8101 10124 8733
C 261 8829 8974 9452 9364 8490 6642 9154 8851 9275 9457 9274 9687 9737 9760 10389 8231 9157 8496 8101 10124 8733
C 262 8829 8974 9452 9364 8490 6642 9154 8851 9275 9457 9274 9687 9737 9760 10389 8231 9157 8496 8101 10124 8733
A 263 8829 8974 9452 9365 8491 6643 9154 8851 9275 9457 9274 9687 9737 9760 10389 8231 9157 8496 8101 10124 8733
C 264 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8231 9157 8496 8101 10124 8733
T 265 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8231 9157 8496 8101 10124 8733
T 266 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8231 9157 8496 8101 10124 8733
T 267 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8231 9157 8496 8101 10124 8733
C 268 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8231 9157 8496 8101 10124 8733
C 269 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8231 9157 8496 8101 10124 8733
A 270 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8231 9157 8496 8101 10124 8733
C 271 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8231 9157 8496 8101 10124 8733
A 272 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8231 9157 8496 8101 10124 8733
C 273 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8231 9157 8496 8101 10124 8733
A 274 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8232 9157 8496 8101 10124 8733
G 275 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8232 9157 8496 8101 10124 8733
A 276 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8232 9157 8496 8101 10124 8733
C 277 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8232 9157 8496 8101 10124 8733
A 278 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10389 8232 9157 8496 8101 10124 8733
T 279 8829 8974 9452 9365 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10390 8232 9157 8496 8101 10124 8733
C 280 8829 8974 9453 9366 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10390 8232 9157 8496 8101 10124 8733
A 281 8829 8974 9453 9366 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10390 8232 9157 8496 8101 10124 8733
T 282 8829 8974 9453 9366 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10390 8232 9157 8496 8101 10124 8733
A 283 8829 8975 9453 9367 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10390 8232 9157 8496 8101 10124 8733
A 284 8829 8975 9453 9367 8491 6643 9155 8851 9275 9457 9274 9687 9737 9760 10390 8232 9157 8496 8101 10124 8733
T 293 8830 8980 9456 9374 8491 6644 9155 8852 9277 9458 9274 9689 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 295 8830 8980 9458 9375 8491 6644 9155 8852 9277 9458 9274 9689 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 296 8830 8980 9459 9375 8491 6644 9155 8852 9277 9458 9274 9689 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 297 8830 8980 9459 9375 8491 6644 9155 8852 9277 9458 9274 9689 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 298 8830 8980 9459 9375 8491 6644 9155 8852 9277 9458 9274 9689 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 300 8830 8980 9459 9375 8491 6644 9155 8852 9277 9458 9274 9689 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 301 8830 8980 9459 9375 8491 6644 9155 8852 9277 9458 9274 9689 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 317 8830 8979 9458 9374 8491 6644 9155 8852 9277 9458 9273 9689 9739 9760 10391 8233 9157 8498 8102 10124 8733
T 318 8830 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9689 9739 9760 10391 8233 9157 8498 8102 10124 8733
T 319 8830 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9689 9739 9760 10391 8233 9157 8498 8102 10124 8733
C 320 8830 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9689 9739 9760 10391 8233 9157 8498 8102 10124 8733
T 321 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9689 9739 9760 10391 8233 9157 8498 8102 10124 8733
G 322 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9689 9739 9760 10391 8232 9157 8498 8102 10124 8733
G 323 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9689 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 324 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9689 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 325 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9689 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 326 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9689 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 327 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 328 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
G 329 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 330 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 331 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 332 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
T 333 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
T 334 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 335 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 336 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 337 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 338 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 339 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 340 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 341 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
T 342 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 343 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
T 344 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 345 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
T 346 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
G 347 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 348 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 349 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 350 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 351 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 363 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 364 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 365 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
G 366 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 367 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 368 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 369 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 370 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 371 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
T 372 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 373 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 374 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 375 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9688 9739 9760 10391 8232 9157 8498 8102 10124 8733
A 376 8829 8979 9458 9374 8491 6644 9155 8852 9277 9457 9273 9687 9739 9760 10391 8232 9157 8498 8102 10124 8733
C 377 8829 8979 9458 9374 8491 6644 9155 8852 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8102 10124 8733
C 378 8829 8979 9458 9374 8491 6644 9155 8852 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8102 10124 8733
A 379 8829 8979 9458 9374 8491 6644 9155 8852 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8102 10124 8733
G 380 8829 8979 9458 9374 8491 6644 9155 8852 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8102 10124 8733
C 381 8829 8979 9458 9374 8491 6644 9155 8852 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8102 10124 8733
C 382 8829 8979 9458 9374 8491 6644 9155 8852 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8102 10124 8733
T 383 8829 8979 9458 9374 8491 6644 9155 8852 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8102 10124 8733
A 384 8829 8979 9458 9374 8491 6644 9155 8852 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8102 10124 8733
A 385 8829 8978 9458 9374 8491 6644 9155 8852 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8102 10124 8733
C 386 8829 8978 9458 9374 8491 6644 9155 8852 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8102 10124 8733
C 387 8829 8978 9458 9374 8491 6644 9155 8852 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8102 10124 8733
A 388 8829 8978 9458 9374 8490 6643 9155 8851 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8101 10124 8733
G 389 8829 8978 9458 9374 8490 6643 9155 8851 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8101 10124 8733
A 390 8829 8978 9458 9374 8490 6643 9155 8851 9277 9456 9273 9687 9739 9760 10391 8232 9157 8497 8101 10124 8733
T 391 8829 8978 9457 9374 8490 6643 9155 8851 9277 9456 9273 9687 9739 9760 10391 8232 9156 8496 8101 10124 8733
T 392 8829 8978 9457 9374 8490 6643 9155 8851 9277 9456 9273 9687 9739 9760 10391 8232 9156 8496 8101 10124 8733
T 393 8829 8978 9457 9374 8490 6643 9155 8851 9277 9456 9273 9687 9739 9760 10391 8232 9156 8496 8101 10124 8733
C 394 8829 8978 9457 9374 8490 6643 9155 8851 9277 9456 9273 9687 9739 9760 10391 8232 9156 8496 8101 10124 8733
A 395 8829 8978 9457 9374 8490 6643 9155 8851 9277 9456 9273 9687 9739 9760 10391 8232 9156 8496 8101 10124 8733
A 396 8829 8978 9457 9374 8490 6643 9155 8851 9277 9456 9273 9687 9739 9760 10391 8232 9156 8496 8101 10124 8733
T 403 8825 8976 9457 9374 8490 6643 9155 8849 9276 9456 9273 9687 9739 9759 10391 8232 9155 8496 8101 10124 8733
G 410 8824 8976 9457 9374 8490 6643 9155 8849 9274 9456 9273 9687 9739 9759 10390 8232 9155 8496 8101 10124 8733
C 411 8824 8976 9457 9374 8490 6643 9155 8849 9274 9456 9273 9687 9739 9759 10390 8231 9155 8496 8101 10124 8733
G 412 8824 8976 9457 9374 8490 6643 9154 8849 9274 9456 9273 9687 9739 9759 10389 8231 9155 8496 8101 10124 8733
G 413 8824 8975 9457 9374 8490 6643 9154 8849 9272 9456 9273 9687 9739 9759 10389 8231 9155 8496 8101 10124 8733
T 414 8824 8975 9456 9374 8490 6643 9154 8849 9272 9456 9273 9687 9739 9759 10389 8231 9155 8496 8101 10124 8733
A 415 8823 8975 9456 9374 8490 6643 9154 8849 9271 9456 9273 9687 9738 9759 10389 8231 9155 8496 8101 10124 8733
T 416 8823 8975 9455 9373 8489 6643 9154 8848 9271 9456 9272 9687 9738 9759 10389 8231 9155 8496 8101 10123 8733
G 417 8823 8975 9455 9373 8489 6643 9154 8848 9271 9456 9272 9687 9738 9759 10389 8231 9155 8496 8101 10123 8733
C 418 8823 8975 9455 9373 8489 6643 9154 8848 9271 9456 9272 9687 9738 9759 10389 8231 9155 8496 8101 10123 8733
A 419 8823 8975 9455 9373 8489 6643 9154 8848 9271 9456 9272 9687 9738 9759 10389 8231 9155 8496 8101 10123 8733
A 426 8823 8974 9453 9372 8489 6643 9154 8848 9271 9456 9271 9685 9738 9757 10388 8231 9154 8496 8101 10123 8733
C 427 8822 8972 9453 9371 8488 6640 9152 8848 9271 9455 9271 9685 9736 9756 10387 8231 9153 8496 8100 10122 8733
A 428 8822 8971 9453 9371 8488 6639 9152 8848 9271 9455 9271 9685 9735 9756 10387 8231 9153 8496 8100 10122 8733
G 429 8822 8970 9453 9371 8488 6635 9152 8848 9271 9455 9271 9685 9735 9756 10387 8231 9153 8496 8100 10122 8733
T 430 8821 8969 9453 9371 8488 6606 9152 8848 9270 9455 9271 9685 9735 9756 10387 8230 9152 8496 8100 10122 8733
C 431 8818 8966 9453 9371 8488 6501 9152 8848 9270 9455 9270 9685 9735 9755 10387 8229 9152 8496 8100 10122 8733
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HVS2 variants
POLG1 POLG1 POLG1 POLG1 HIV+/NRTI- HIV+/NRTI- HIV+/NRTI- HIV+/NRTI- HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV+/NRTI+ HIV- HIV- HIV- HIV- clone
Subject P1 P2 P3 P4 29 23 32 25 17 20 18 16 7 12 15 5 35 38 37 39
HVS2 seq HVS2 pos
G 185 0.74% 0.67% 0.13% 0.10% 0.05% 2.67% 0.37% 0.34% 0.38% 0.72% 0.35% 0.13% 0.13% 0.08% 0.31% 0.05% 0.10% 0.16% 0.23% 0.79% 0.05%
C 186 0.98% 1.32% 0.03% 18.66% 0.04% 0.89% 0.11% 0.50% 0.65% 0.94% 0.51% 0.18% 0.09% 0.08% 0.26% 0.04% 0.13% 0.06% 0.04% 1.08% 0.06%
G 187 0.15% 0.26% 0.05% 0.03% 0.01% 0.62% 0.02% 0.08% 0.08% 0.26% 0.12% 0.05% 0.01% 0.04% 0.06% 0.00% 0.01% 0.01% 0.00% 0.25% 0.02%
A 188 0.27% 0.43% 0.01% 0.00% 0.04% 0.64% 0.03% 0.11% 0.14% 0.36% 0.15% 0.04% 0.01% 0.01% 0.11% 0.00% 0.03% 0.01% 0.00% 0.51% 0.00%
A 189 3.00% 4.96% 0.01% 0.09% 0.39% 7.55% 0.45% 1.41% 2.63% 3.41% 1.67% 0.37% 0.26% 0.27% 1.20% 0.01% 0.54% 0.54% 0.20% 3.65% 0.01%
C 190 0.02% 0.01% 0.00% 0.03% 0.02% 1.56% 0.00% 0.02% 0.00% 0.02% 0.02% 0.03% 0.01% 0.01% 0.02% 0.00% 0.01% 0.00% 0.01% 0.02% 0.00%
A 191 0.00% 0.01% 0.00% 0.07% 0.00% 2.72% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 192 0.00% 0.00% 0.01% 0.73% 0.00% 0.09% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
A 193 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.03%
C 194 0.05% 0.03% 0.03% 0.06% 0.07% 0.00% 0.02% 0.00% 0.01% 0.04% 0.00% 0.03% 0.03% 0.04% 0.00% 0.01% 0.02% 0.00% 0.04% 0.02% 0.02%
T 195 0.06% 0.03% 0.04% 0.06% 0.06% 8.58% 0.02% 1.25% 0.02% 0.14% 0.53% 0.05% 0.75% 0.06% 0.42% 0.01% 0.03% 0.68% 0.05% 0.28% 0.00%
T 196 0.10% 0.08% 0.01% 0.03% 0.04% 5.36% 0.07% 0.67% 0.08% 0.19% 0.26% 0.12% 0.20% 0.07% 0.23% 0.09% 0.05% 0.21% 0.04% 0.12% 0.00%
A 197 0.01% 0.01% 0.01% 0.00% 0.00% 4.06% 0.00% 0.00% 0.01% 0.03% 0.00% 0.04% 0.01% 0.01% 0.00% 0.04% 0.00% 0.00% 0.02% 0.03% 0.00%
C 198 0.00% 0.00% 0.00% 0.00% 0.01% 0.55% 0.00% 0.05% 0.02% 0.01% 0.06% 0.03% 0.02% 0.02% 0.10% 0.01% 0.03% 0.75% 0.01% 0.18% 0.01%
T 199 0.02% 0.02% 0.00% 0.03% 0.00% 0.11% 0.01% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.04% 0.00%
A 200 0.01% 0.01% 0.00% 0.01% 0.00% 49.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.09% 0.01% 0.00% 0.00%
A 201 0.00% 0.01% 0.00% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
A 202 0.12% 0.08% 0.15% 0.04% 0.08% 0.15% 0.09% 0.07% 0.04% 0.10% 0.12% 0.10% 0.11% 0.09% 0.10% 0.06% 0.04% 0.01% 0.07% 0.11% 0.06%
G 203 0.01% 0.01% 0.00% 0.03% 0.01% 0.03% 0.01% 0.00% 0.00% 0.00% 0.00% 0.03% 0.01% 0.00% 0.01% 0.01% 0.00% 0.01% 0.02% 0.01% 0.01%
T 204 0.02% 0.03% 0.00% 0.00% 0.04% 0.15% 0.02% 0.02% 0.01% 0.04% 0.03% 0.02% 0.00% 0.02% 0.01% 0.16% 0.00% 0.47% 0.01% 0.00% 0.00%
G 205 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00%
T 206 0.00% 0.00% 0.00% 0.00% 0.02% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.02% 0.01% 0.01% 0.02% 0.00% 0.00%
G 207 0.02% 0.00% 0.00% 0.12% 0.00% 0.00% 0.02% 0.01% 0.02% 0.01% 0.03% 0.00% 0.02% 0.01% 0.03% 0.01% 0.03% 0.86% 0.01% 0.20% 0.02%
T 208 0.00% 0.00% 0.03% 0.00% 0.01% 0.00% 0.02% 0.00% 0.00% 0.02% 0.02% 0.01% 0.00% 0.01% 0.02% 0.01% 0.00% 0.11% 0.01% 0.00% 0.00%
T 209 0.00% 0.01% 0.05% 0.00% 0.01% 0.03% 0.03% 0.00% 0.00% 0.02% 0.06% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.12% 0.04% 0.01% 0.01%
A 210 0.00% 0.00% 0.04% 0.00% 0.01% 0.02% 0.02% 0.00% 0.00% 0.02% 0.02% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.12% 0.02% 0.00% 0.01%
A 211 0.10% 0.07% 0.14% 0.10% 0.09% 0.09% 0.12% 0.09% 0.05% 0.14% 0.10% 0.11% 0.03% 0.03% 0.09% 0.10% 0.03% 0.02% 0.07% 0.05% 0.00%
T 212 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.02% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 213 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00%
A 214 11.58% 9.21% 1.82% 1.99% 0.00% 0.54% 0.01% 0.16% 0.28% 0.34% 0.02% 0.03% 0.04% 0.00% 0.00% 0.01% 0.01% 0.20% 0.19% 0.08% 0.00%
A 215 6.66% 4.47% 1.80% 1.51% 0.01% 0.54% 0.03% 0.49% 0.25% 0.32% 0.03% 0.03% 0.10% 0.04% 0.01% 0.02% 0.12% 0.15% 0.37% 0.12% 0.05%
T 216 0.00% 0.00% 0.00% 0.03% 0.00% 0.00% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 217 0.06% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.02% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
A 218 0.02% 0.03% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.02% 0.01% 0.02% 0.02% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00%
A 219 0.05% 0.03% 0.01% 0.03% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.03% 0.03% 0.03% 0.02% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00%
T 220 0.02% 0.00% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.02% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
G 221 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01%
C 222 0.02% 0.00% 0.06% 0.01% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.01%
T 223 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 224 0.03% 0.02% 0.00% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.02% 0.00%
G 225 0.05% 0.01% 0.00% 0.02% 0.00% 0.00% 0.00% 0.03% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.03% 0.00% 0.00% 0.02% 0.00% 0.00% 0.02%
T 226 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
A 227 0.03% 0.01% 0.00% 0.01% 0.02% 0.00% 0.01% 0.02% 0.00% 0.01% 0.01% 0.02% 0.02% 0.02% 0.06% 0.00% 0.01% 0.01% 0.00% 0.00% 0.02%
G 228 0.02% 0.04% 0.06% 0.03% 0.01% 0.14% 0.23% 0.18% 0.00% 0.02% 0.02% 0.00% 0.01% 0.04% 0.04% 0.00% 0.05% 0.02% 0.15% 0.01% 0.00%
G 229 0.03% 0.03% 0.02% 0.14% 0.00% 0.15% 0.10% 0.05% 0.00% 0.01% 0.00% 0.02% 0.05% 0.02% 0.00% 0.00% 0.05% 0.15% 0.04% 0.00% 0.05%
A 230 0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00%
C 231 0.00% 0.01% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.04% 0.00% 0.00% 0.01% 0.00% 0.02% 0.00% 0.01%
A 232 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 233 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
A 234 0.05% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00%
A 235 0.24% 0.30% 0.03% 0.02% 0.01% 0.05% 0.01% 0.01% 0.04% 0.02% 0.01% 0.03% 0.03% 0.03% 0.07% 0.00% 0.00% 0.02% 0.02% 0.03% 0.00%
T 236 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00%
A 237 0.11% 0.23% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.05% 0.00% 0.05% 0.00%
A 238 0.20% 0.11% 0.02% 0.15% 0.00% 0.00% 0.00% 0.00% 0.04% 0.03% 0.01% 0.00% 0.03% 0.01% 0.01% 0.00% 0.01% 0.01% 0.02% 0.00% 0.06%
T 239 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
A 240 0.29% 0.21% 0.00% 0.16% 0.00% 0.02% 0.00% 0.08% 0.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00%
A 241 0.25% 0.18% 0.02% 0.06% 0.00% 0.06% 0.01% 0.00% 0.09% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.02% 0.04% 0.01% 0.00%
C 242 0.00% 0.00% 0.01% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
A 243 0.14% 0.07% 0.00% 0.10% 0.00% 0.00% 0.00% 0.05% 0.00% 0.00% 0.00% 0.02% 0.00% 0.01% 0.03% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00%
A 244 0.12% 0.09% 0.00% 0.12% 0.00% 0.00% 0.00% 0.08% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00%
T 245 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 246 0.12% 0.06% 0.01% 0.41% 0.00% 0.00% 0.00% 0.02% 0.03% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.02% 0.05% 0.00% 0.00%
G 247 0.02% 0.01% 0.01% 0.03% 0.00% 0.02% 0.00% 0.00% 0.02% 0.02% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
A 248 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01%
A 249 0.01% 0.02% 0.00% 0.01% 0.00% 0.02% 0.00% 0.00% 0.01% 0.02% 0.00% 0.03% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01%
T 250 0.03% 0.01% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
G 251 0.85% 0.71% 0.00% 0.37% 0.00% 0.02% 0.00% 0.05% 0.04% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.04% 0.12% 0.24% 0.00%
T 252 0.02% 0.02% 0.01% 0.05% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00%
C 253 0.43% 0.50% 0.05% 0.12% 0.00% 0.00% 0.00% 0.00% 0.04% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.02% 0.00%
T 254 0.19% 0.19% 0.02% 0.02% 0.00% 0.00% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01%
G 255 0.02% 0.02% 0.00% 0.02% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.02%
C 256 0.01% 0.02% 0.01% 0.00% 0.01% 0.02% 0.02% 0.00% 0.01% 0.01% 0.01% 0.00% 0.02% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00%
A 257 0.02% 0.00% 0.00% 0.00% 0.01% 0.00% 0.02% 0.00% 0.03% 0.01% 0.02% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00%
C 258 0.02% 0.01% 0.02% 0.01% 0.00% 0.00% 0.02% 0.01% 0.01% 0.00% 0.02% 0.04% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01%
A 259 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00%
G 260 0.01% 0.00% 0.02% 0.02% 0.01% 0.00% 0.00% 0.03% 0.00% 0.02% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.02% 0.00% 0.00%
C 261 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.04% 0.00% 0.00% 0.01%
C 262 0.00% 0.03% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.02% 0.01% 0.01%
A 263 0.03% 0.03% 0.05% 0.07% 0.01% 0.03% 0.01% 0.01% 0.04% 0.01% 0.01% 0.07% 0.06% 0.00% 0.07% 0.04% 0.01% 0.04% 0.04% 0.04% 0.14%
C 264 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00%
T 265 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00%
T 266 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 267 0.00% 0.01% 0.00% 0.01% 0.02% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.06%
C 268 0.00% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
C 269 0.01% 0.02% 0.05% 0.03% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.02% 0.01% 0.02% 0.01% 0.04% 0.01% 0.02% 0.02% 0.02% 0.01%
A 270 0.00% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.05% 0.00% 0.00% 0.00% 0.00% 0.01%
C 271 0.01% 0.02% 0.01% 0.03% 0.01% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.01% 0.00% 0.00% 0.02% 0.00% 0.04% 0.01%
A 272 0.00% 0.00% 0.01% 0.01% 0.00% 0.02% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01%
C 273 0.70% 0.40% 0.01% 0.07% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.02% 0.00% 0.00% 0.03% 0.00% 0.00% 0.06% 0.05% 0.04% 0.02%
A 274 0.19% 0.19% 0.01% 0.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01%
G 275 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01%
A 276 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.02% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.02% 0.00% 0.00% 0.01% 0.00%
C 277 0.58% 0.57% 0.00% 0.33% 0.00% 0.00% 0.02% 0.06% 0.00% 0.00% 0.00% 0.00% 0.02% 0.01% 0.00% 0.00% 0.02% 0.01% 0.00% 0.02% 0.00%
A 278 0.01% 0.04% 0.02% 0.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 279 0.08% 0.08% 0.01% 0.07% 0.00% 0.00% 0.00% 0.18% 0.00% 0.01% 0.05% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00%
C 280 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00%
A 281 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
T 282 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.08% 0.00% 0.61% 0.01% 0.01% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00%
A 283 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.02%
A 284 0.24% 0.30% 0.53% 0.38% 0.60% 0.69% 0.23% 0.16% 0.50% 0.41% 0.26% 0.44% 0.27% 0.32% 0.22% 0.55% 0.41% 0.14% 0.65% 0.37% 0.02%
T 293 0.01% 0.02% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01%
C 295 0.01% 0.01% 0.01% 0.02% 0.01% 0.03% 0.10% 0.01% 0.00% 0.00% 0.01% 0.02% 0.00% 0.00% 0.02% 0.01% 0.02% 0.00% 0.07% 0.00% 0.00%
C 296 0.02% 0.02% 0.03% 0.12% 0.00% 0.21% 0.15% 0.01% 0.04% 0.01% 0.01% 0.03% 0.01% 0.01% 0.02% 0.07% 0.04% 0.14% 0.10% 0.00% 0.00%
A 297 0.02% 0.03% 0.02% 0.00% 0.01% 0.05% 0.01% 0.02% 0.05% 0.00% 0.01% 0.03% 0.01% 0.01% 0.05% 0.07% 0.02% 0.01% 0.02% 0.01% 0.00%
C 298 0.00% 0.01% 0.03% 0.00% 0.00% 0.02% 0.00% 0.00% 0.02% 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00%
A 300 0.00% 0.03% 0.04% 0.01% 0.02% 0.02% 0.02% 0.00% 0.02% 0.01% 0.00% 0.01% 0.01% 0.02% 0.01% 0.04% 0.00% 0.01% 0.01% 0.02% 0.05%
A 301 0.00% 0.00% 0.03% 0.01% 0.00% 0.03% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00%
C 317 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00%
T 318 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.03% 0.00% 0.00% 0.01% 0.01% 0.02% 0.00% 0.00% 0.02% 0.00%
T 319 0.03% 0.02% 0.03% 0.01% 0.01% 0.03% 0.01% 0.02% 0.02% 0.03% 0.02% 0.01% 0.05% 0.00% 0.01% 0.02% 0.00% 0.01% 0.02% 0.02% 0.34%
C 320 0.01% 0.00% 0.00% 0.00% 0.01% 0.02% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.02% 0.00% 0.02% 0.01% 0.00%
T 321 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.02% 0.00% 0.01% 0.00% 0.01% 0.02% 0.00% 0.00% 0.00% 0.01%
G 322 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01%
G 323 0.02% 0.02% 0.02% 0.00% 0.01% 0.02% 0.00% 0.00% 0.02% 0.00% 0.01% 0.03% 0.03% 0.00% 0.01% 0.04% 0.00% 0.00% 0.01% 0.01% 0.22%
C 324 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01%
C 325 0.00% 0.01% 0.06% 0.05% 0.01% 0.02% 0.01% 0.00% 0.02% 0.01% 0.02% 0.03% 0.00% 0.03% 0.03% 0.00% 0.07% 0.01% 0.00% 0.02% 0.03%
A 326 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01%
C 327 0.01% 0.01% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.04% 0.01% 0.00% 0.00% 0.00% 0.01%
A 328 0.02% 0.00% 0.00% 0.07% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.03% 0.00%
G 329 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.03% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
C 330 0.02% 0.00% 0.02% 0.00% 0.00% 0.02% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.02%
A 331 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
C 332 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.02% 0.00%
T 333 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00%
T 334 0.00% 0.01% 0.00% 0.00% 0.00% 0.02% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.01% 0.02% 0.02%
A 335 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
A 336 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00%
A 337 0.01% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
C 338 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.01% 0.01% 0.00% 0.02% 0.01% 0.02% 0.01% 0.02% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00%
A 339 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.02% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01%
C 340 0.03% 0.00% 0.06% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.01% 0.00% 0.02% 0.00% 0.02% 0.04% 0.00% 0.01% 0.00% 0.00% 0.03%
A 341 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.05% 0.01% 0.00% 0.00%
T 342 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
C 343 0.00% 0.00% 0.01% 0.01% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
T 344 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
C 345 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01%
T 346 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01%
G 347 0.00% 0.00% 0.00% 0.00% 0.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.02% 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00%
C 348 0.01% 0.00% 0.02% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.01% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00%
C 349 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.05% 0.01% 0.00% 0.01% 0.05% 0.00% 0.02% 0.00% 0.02% 0.00% 0.01% 0.00% 0.01% 0.06%
A 350 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01%
A 351 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
A 363 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00%
A 364 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00%
A 365 0.11% 0.11% 0.11% 0.16% 0.13% 0.09% 0.14% 0.06% 0.12% 0.11% 0.19% 0.12% 0.08% 0.10% 0.12% 0.19% 0.16% 0.18% 0.10% 0.13% 0.25%
G 366 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01%
A 367 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
A 368 0.01% 0.01% 0.01% 0.02% 0.00% 0.02% 0.00% 0.01% 0.02% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.04% 0.01% 0.01% 0.01% 0.05% 0.02%
C 369 0.03% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.02% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00%
C 370 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00%
C 371 0.02% 0.01% 0.01% 0.02% 0.04% 0.00% 0.01% 0.00% 0.03% 0.04% 0.00% 0.03% 0.04% 0.00% 0.01% 0.00% 0.03% 0.01% 0.01% 0.00% 0.00%
T 372 0.01% 0.00% 0.02% 0.02% 0.02% 0.00% 0.04% 0.02% 0.03% 0.01% 0.01% 0.03% 0.01% 0.00% 0.02% 0.00% 0.02% 0.02% 0.00% 0.00% 0.00%
A 373 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00%
A 374 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.02% 0.04% 0.01% 0.00% 0.00% 0.02%
C 375 0.00% 0.00% 0.01% 0.01% 0.02% 0.02% 0.00% 0.02% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.02% 0.04% 0.05% 0.01% 0.01% 0.02% 0.00%
A 376 0.00% 0.00% 0.00% 0.01% 0.00% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00%
C 377 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01%
C 378 0.01% 0.00% 0.02% 0.03% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.02% 0.04% 0.00% 0.00% 0.00% 0.03% 0.00%
A 379 0.00% 0.00% 0.00% 0.01% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.03% 0.04% 0.01% 0.01% 0.00% 0.00% 0.01%
G 380 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00%
C 381 0.01% 0.00% 0.00% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.01% 0.00%
C 382 0.00% 0.07% 0.04% 0.03% 0.07% 0.02% 0.02% 0.00% 0.04% 0.00% 0.01% 0.06% 0.02% 0.02% 0.01% 0.02% 0.05% 0.06% 0.01% 0.02% 0.02%
T 383 0.02% 0.03% 0.02% 0.00% 0.00% 0.00% 0.02% 0.01% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.02% 0.01% 0.01% 0.02% 0.00% 0.00% 0.00%
A 384 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
A 385 0.16% 0.06% 0.00% 0.05% 0.01% 0.02% 0.01% 0.02% 0.08% 0.01% 0.00% 0.02% 0.00% 0.01% 0.01% 0.00% 0.02% 0.01% 0.04% 0.01% 0.00%
C 386 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
C 387 0.02% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.02% 0.00% 0.01% 0.01% 0.02% 0.01% 0.00% 0.01% 0.00% 0.01% 0.01%
A 388 0.02% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
G 389 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.02%
A 390 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 391 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00%
T 392 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 393 0.11% 0.08% 0.10% 0.05% 0.12% 0.12% 0.10% 0.14% 0.14% 0.14% 0.14% 0.12% 0.05% 0.14% 0.08% 0.09% 0.12% 0.07% 0.11% 0.08% 0.05%
C 394 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.02% 0.02% 0.00% 0.01% 0.03% 0.00% 0.02% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00%
A 395 0.05% 0.01% 0.02% 0.02% 0.00% 0.00% 0.01% 0.02% 0.03% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
A 396 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
T 403 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01%
G 410 0.02% 0.03% 0.05% 0.03% 0.04% 0.06% 0.02% 0.02% 0.05% 0.03% 0.02% 0.05% 0.02% 0.03% 0.03% 0.01% 0.07% 0.05% 0.02% 0.06% 0.10%
C 411 0.53% 0.53% 0.06% 0.15% 0.06% 0.08% 0.04% 0.05% 0.36% 0.03% 0.08% 0.01% 0.01% 0.03% 0.13% 0.02% 0.07% 0.06% 0.09% 0.06% 0.02%
G 412 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
G 413 0.00% 0.06% 0.01% 0.01% 0.02% 0.02% 0.03% 0.01% 0.03% 0.00% 0.02% 0.03% 0.03% 0.01% 0.00% 0.00% 0.01% 0.00% 0.01% 0.03% 0.05%
T 414 0.48% 0.65% 0.01% 0.09% 0.01% 0.51% 0.01% 0.16% 3.69% 0.23% 0.06% 0.18% 0.05% 0.05% 0.05% 0.05% 0.00% 0.00% 0.06% 0.03% 0.00%
A 415 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
T 416 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
G 417 0.01% 0.00% 0.04% 0.02% 0.00% 0.03% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.02% 0.00% 0.03% 0.01% 0.02% 0.00% 0.01% 0.00% 0.00%
C 418 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.04% 0.01% 0.00% 0.00% 0.01% 0.00%
A 419 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
A 426 0.01% 0.00% 0.01% 0.00% 0.01% 0.03% 0.01% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.05% 0.01%
C 427 0.00% 0.00% 0.02% 0.03% 0.04% 0.03% 0.01% 0.00% 0.02% 0.00% 0.01% 0.03% 0.03% 0.13% 0.00% 0.01% 0.02% 0.00% 0.02% 0.01% 0.05%
A 428 0.00% 0.01% 0.03% 0.01% 0.01% 0.00% 0.01% 0.00% 0.02% 0.01% 0.02% 0.01% 0.01% 0.02% 0.00% 0.04% 0.04% 0.01% 0.00% 0.01% 0.01%
G 429 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.02% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01%
T 430 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.01%
C 431 0.01% 0.00% 0.10% 0.00% 0.00% 0.00% 0.01% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00%
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autosomal
BRCA2 (genomic 1) BRCA2 (genomic 2) BRCA2 (clonal)
position Chr13 seq coverage coverage coverage
32907125 T 53488 0.0000% 6906 0.0000% 12264 0.0245%
32907126 C 53489 0.0019% 6906 0.0145% 12264 0.0082%
32907127 T 53491 0.0150% 6906 0.0000% 12264 0.0163%
32907128 A 53491 0.0000% 6906 0.0000% 12264 0.0000%
32907129 T 53492 0.0019% 6906 0.0290% 12264 0.0082%
32907130 A 53495 0.0019% 6906 0.0000% 12264 0.0000%
32907131 T 53499 0.0019% 6906 0.0000% 12264 0.0082%
32907132 T 53500 0.0075% 6906 0.1448% 12264 0.1223%
32907133 C 53501 0.0075% 6906 0.0000% 12264 0.0163%
32907134 A 53503 0.0224% 6906 0.0145% 12264 0.0326%
32907135 G 53561 0.0000% 6906 0.0145% 12264 0.0082%
32907136 A 53575 0.0019% 6906 0.0145% 12264 0.0000%
32907137 A 53584 0.0093% 6906 0.0290% 12264 0.0000%
32907138 T 53584 0.0037% 6906 0.0000% 12264 0.0000%
32907139 A 53585 0.0000% 6906 0.0000% 12264 0.0000%
32907140 A 53586 0.0056% 6906 0.0000% 12264 0.0000%
32907141 G 53586 0.0019% 6906 0.0145% 12264 0.0000%
32907142 A 53587 0.0019% 6906 0.0145% 12264 0.0000%
32907143 G 53588 0.0000% 6906 0.0145% 12264 0.0163%
32907144 A 53588 0.0037% 6906 0.0000% 12264 0.0082%
32907145 A 53589 0.0000% 6906 0.0000% 12264 0.0000%
32907146 T 53589 0.0000% 6906 0.0000% 12264 0.0000%
32907147 C 53590 0.0000% 6906 0.0145% 12264 0.0000%
32907148 A 53591 0.0000% 6906 0.0000% 12264 0.0000%
32907149 C 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907150 C 53592 0.0019% 6906 0.0000% 12264 0.0245%
32907151 T 53592 0.0000% 6906 0.0434% 12264 0.0163%
32907152 A 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907153 A 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907154 A 53592 0.0019% 6906 0.0579% 12264 0.0245%
32907155 G 53592 0.0000% 6906 0.0290% 12264 0.0245%
32907156 A 53592 0.0000% 6906 0.0000% 12264 0.0082%
32907157 G 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907158 A 53592 0.0000% 6906 0.0145% 12264 0.0000%
32907159 C 53592 0.0019% 6906 0.0290% 12264 0.0408%
32907160 T 53592 0.0000% 6906 0.0145% 12264 0.0000%
32907161 T 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907162 T 53592 0.0056% 6906 0.1014% 12264 0.0897%
32907163 C 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907164 A 53592 0.0000% 6906 0.0000% 12264 0.0163%
32907165 A 53592 0.0075% 6906 0.0000% 12264 0.0000%
32907166 T 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907167 G 53592 0.0037% 6906 0.0145% 12264 0.0082%
32907168 C 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907169 A 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907170 A 53592 0.0243% 6906 0.0000% 12264 0.0163%
32907178 A 53592 0.0037% 6906 0.0434% 12264 0.0245%
32907179 G 53592 0.0000% 6906 0.0000% 12264 0.0082%
32907180 G 53592 0.0019% 6906 0.0290% 12264 0.0000%
32907181 T 53592 0.0075% 6906 0.0145% 12264 0.0815%
32907182 C 53592 0.0000% 6906 0.0000% 12264 0.0245%
32907183 A 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907184 T 53592 0.0093% 6906 0.0145% 12264 0.0000%
32907185 A 53592 0.0131% 6906 0.0000% 12264 0.0082%
32907186 T 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907187 G 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907188 A 53592 0.0485% 6906 0.0145% 12264 0.0082%
32907189 C 53592 0.0000% 6906 0.0579% 12264 0.1060%
32907190 T 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907191 G 53592 0.0019% 6906 0.0000% 12264 0.0000%
32907192 A 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907193 T 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907194 C 53592 0.0019% 6906 0.0145% 12264 0.0163%
32907195 C 53592 0.0056% 6906 0.0000% 12264 0.0082%
32907196 A 53592 0.0019% 6906 0.0000% 12264 0.0000%
32907197 A 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907198 A 53592 0.0299% 6906 0.0145% 12264 0.0082%
32907199 C 53592 0.0037% 6906 0.0145% 12264 0.0082%
32907200 T 53592 0.0019% 6906 0.0000% 12264 0.0000%
32907201 T 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907210 A 53592 0.0000% 6906 0.0145% 12264 0.0000%
32907211 A 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907212 A 53592 0.0205% 6906 0.0000% 12264 0.0408%
32907213 C 53592 0.0000% 6906 0.0000% 12264 0.0163%
32907214 T 53592 0.0000% 6906 0.0000% 12264 0.0082%
32907215 G 53592 0.0000% 6906 0.0000% 12264 0.0245%
32907216 A 53592 0.0075% 6906 0.0000% 12264 0.0082%
32907217 A 53592 0.0056% 6906 0.0290% 12264 0.0163%
32907218 G 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907219 C 53592 0.0019% 6906 0.0000% 12264 0.0082%
32907220 C 53592 0.0149% 6906 0.0145% 12264 0.0163%
32907221 T 53592 0.0019% 6906 0.0145% 12264 0.0082%
32907222 C 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907223 T 53592 0.0112% 6906 0.0579% 12264 0.0000%
32907224 G 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907225 A 53592 0.0000% 6906 0.0000% 12264 0.0082%
32907226 A 53592 0.0056% 6906 0.0000% 12264 0.0000%
32907227 A 53592 0.0131% 6906 0.0145% 12264 0.0245%
32907228 G 53592 0.0075% 6906 0.0145% 12264 0.0082%
32907229 T 53592 0.0000% 6906 0.0434% 12264 0.0163%
32907230 G 53592 0.0000% 6906 0.0000% 12264 0.0082%
32907231 G 53592 0.0037% 6906 0.0145% 12264 0.0082%
32907232 A 53592 0.0000% 6906 0.0145% 12264 0.0000%
32907233 C 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907234 T 53592 0.0019% 6906 0.0145% 12264 0.0000%
32907235 G 53592 0.0019% 6906 0.0000% 12264 0.0000%
32907236 G 53592 0.0056% 6906 0.0145% 12264 0.0000%
32907237 A 53592 0.0019% 6906 0.0145% 12264 0.0000%
32907238 A 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907239 A 53592 0.0019% 6906 0.0290% 12264 0.0489%
32907240 T 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907241 A 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907242 C 53592 0.0056% 6906 0.0290% 12264 0.0163%
32907243 A 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907244 T 53592 0.0056% 6906 0.0000% 12264 0.0000%
32907245 A 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907246 C 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907247 T 53592 0.0000% 6906 0.0000% 12264 0.0000%
32907248 G 53592 0.0000% 6906 0.0145% 12264 0.0245%
32907249 T 53591 0.0000% 6906 0.0000% 12264 0.0000%
32907250 T 53591 0.0000% 6906 0.0000% 12264 0.0000%
32907251 T 53590 0.0019% 6906 0.1014% 12264 0.0734%
32907252 G 53590 0.0056% 6906 0.0290% 12264 0.0245%
32907253 C 53590 0.0019% 6906 0.0145% 12264 0.0000%
32907254 T 53590 0.0037% 6906 0.0000% 12264 0.0082%
32907255 C 53590 0.0000% 6906 0.0000% 12264 0.0000%
32907256 A 53588 0.0000% 6906 0.0145% 12264 0.0082%
32907257 C 53584 0.0112% 6906 0.0000% 12264 0.0000%
32907258 A 53572 0.0037% 6906 0.0000% 12264 0.0163%
32907259 G 53545 0.0000% 6906 0.0000% 12264 0.0000%
32907260 A 53542 0.0019% 6906 0.0290% 12264 0.0000%
32907261 A 53542 0.0131% 6906 0.0145% 12264 0.0245%
32907262 G 53541 0.0000% 6906 0.0145% 12264 0.0000%
32907263 G 53541 0.0019% 6906 0.0145% 12264 0.0163%
32907264 A 53538 0.0112% 6906 0.0434% 12264 0.0163%
32907265 G 53537 0.0019% 6906 0.0145% 12264 0.0163%
32907266 G 53537 0.0262% 6906 0.1158% 12264 0.0734%
32907267 A 53537 0.0037% 6906 0.0000% 12264 0.0082%
32907268 C 53537 0.0448% 6906 0.0145% 12264 0.0163%
32907269 T 53536 0.0318% 6906 0.0145% 12264 0.0000%
32907270 C 53535 0.0411% 6906 0.0000% 12264 0.0082%
32907271 C 53535 0.2821% 6906 0.1014% 12263 0.0815%
32907272 T 53535 0.1476% 6906 0.0000% 12263 0.0163%
32907273 T 53535 0.1662% 6906 0.1158% 12263 0.0652%
32907274 A 53535 0.0411% 6906 0.0000% 12263 0.0245%
32907275 T 53534 0.0747% 6906 0.0000% 12263 0.0163%
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Abstract 
Mammalian cells contain thousands of copies of mitochondrial DNA (mtDNA). At 
birth, these are thought to be identical in most humans. Here, we use long read length 
ultra-deep resequencing-by-synthesis to interrogate regions of the mtDNA genome from 
related and unrelated individuals at unprecedented resolution. We show that very low-
level heteroplasmic variance is present in all tested healthy individuals, and is likely to 
be due to both inherited and somatic single base substitutions. Using this approach, we 
demonstrate an increase in mtDNA mutations in the skeletal muscle of patients with a 
proofreading-deficient mtDNA polymerase γ due to POLG mutations. In contrast, we 
show that OPA1 mutations, which indirectly affect mtDNA maintenance, do not 
increase point mutation load. The demonstration of universal mtDNA heteroplasmy has 
fundamental implications for our understanding of mtDNA inheritance and evolution. 
Ostensibly de novo somatic mtDNA mutations, seen in mtDNA maintenance disorders 
and neurodegenerative disease and aging, will partly be due to the clonal expansion of 
low-level inherited variants. 
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Introduction 
Nucleated mammalian cells contain thousands of copies of the mitochondrial genome. 
Until recently, it has been generally accepted that, for the vast majority of humans, all 
mitochondrial DNA (mtDNA) molecules are identical at birth (homoplasmy) (Parsons 
et al., 1997; Taylor and Turnbull, 2005). However, recent work has shown that ∼25% 
of healthy individuals inherit a mixture of wild-type and variant mtDNA 
(heteroplasmy), which almost exclusively involves the non-coding mtDNA D-loop (Li 
et al., 2010). Even less frequently, <1 in 200 inherit a potentially pathogenic variant of 
mtDNA in the coding region (Elliott et al., 2008). Being exclusively maternally 
inherited, mtDNA undergoes negligible recombination manifested at the population 
level. As a result, homoplasmic variation of mtDNA has played a key role in 
determining population migrations on a global scale (Torroni et al., 2006) and in the 
confident identification of biological samples in forensic medicine (Just et al., 2009). 
Heteroplasmic variants can confound the situation in both circumstances. 
 
MtDNA is highly mutable, with an estimated mutation rate of at least ∼5–15 times that 
of the nuclear genome. This is partly a result of proximity to the electron transport chain 
that is the major intracellular source of oxidative free radicals, and partly a result of the 
relatively limited mtDNA protection and repair mechanisms (Wallace, 2010a). The high 
mutation rate contributes to the high levels of mtDNA diversity and also the generation 
of somatic mtDNA mutations with aging (Wallace, 2010b). Once present, the 
intracellular level of both inherited and somatic mtDNA mutations can change during 
life through the unequal partitioning of mitochondrial genotypes, which can occur 
during cytokinesis in dividing cells (vegetative segregation) or within a non-dividing 
cell through the relaxed replication of mtDNA. An increase in heteroplasmy is often 
referred to as ‘clonal expansion’ that may be enhanced by a replicative advantage for 
specific mutation types (Birky, 1994). If deleterious mutations exceed a critical 
threshold level within a cell, they can cause a biochemical defect in the mitochondrial 
respiratory chain (Schon et al., 1997). This often involves cytochrome c oxidase (COX), 
leads to increased free radical production, a defect of ATP synthesis, cell dysfunction 
and ultimately cell death (Taylor and Turnbull, 2005). High percentage levels of 
inherited mtDNA mutations cause multisystem mitochondrial diseases in ∼1 in 10 000 
of the population (Schaefer et al., 2008), and high percentage levels of somatic 
mutations have been described in several age-associated degenerative diseases and 
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possibly contribute to the aging process (Park and Larsson, 2011). Understanding the 
origin of mtDNA variants, therefore, has far-reaching implications, with impact on 
medicine, human anthropology and forensic science. 
 
Although generally assumed that age-related mtDNA mutations originate during life, it 
is equally plausible that some ostensibly somatic variants are actually inherited, but fall 
below the detection threshold of previously applied technologies. With the recent 
development of massively parallel sequencing, it is now possible to definitively address 
this issue through the detection of very low-level heteroplasmic variants. Recent studies 
using whole mtDNA genome sequencing on the Illumina GA / Solexa platforms have 
suggested that a single heteroplasmic variant can be detected in ∼25% of individuals 
(He et al., 2010; Li et al., 2010; Tang and Huang, 2010; Goto et al., 2011). However, 
the relatively conservative detection thresholds (a minor allele frequency of >1.5–10%) 
used in these studies mean that lower frequency variants were not reported, despite the 
fact that, from first principles, most somatic mtDNA variants will be expected to fall 
below this level. 
 
We, therefore, sought to improve the depth of resolution for very low-frequency 
heteroplasmy by developing an amplicon-based resequencing method on the Roche 454 
GS FLX platform. Despite the very great depth of coverage per base position achieved 
in previous studies using other platforms (He et al., 2010; Li et al., 2010; Tang and 
Huang, 2010; Goto et al., 2011), the achievable lower limit of resolution for 
heteroplasmic mtDNA variants is pragmatically limited by the ‘noise’ generated 
principally during the sequencing reaction. Amplicon resequencing on the 454 GS FLX 
platform has, thus, become the method of choice for ultra-deep resequencing (UDS) of 
mutants and quasi-species within other small genomes, for example viruses (Daly et al., 
2011) and bacteria (Soares et al., 2012), where resolution in the 0.1–1% variant 
frequency range has been described. 
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Results 
Developing a highly sensitive and specific method of detecting very low-level mtDNA 
sequence variants 
At the population level, MT-HV2 within the mtDNA non-coding control region is 
observed to be more polymorphic than the coding region (Macaulay et al., 1999). We, 
therefore, designed two mtDNA amplicons to compare the base substitution rate in two 
regions in different subjects: one in MT-HV2 (nt 162–455, 294 bp) and one in the 
coding region MT-CO3 (nt 9307–9591, 285 bp) (see Supplementary Material, Table 
S1). As nuclear pseudogenes [nuclear mitochondrial sequences (NumtS)] have the 
potential to confound deep resequencing of mtDNA, we took a three-stage process to 
exclude the possibility of this affecting our data. Firstly, we compared our amplicon loci 
with published NumtS to determine the extent to which they nested within these regions 
and the corresponding degree of sequence identity (Simone et al., 2011). Only one of 
the NumtS had a high sequence identity with modern mtDNA (>90%) and was 
predicted to lie within our MT-CO3 amplicon (Supplementary Material, Table S2). 
However, this NumtS was still predicted to differ by six nucleotide substitutions from 
modern mtDNA, which significantly exceeded the number of variants ever seen on 
single reads within our dataset. Secondly, we used Primer-BLAST analysis of each 
amplicon primer pair (hg19 build), which showed no predicted non-mtDNA PCR 
product generation (Ye et al., 2012). Finally, we attempted to PCR amplify a product 
using genomic DNA extracted from rho0 cells that contained no mtDNA, following 
ethidium bromide-induced mtDNA depletion to directly confirm our predictions and to 
look for unexpected NumtS hits. No product was obtained with either amplicon primer 
set, despite a strong band with a positive control (nuclear gene primers). We, therefore, 
concluded that nuclear pseudogene amplification was highly unlikely with the specific 
primers that we designed to amplify MT-HV2 and MT-CO3. In the 454 assay, the mean 
depth of coverage using these primers was 8391 reads (range 4158 – 20 803). 
 
Although commercially available lambda phage controls can be used to estimate the 
level of background sequencing artifacts, differences in guanine-cytosine content of the 
cloned templates can influence the outcome. We, therefore, designed several in-house 
controls to determine the level of background noise using the 454 platform on mtDNA 
templates: (i) a nuclear DNA amplicon in BRCA2 (NC_000013.10, 32907099–
32907295, 197 bp) was designed to compare the intrinsic properties of mtDNA and 
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nuclear genomic DNA, (ii) a cloned nuclear DNA template corresponding exactly to 
the BRCA2 amplicons was generated from genomic DNA and (iii) we cloned mtDNA 
templates from exactly the same mtDNA sequences (MT-HV2, MT-CO3). On this basis, 
any difference in sequence variants between the cloned and genomic DNA templates 
from the same individual is highly likely to reflect ‘biological’ sequence variants 
generated in vivo and not technical artifact arising from the sequencing process. 
 
Being based on pyrosequencing, the base-calling errors on the 454 platform are very 
largely dependent on poly-mononucleotide tracts (Quince et al., 2009). As our goal was 
to maximize specificity in calling very low-level variants, we, therefore, excluded these 
tracts from all of the analysis. We also introduced a further quality-control step, 
requiring observed variants to be present in both forward and reverse reads at 
comparable frequencies. A 3-fold difference was permitted to allow for the effects of a 
binomial sampling distribution at very low variant levels. 
 
Using this highly stringent approach, there were no variants present at >0.2% 
heteroplasmy in any of the cloned or genomic DNA templates (Fig. 1). This 
demonstrated the low background noise level using the 454 UDS approach and 
indicated that variants detected at >0.2% heteroplasmy are highly likely to be 
generated in vivo and to be of biological origin. 
 
Further validation of this approach came from repeated experiments performed using 
the same 454 platform, but different chemistry (Titanium) and different amplicon 
generation primers. Duplicate experiments were performed on four samples of genomic 
DNA. There was 100% consistency of variant detection between runs, but 6% of the 
variants present in the first run fell below the 0.2% threshold in the second run. The 
heteroplasmy level range for these variants in the second run was 0.12 – 0.19%, 
demonstrating that these fell just outside our defined threshold for detection, but were 
indeed present. 
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Frequency of very low-level mtDNA sequence variants in healthy control subjects 
Next, we studied genomic DNA extracted from whole blood and the skeletal muscle 
from unrelated and related healthy individuals at different ages. Demographic and 
genotypic details of the subjects are shown in Supplementary Material, Table S3. 
Detected mtDNA sequence variants are shown in Supplementary Material, Table S4. 
 
All of the healthy control subjects showed variants at >0.2% heteroplasmy in both the 
blood and skeletal muscle DNA samples at one or more base positions. These data 
indicate that very low-level single-base heteroplasmy appears to be a universal finding 
among different control subjects (Fig. 2A and B). The total number of variant base 
positions was the same in the blood and skeletal muscle samples, but variants at higher 
percentage heteroplasmy levels (>2%) were present only in the skeletal muscle of some 
individuals (three of seven healthy subjects) and never seen in the blood. Higher level 
variants (>2%) were only found in the MT-HV2 amplicon. 
 
Overall, the number of variants per base position was significantly more common in the 
skeletal muscle than in the blood (P = 0.001), and this difference was greater for MT-
HV2 than MT-CO3 (P < 0.001). In addition, the number of variants per base position 
was significantly greater in MT-HV2 than MT-CO3 (P < 0.001). In summary, the 
greatest frequency of very low-frequency variants was seen in the MT-HV2 region, and 
both the greatest number of different variants and the highest heteroplasmy levels were 
seen in the skeletal muscle. 
 
The frequency of very low-level variants in disorders of mtDNA maintenance 
We studied patients with inherited defects of POLG encoding the sole mtDNA 
polymerase γ, predicted to have error-prone mtDNA replication (Van Goethem et al., 
2001; Naviaux and Nguyen, 2004; Hakonen et al., 2005). For comparison, we also 
studied subjects with defects of OPA1. Skeletal muscle biopsies from these individuals 
show an excess of cells containing clonally amplified mtDNA somatic mutations; 
however, unlike for POLG defects, the mechanism is believed to be indirect, mediated 
through defects in mitochondrial fission and fusion, rather than by any direct effect on 
112 
 
the polymerase (Alexander et al., 2000; Amati-Bonneau et al., 2008; Hudson et al., 
2008). Clinical details and pedigrees are shown in Supplementary Material, Table S3 
and Supplementary Material, Figure S1. 
 
First, we studied eight patients with a variety of POLG mutations (A467T/A467T, 
A467T/G848S, A467T/W748S, R627Q/W748S and R627Q/R1096H). In skeletal 
muscle biopsies, the overall burden of mtDNA variants was greater in patients 
with POLG mutations when compared with healthy control subjects, but only for MT-
HV2, where the majority of variants were seen (P = 0.004) (Fig. 2A). The excess of 
mtDNA variants was present across all levels of heteroplasmy, and increased 
significantly with age (r = 0.86, P = 0.006), suggestive of a time-dependent 
accumulation of low-level somatic mutations. There was no significant correlation of 
mutation burden with age in healthy controls (r = 0.62, P = 0.14). Given that the 
mutational burden was significantly greater at lower heteroplasmy levels in POLG when 
compared with control subjects (for <1% heteroplasmy level variants, P = 0.019), these 
findings imply that that the higher mutational burden is primarily due to de 
novo somatic mutation in POLG patients. 
 
We, then, studied multiple tissues from patients with mutations in OPA1 (M1fsX208, 
S545R, V294fsX667, R905X and intron 8 and intron 15 splicing defects). In contrast to 
the POLG patients, there was no significant increase in mutational burden 
in OPA1 patients when compared with healthy controls in either the blood or skeletal 
muscle for the MT-HV2 or MT-CO3 amplicons (Fig. 2A and B). These findings argue 
against an increased rate of de novo mutagenesis in patients with OPA1 mutations, 
consistent with there being no direct effect on the polymerase γ and in keeping with 
previous suggestions that accelerated clonal expansion of existing somatic mutations is 
responsible for the cellular cytochrome c oxidase defects (Yu-Wai-Man et al., 2010). 
We studied the mutational burden in the skeletal muscle of one subject on two 
occasions 10 years apart. Six heteroplasmic variants were detected in the first muscle 
sample of this individual. All six variants were also detectable at comparable levels in 
the follow-up muscle sample taken 10 years later, although two variants in the second 
sample fell below the 0.2% threshold (0.17%, 0.06%). Overall, five variants showed a 
decrease in heteroplasmy level and one showed an increase over the 10 year period; 
however, the absolute changes were small (Supplementary Material, Table S5). 
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Determining whether very low-level variants are maternally inherited 
Having identified low-level heteroplasmic mtDNA variants in the different pedigrees, 
we, then, compared related and unrelated individuals to determine the extent to which 
the mtDNA variants arose through maternal transmission or somatic mutation. We 
focused on families with known nuclear genetic defects associated with mtDNA 
maintenance because of the larger number of variants available for scrutiny (i.e. 
increased signal strength). 
 
We compared 13 pairs of samples from 12 maternal first-degree relatives, including one 
subject with repeated blood and muscle samples taken 10 years apart. To determine the 
background level of similarity between unrelated individuals, we compared the same 
tissue between 79 different random pairs of unrelated subjects. Out of 485 variants, 59 
variants were common in unrelated subjects (12%). In contrast, when the analysis was 
restricted to first-degree maternal relatives, 25/63 variants were shared (40%, P < 0.001, 
Table 1). We also compared the frequency of sharing between 13 pairs of related 
individuals and 13 random pairs of unrelated controls. This also repeatedly revealed a 
highly significant difference (P < 0.001), adding further weight to our conclusions. On 
average, 39% of variants in a given individual were shared with their maternal relative. 
Interestingly, shared variants in related subjects were principally seen in the skeletal 
muscle mtDNA, where 17/24 variants were shared (71%), compared with 50/395 
variants shared in unrelated subjects (13%, P < 0.001). In contrast, variant sharing in 
related subjects was rather uncommon in the blood mtDNA, where 8/39 variants were 
shared (21%) when compared with 9/90 variants in unrelated subjects (10%, P = 0.10). 
 
These findings have two implications. First, some of the more common MT-
HV2 variants are present in the background population at very low heteroplasmy levels. 
Second, 4-fold more variants are family specific and are transmitted between first-
degree maternal relatives. Although it is not possible, without longitudinal study, to 
state exactly what proportion of variants are due to somatic mutation, the data clearly 
show that a large proportion appear to be inherited at very low heteroplasmy levels. 
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Discussion 
Using amplicon-based UDS at unprecedented depth, we have shown that detectable 
very low-frequency mtDNA variants (0.2 – 2% heteroplasmy) are present in all tested 
healthy subjects. 
 
It is highly unlikely that nuclear pseudogene (NumtS) contamination influenced our 
results for the following reasons: Primer-BLAST analysis (hg19 build) failed to identify 
any predicted non-mtDNA PCR products using our specific MT-HV2 and MT-
CO3 primers; we were unable to generate a product from rho0 genomic DNA using 
these primers. Moreover, further evidence came from the post hoc analysis of individual 
sequence reads and scrutiny of all predicted nuclear pseudogenes (Supplementary 
Material, Table S2) (Simone et al., 2011). Based on this analysis, a minimum of six 
changes from the mtDNA consensus sequence would be expected in a read from a 
pseudogene with our MT-CO3 primers and ∼48 changes for the MT-HV2 primers. 
Read-by-read analysis never identified this number of variants, so pseudogene 
contamination is extremely unlikely in our dataset. We conclude, therefore, that 
heteroplasmy is a universal finding in humans. Although our approach does not allow 
us to state with absolute certainty whether any one variant is inherited or a somatic 
mutation, a comparison of maternal relatives shows substantial sharing between first-
degree relatives, and our findings, therefore, show that inherited variants make a 
significant contribution to the overall mutation load in any one individual. 
 
None of the heteroplasmic variants detected were haplogroup defining or haplogroup 
specific. Twelve of 40 base positions containing heteroplasmic variants are reported to 
be polymorphic (>1% of reported sequences with variants) at the population level 
(http://www.mtdb.igp.uu.se/). None of the variants detected have been ascribed definite 
pathogenic potential, although a single mutation at position m.9544 has previously been 
associated with optic neuropathy. We also examined whether variants detected had 
previously been reported as somatic mutations. In our data, 21 of 31 control region 
(MT-HV2) heteroplasmic variants we detected, and 2 of 9 coding region (MT-CO3) 
variants have previously been reported as somatic variants 
(http://www.mitomap.org/MITOMAP) (Supplementary Material, Table S4). 
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Using this approach, we also show that a disrupted mtDNA polymerase γ due to 
a POLG defect leads to increased levels of mutations, and that these increase during life, 
mirroring observations in POLG-deficient mice (Trifunovic et al., 2004; Kujoth et al., 
2005). In contrast, we did not observe a correlation between age and mutation burden in 
control subjects, whether in the blood or muscle. This suggests that de 
novo mutagenesis throughout life is unlikely to contribute significantly to the cellular 
COX defects observed in healthy aged individuals. Rather, age-related COX defects are 
more likely to be the result of clonal expansions of mutations occurring during early life 
(Elson et al., 2001). This notion has recently been demonstrated in aged colonic crypt 
cells, where multi-method measurement of mtDNA mutation load failed to demonstrate 
an age-dependent increase (Greaves et al., 2010). However, our observation of very 
low-frequency heteroplasmy transmission indicates that that many of these mutations 
will be inherited down the maternal line. As a result, all clonally expanded species need 
not be the result of somatic mutation events in early life, and some could have arisen 
from low-level inherited variants. 
 
The changes in low-level heteroplasmy value between each mother and offspring 
(Supplementary Material, Figure S1 and Supplementary Material, Table S4) are 
relatively small when compared with the shifts observed in patient pedigrees carrying 
higher levels of pathogenic mutations (Chinnery et al., 2000). However, this is 
consistent with the neutral drift theory (Wonnapinij et al., 2010) which predicts that the 
variance in the offspring heteroplasmy due to the mtDNA bottleneck decreases as the 
mother's mutation level decreases. These are the first data to show the inheritance of 
such low-level mtDNA mutations. The high rate of inheritance of the low-level 
mutation in muscle (71%) may be surprising, considering our expectations of the effect 
of the mtDNA inheritance bottleneck; however, two points should be considered here. 
First, that muscle data is from only two sibling pairs [subjects A-B and P-Q 
(Supplementary Material, Figure S1 and Supplementary Material, Table S4)]. Second, 
as noted above, the neutral drift theory predicts that very low-level mutations will have 
low variance in the offspring, making them more likely to be preserved through the 
mtDNA inheritance bottleneck. 
 
116 
 
The different patterns of mutation observed in the blood and skeletal muscle are, at least 
in part, likely to be a consequence of different rates of cell and mtDNA turnover 
between dividing (blood) and post mitotic tissues. Rapid turnover of blood cells can 
lead to the loss of mtDNA mutations during life, either through selection against a 
particular mutation (Pyle et al., 2007) or simply by genetic drift (Chinnery and Samuels, 
1999). On the other hand, the loss of mutations is much less likely in a post mitotic 
tissue such as the skeletal muscle, where the replication of mtDNA can lead to an 
increase in mutation load during life within individual cells and the tissue as a whole, 
even from very low levels of heteroplasmy (Elson et al., 2001). Thus, it is plausible that 
an inherited mutation is lost from the blood, but detected in the muscle, explaining why 
some inherited mutations are more likely to be detected in the muscle than in the blood. 
 
It is intriguing that the frequency of low-level variants in MT-HV2 is significantly 
greater than in MT-CO3 in healthy control subjects (OR 3.3). Why should this be the 
case, given that our UDS of cloned mtDNA showed no intrinsic sequence-specific 
difference between the two templates? One possible explanation is that much of the 
non-coding D-loop heteroplasmy is actually inherited at a very low level. Being a non-
coding region, these substitutions may be tolerated during transmission, unlike coding 
region variants that undergo strong negative selection during transmission (Stewart et 
al., 2008). 
 
Perhaps most importantly, we show here that next generation sequencing has the 
potential to reliably detect very low levels of heteroplasmy, when a very stringent 
analytical approach is employed. It is important to note that we did not perform a head-
to-head comparison of different next generation sequencing platforms, so it would be 
premature to conclude that the 454 approach is superior to other platforms. However, 
using this method, we have gained novel insight into mtDNA within individuals and 
within pedigrees. Prospective studies in larger family-based cohorts will substantiate 
these findings. However, given that mtDNA heteroplasmy levels can change 
dramatically during life, and during maternal transmission, the finding of universal 
mtDNA heteroplasmy has significant implications for our understanding of mtDNA at 
the population, family and individual level. If deleterious mutations are inherited, these 
have the potential to accumulate within single cells during life and thus contribute to 
neurodegenerative disease. Or, if they segregate rapidly through the mtDNA bottleneck, 
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they could lead to a maternally inherited mitochondrial disorder. This places greater 
emphasis on the importance of developing techniques to prevent the transmission of 
mtDNA heteroplasmy and preventing the clonal expansion of pre-existing mtDNA 
mutations. 
 
Materials and Methods 
Patient and samples 
All subjects gave informed consent for participation in research. Characteristics of 
patient and control samples are shown in Supplementary Material, Table S3 and 
Supplementary Material, Figure S1. 
 
Molecular analyses 
Amplicon resequencing was performed on the Roche 454 GS FLX platform. Two 
mtDNA amplicons were used: MT-HV2 (NC_012920, nt.162–455) and MT-
CO3 (nt.9307–9591). Confirmatory experiments on a subset of samples used the 
following amplicon positions: MT-HV2 (nt.109–483) and MT-CO3 (nt.9304–9653). Full 
primer sequences are shown in Supplementary Material, Table S1. Owing to the 
potential of nuclear pseudogenes to confound deep resequencing studies of mtDNA, we 
used BLAST to ensure that our primers avoided these areas and confirmed this by lack 
of amplification from mtDNA deplete rho0 DNA. Amplicon-specific mtDNA clones 
comprised the following inserts in a pGEM-T-easy vector (Promega): MT-HV2 clone 
(nt.16548–771) and MT-CO3 clone (nt.9127–9661). Autosomal negative control 
comprised amplicon BRCA2 (NC_000013.10, 32907099–32907295) and BRCA2 clone 
(32906828–32907480). Amplicon generation PCR reactions were performed in a 50 µl 
volume comprising: 1x buffer for KOD Hot Start DNA Polymerase (Novagen), 1.5 
mM MgSO4, 0.2 mM dNTPs, 0.3 μM primers, 1 U KOD Hot Start DNA Polymerase 
(Novagen) and 100 ng DNA. Cycling conditions were 95°C for 2 min followed by 30 
cycles of 95°C for 20 s, 60°C for 10 s and 70°C for 4 s. EmPCR and bidirectional 
sequencing were performed according to the manufacturer's instructions (Roche 454). 
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Bioinformatic analyses 
Base calling and alignment were performed using the algorithm of PyroBayes and 
Mosaik. Subsequent analysis of variants was performed using the custom R library 
flowgram. To maximize specificity for very low-level variants, base positions within or 
immediately adjacent to poly-mononucleotide tracts were excluded from analysis. 
Variant calls were then validated by comparison of read directions. 
 
Primer-BLAST (Ye et al., 2012) analysis to confirm complete specificity of amplicon 
generation primer pairs was performed using standard stringent parameters: human 
genome assembly hg19, blast E value 30 000, and unintended targets with <6 
mismatches were considered. 
 
Statistical analyses 
Comparison of proportions of base positions between groups was done using the chi-
squared test. 
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Figure 1. Resolution of ultra-deep sequencing-by-synthesis assay.  
Demonstration of very low levels of noise in negative controls after quality-control 
filtering for poly-mononucleotide tracts and bidirectional validation of variants. An 
amplicon was produced from cloned DNA for each mtDNA amplicon (MT-HV2, MT-
CO3) along with an autosomal amplicon (BRCA2) and a clone. All negative controls 
showed minimal numbers of base positions with any variants, and none at >0.2% 
heteroplasmy level, with no inherent differences between the different DNA templates. 
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Figure 2. Very low-level heteroplasmic mtDNA variance was detected by ultra-deep amplicon resequencing.  
(A) Comparison of variants detected in the skeletal muscle (skm) DNA within theMT-HV2 amplicon in different patient groups shows no difference 
between healthy control (n = 7) and OPA1 (n = 8) subjects, but a significant excess of variance at all heteroplasmy levels in POLG subjects (n= 8). (B) 
Comparison of variants detected in the blood DNA in healthy control (n = 7), POLG (n = 4) and OPA1 (n = 7) subjects shows that variants are present, 
but less common than in the skeletal muscle DNA with the absence of higher level variants (>2% heteroplasmy) and no difference between patient 
groups. 
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Table 1. Extent of sharing of variants in 13 pairs of maternally related and 79 pairs of unrelated samples 
 
 
Maternally related samples Unrelated samples 
p-value 
 
Shared 
variants (n) 
Unshared 
variants (n) 
Shared 
variants (%) 
Shared 
variants (n) 
Unshared 
variants (n) 
Shared 
variants (%) 
Skeletal muscle 17 7 70.8% 50 345 12.7% <0.0001 
Blood 8 31 20.5% 9 81 10.0% 0.10 
All samples 25 38 39.7% 59 426 12.2% <0.0001 
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Supplementary Material 
 
Supplementary Figure 1: Pedigrees. 
 
Supplementary Table 1: Amplicon generation for ultra-deep sequencing-by-synthesis. 
 
Supplementary Table 2: Published nuclear pseudogenes corresponding to mtDNA 
amplicons. 
 
Supplementary Table 3: Characteristics of patient and control samples. 
 
Supplementary Table 4: Variants detected in patient and control samples. 
 
Supplementary Table 5: Variants detected in skeletal muscle mtDNA of two samples 
taken from same individual at 10 year interval.  
 
123 
 
Supplementary Figure 1. Pedigrees. 
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Supplementary Table 1.  
Amplicon generation for ultra-deep sequencing-by-synthesis (454 GS FLX 
Standard Chemistry) 
Primers comprised a sequence-specific segment, a barcode, and a fusion primer 
segment. 
 
Fusion primer segments 
Forward:  GCCTCCCTCGCGCCATCAG 
Reverse:  GCCTTGCCAGCCCGCTCAG 
 
Sequence-specific segments 
HVS2:  forward, nt162-184 (CGCACCTACGTTCAATATTACAG) 
reverse, nt455-434 (AAAATAATGTGTTAGTTGGGGG) 
CO3:  forward, nt9307-9329 (GATTTCACTTCCACTCCATAACG) 
reverse, nt9591-9572 (CTTCTAGGGGATTTAGCGGG) 
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Barcode segments 
1  AAGGAAGGT 
2  TTAAGGACT 
3  TAAGGCCGT 
4  TTAAGTAAT 
5  TAAGTACGT 
6  AAGTCCGGT 
7  TAATTAAGT 
8  AATTACGGT 
9  TTAATTACT 
10  TTACGGAAT 
11  TACGGACGT 
12  ACGGCCGGT 
13  TACGTAAGT 
14  ACGTACGGT 
 
 
15  TTACGTCCT 
16  ACTTAAGGT 
17  TTACTTACT 
18  TACTTCCGT 
19  TCCGGAAGT 
20  CCGGACGGT 
21  TTCCGGCCT 
22  CCGTAAGGT 
23  TTCCGTACT 
24  TCCGTCCGT 
25  TTCCTTAAT 
26  TCCTTACGT 
27  CCTTCCGGT 
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Amplicon generation for ultra-deep sequencing-by-synthesis (454 GS FLX 
Titanium XLR70 chemistry) 
Primers comprised a sequence-specific segment, a barcode, and a fusion primer 
segment. 
 
Sequence-specific segments 
HVS2:  forward, nt.109-130 (GCACCCTATGTCGCAGTATCTG) 
reverse, nt.483-458 (GAGATTAGTAGTATGGGAGTGGGAGG) 
CO3:  forward, nt.9304-9329 (TGTGATTTCACTTCCACTCCATAACG) 
reverse, nt.9653-9629 (ATGGTGAGCTCAGGTGATTGATACT) 
 
Barcode segments 
1  ACGAGTGCGT 
2  ACGCTCGACA 
3  AGACGCACTC 
4  AGCACTGTAG 
5   ATCAGACACG 
 
Fusion primer segments 
Forward: CGTATCGCCTCCCTCGCGCCATCAG 
Reverse: CTATGCGCCTTGCCAGCCCGCTCAG 
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Supplementary Table 2. List of published nuclear mitochondrial pseudogene (Nuclear 
mitochondrial sequences, NumtS) loci within which our 454 FLX amplicons would 
potentially nest. NumtS were defined according to Simone et al. (19). All but one 
NumtS locus shows low sequence identity (compared between NumtS and rCRS 
(NC_012920)). Only one high sequence identity NumtS (HSA_NumtS_001, indicated 
*) was identified, and would be predicted to show 6 nucleotide substitutions from our 
mitochondrial DNA amplicon sequence.  
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454 FLX Amplicon NumtS ID Chromosome Sequency identity (%) 
MT-HV2 HSA_NumtS_227 5 82 
MT-HV2 HSA_NumtS_508 17 80 
    
MT-CO3 HSA_NumtS_001 1   98* 
MT-CO3 HSA_NumtS_075 2 73 
MT-CO3 HSA_NumtS_080 2 76 
MT-CO3 HSA_NumtS_084 2 76 
MT-CO3 HSA_NumtS_090 2 71 
MT-CO3 HSA_NumtS_100 2 65 
MT-CO3 HSA_NumtS_101 2 74 
MT-CO3 HSA_NumtS_146 3 74 
MT-CO3 HSA_NumtS_160 3 75 
MT-CO3 HSA_NumtS_199 4 76 
MT-CO3 HSA_NumtS_222 5 88 
MT-CO3 HSA_NumtS_237 6 78 
MT-CO3 HSA_NumtS_258 6 72 
MT-CO3 HSA_NumtS_269 7 74 
MT-CO3 HSA_NumtS_270 7 74 
MT-CO3 HSA_NumtS_272 7 76 
MT-CO3 HSA_NumtS_312 8 73 
MT-CO3 HSA_NumtS_329 9 73 
MT-CO3 HSA_NumtS_344 9 77 
MT-CO3 HSA_NumtS_346 9 76 
MT-CO3 HSA_NumtS_407 11 75 
MT-CO3 HSA_NumtS_495 16 74 
MT-CO3 HSA_NumtS_508 17 83 
MT-CO3 HSA_NumtS_561 22 69 
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Supplementary Table 3. Characteristics of patient and control samples (skm, skeletal 
muscle; bld, blood). * patient O had two blood (1997 and 2009) and two skeletal muscle 
(1999 and 2009) DNA samples analyzed.  
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SUBJECT DISEASE MUTATION TISSUE AGE 
(years) A POLG R627Q / W748S SKM / BLD 57 
B POLG R627Q / W748S SKM / BLD 57 
C POLG R627Q / R1096H SKM / BLD 17 
D POLG A467T (homozygous) SKM / BLD 45 
E POLG A467T (homozygous) SKM 35 
F POLG A467T / G848S SKM 4 
G POLG A467T / W748S SKM 28 
H POLG A467T (homozygous) SKM 30 
I OPA1 M1fsX208 SKM / BLD 59 
J OPA1 M1fsX208 BLD 33 
K OPA1 S545R BLD 63 
L OPA1 S545R SKM / BLD 30 
M OPA1 S545R BLD 38 
N OPA1 S545R BLD 3 
O OPA1 V294fsX667 SKM* / 
BLD* 
50 / 60* 
P OPA1 Intron 8 (splice site) SKM 37 
Q OPA1 Intron 8 (splice site) SKM 56 
R OPA1 R905X SKM 60 
S OPA1 R905X SKM 41 
T OPA1 Intron 15 (splice site) SKM 54 
U CONTROL N/A SKM 31 
V CONTROL N/A SKM 36 
W CONTROL N/A SKM 47 
X CONTROL N/A SKM 42 
Y CONTROL N/A SKM 1 
Z CONTROL N/A SKM 67 
AA CONTROL N/A SKM 94 
AB CONTROL N/A BLD 25 - 30 
AC CONTROL N/A BLD 25 - 30 
AD CONTROL N/A BLD 25 - 30 
AE CONTROL N/A BLD 85 - 90 
AF CONTROL N/A BLD 85 - 90 
AG CONTROL N/A BLD 85 - 90 
AH CONTROL N/A BLD 59 
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Supplementary Table 4: Variants detected in patient and control samples.  
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Supplementary Table 5: Variants detected in skeletal muscle mtDNA of two samples 
taken from same individual (patient O) at 10 year interval. Italicized heteroplasmy 
levels indicate that variant was detected but level is below the established experimental 
threshold (>0.2%). 
 
Timepoint Baseline plus 10 years 
Variant Heteroplasmy level 
189 0.38% 0.28% 
214 0.62% 0.51% 
235 0.67% 1.47% 
411 0.29% 0.17% 
414 0.80% 0.30% 
9565 0.49% 0.06% 
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SUBJECT A A B B C C D D E F G H I I J K L L M N O O O O P Q R S T U V W X Y Z AA AB AC AD AE AF AG AH population reported
SAMPLE SKM BLD SKM BLD SKM BLD SKM BLD SKM SKM SKM SKM SKM BLD BLD BLD SKM BLD BLD BLD SKM(1) SKM(2) BLD(1) BLD(2) SKM SKM SKM SKM SKM SKM SKM SKM SKM SKM SKM SKM BLD BLD BLD BLD BLD BLD BLD level reported somatic codon
GROUP POLG POLG POLG POLG POLG POLG POLG POLG POLG POLG POLG POLG OPA1 OPA1 OPA1 OPA1 OPA1 OPA1 OPA1 OPA1 OPA1 OPA1 OPA1 OPA1 OPA1 OPA1 OPA1 OPA1 OPA1 CONT CONT CONT CONT CONT CONT CONT CONT CONT CONT CONT CONT CONT CONT polymorphic? % pathogenic? mutation? position
nt (MT-HV2 )
185 27.31% 0.30% 0.23% 8.89% Y 3.1% Y
186 18.66% N Y
189 3.00% 4.96% 2.52% 2.92% 1.14% 0.38% 0.28% 0.21% 1.48% 1.32% 0.67% 10.38% 0.54% 0.54% 3.65% 46.64% Y 4.5% Y
192 0.73% N Y
194 20.08% Y 3.6% Y
195 32.07% 0.66% 0.25% 0.28% 0.25% Y 15.6% Y
196 0.22% N N
199 1.15% 0.62% Y 6.5% Y
204 1.11% 1.16% 0.45% 0.79% 0.63% 0.21% 0.98% 1.02% 0.47% 0.68% 0.26% Y 6.6% Y
207 0.59% Y 6.6% Y
214 11.58% 9.21% 1.82% 1.99% 4.41% 0.35% 0.46% 0.62% 0.51% 0.20% N Y
215 6.66% 4.47% 1.80% 0.32% 0.31% N Y
217 1.43% N N
235 0.24% 0.30% 0.91% 1.87% 0.23% 0.67% 1.47% Y 3.2% Y
238 0.20% N N
240 0.29% 0.21% N Y
241 0.25% N N
246 0.41% N N
251 0.85% 0.71% 0.37% 0.55% 0.24% N Y
253 0.43% 0.50% N Y
255 1.17% N N
263 0.83% N Y
273 0.70% 0.40% N Y
277 0.58% 0.57% 0.33% N Y
279 0.34% N N
295 0.34% Y 4.2% Y
297 0.25% N Y
299 0.29% 0.25% N N
365 0.28% N N
385 0.50% N Y
411 0.53% 0.53% 0.29% 0.23% 0.31% N N
414 0.48% 0.65% 0.35% 0.80% 0.30% 0.44% 0.37% N Y
nt (MT-CO3 )
9342 0.62% N N N 1
9377 0.94% Y 1.6% N N 3
9384 0.36% N N N 1
9386 0.67% N N N 3
9540 0.20% 0.61% 0.51% 0.69% 0.21% 0.29% Y 34.9% N Y 1
9544 0.28% N possible Y 2
9545 13.66% 0.65% 0.20% 0.53% 0.73% 0.27% Y 2.0% N N 3
9548 0.55% 0.52% 0.75% 0.25% 0.21% N N N 3
9565 0.49% N N N 2
N
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Abstract 
Background 
Anti-retroviral treated HIV-infected patients are at risk of mitochondrial toxicity, but 
non-invasive markers are lacking. Serum FGF-21 (fibroblast growth factor 21) levels 
correlate strongly with muscle biopsy findings in inherited mitochondrial disorders. We 
therefore aimed to determine whether serum FGF-21 levels correlate with muscle 
mitochondrial dysfunction in HIV-infected patients. 
 
Findings  
We performed a cross-sectional study of anti-retroviral treated HIV-infected subjects 
(aged 29 – 71 years, n = 32). Serum FGF-21 levels were determined by quantitative 
ELISA. Cellular mitochondrial dysfunction was assessed by COX (cytochrome c 
oxidase) histochemistry of lower limb skeletal muscle biopsy. Serum FGF-21 levels 
were elevated in 66% of subjects. Levels correlated significantly with current CD4 
lymphocyte count (p = 0.042) and with total CD4 count gain since initiation of anti-
retroviral therapy (p = 0.016), but not with the nature or duration of past or current anti-
retroviral treatment. There was no correlation between serum FGF-21 levels and 
severity of the muscle mitochondrial (COX) defect. 
 
Conclusions 
Serum FGF-21 levels are a poor predictor of muscle mitochondrial dysfunction in 
contemporary anti-retroviral treated patients. Serum FGF-21 levels are nevertheless 
commonly elevated, in association with the degree of immune recovery, suggesting a 
non-mitochondrial metabolic disturbance with potential implications for future 
comorbidity. 
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Findings 
Mitochondrial dysfunction is a well-described complication of anti-retroviral therapy 
(Dalakas et al., 1990; Arnaudo et al., 1991; Shikuma et al., 2001; Zaera et al., 2001; 
Miro et al., 2003; van der Valk et al., 2004; Walker et al., 2004). It is most strongly 
associated with several of the older nucleoside analogue reverse transcriptase inhibitors 
(NRTIs): zidovudine (AZT), stavudine (d4T), didanosine (ddI), and zalcitabine (ddC). 
Although these drugs are no longer in common usage in industrialised countries, there 
are nevertheless large numbers of patients who have had extensive prior exposure to 
these drugs, and some remain in common usage in developing countries. We have 
recently demonstrated that patients with previous exposure to these NRTIs may have 
persistent cellular mitochondrial COX (cytochrome c oxidase) defects in skeletal 
muscle, consequent on an NRTI-induced accumulation of somatic (acquired) 
mitochondrial DNA (mtDNA) mutations (Payne et al., 2011).  
 
Non-invasive measures of mitochondrial damage would be very valuable in the HIV 
clinic, both for the diagnosis of anti-retroviral associated mitochondrial dysfunction and 
the serial monitoring of such patients. The determination of mtDNA content in 
peripheral blood mononuclear cells (PBMCs) has previously been proposed as such a 
measure (Cote et al., 2002; Montaner et al., 2003; Chiappini et al., 2004; van der Valk 
et al., 2004). This consideration arises from the fact that the mitochondrially-toxic 
NRTIs (as listed above) cause a reduction in cellular mtDNA content (depletion) during 
therapy (Arnaudo et al., 1991; Dalakas et al., 2001; Lim and Copeland, 2001; Shikuma 
et al., 2001; Cherry et al., 2002; Cote et al., 2002; Hammond et al., 2004; Walker et al., 
2004; Hoschele, 2006). However, modern N(t)RTIs such as tenofovir (TDF) and 
abacavir (ABC) do not cause mtDNA depletion (Birkus et al., 2002), and as a result, 
mtDNA levels return to normal with a switch away from a mitochondrially-toxic NRTI. 
Thus, measuring mtDNA levels is not a useful measure of on-going mitochondrial 
dysfunction due to an NRTI exposure in the distant past. 
 
In contrast, FGF-21 (fibroblast growth factor 21) has recently been proposed as a 
valuable serum measure in inherited mitochondrial disease (Suomalainen et al., 2011). 
In these patients, serum FGF-21 levels showed a very strong correlation with 
mitochondrial dysfunction on skeletal muscle biopsy, as determined by the percentage 
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of cells expressing a COX defect (Suomalainen et al., 2011). FGF-21 is thought to 
regulate mitochondrial activity and enhance oxidative capacity, mediated via PGC-1α 
(peroxisome proliferator-activated receptor gamma co-activator 1-alpha) expression 
(Moyers et al., 2007). To date, one study has assessed serum FGF-21 in HIV infection, 
and demonstrated elevated levels (Affandi et al., 2008). Given the recently described 
association between serum FGF-21 elevation and muscle COX defects in inherited 
mitochondrial disorders (Suomalainen et al., 2011), and the recent observation of 
significant COX defects in long-term anti-retroviral treated HIV-infected patients 
(Payne et al., 2011), we speculated that muscle mitochondrial dysfunction might also 
drive the FGF-21 elevation in anti-retroviral treated HIV infection.  
 
Patient characteristics  
All subjects gave informed written consent for participation, and the study was 
approved by local research ethics committee. We performed a cross-sectional study of 
adult HIV-1 infected patients, receiving ambulatory care at one of two specialist clinics 
in Newcastle-upon-Tyne, UK. Patients with current active hepatitis B or C co-infection, 
known inherited or non-HIV-associated neuromuscular disease, and diabetes mellitus 
were excluded. No subjects were clinically obese (BMI >30). 32 HIV-infected subjects 
participated, of whom 81% were male. 84% were of white Caucasian ethnicity and the 
remainder black African. Mean age was 48.7 years, with age range of 29 - 71 years. 
Mean duration of diagnosed HIV infection was 10.8 years. Mean current CD4 
lymphocyte count was 663 cells/µl, and 61% of subjects had nadir CD4 count of <200 
cells/µl. All subjects were currently receiving combination anti-retroviral therapy, with 
a mean duration of treatment of 9.2 years. 97% of patients had fully suppressed HIV 
plasma viral load (<50 HIV-1 RNA copies/ml). 81% of subjects were receiving a non-
nucleoside reverse transcriptase inhibitor (NNRTI) and 22% a ritonavir-boosted 
protease inhibitor (PI). Regarding past (lifetime) NRTI treatment experience, 72% of 
patients had a history of AZT exposure, and 25% had a history of prior d-drug 
(dideoxynucleoside analogue) exposure. Characteristics of individual subjects are 
shown in Table 1.  
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FGF-21 determination 
Serum FGF-21 levels were determined by quantitative ELISA (BioVendor, Brno, Czech 
Republic), performed in triplicate, and normalised by log10 transformation. A serum 
FGF-21 level of <200 pg/ml was considered as normal in keeping with recent data 
(Suomalainen et al., 2011). Statistical analyses were performed in SPSS 19, using 
student’s t-test to compare binary variables and Pearson’s correlation coefficient (r) to 
examine the relationship between log10 serum FGF-21 levels and continuous variables. 
Twenty-one of 32 subjects (66%) had serum FGF-21 levels greater than the normal 
range, with four being very elevated (>800 pg/ml). On univariate analysis, serum FGF-
21 levels were positively correlated with current CD4 lymphocyte count (r = 0.36, p = 
0.042), but more strongly correlated with total CD4 cell count gain since initiation of 
anti-retroviral therapy (current minus nadir) (r = 0.45, p = 0.016) (Figure 1). In 
addition, plasma glucose levels correlated with serum FGF-21 levels, although this did 
not quite reach statistical significance (r = 0.34, p = 0.06, Figure 2), whereas as serum 
lipids and liver function did not. No other demographic or treatment variables were 
significantly associated with serum FGF-21 levels, including the nature of current or 
prior anti-retroviral therapy (Table 2). FGF-21 levels did not differ significantly 
between patients with or without clinical lipodystrophy syndrome. Only CD4 
lymphocyte count gain was independently associated with serum FGF-21 levels on 
multivariate linear regression analysis (p = 0.016).  
 
Skeletal muscle mitochondrial histochemistry 
COX histochemistry was performed on cryo-sections obtained from lower limb skeletal 
muscle biopsies on 31 of the 32 subjects (biopsy data for one subject was not 
analysable).  Results of 22 of these biopsies have been reported in our previous work 
(Payne et al., 2011), whereas the remaining 9 have not. COX contains respiratory chain 
subunits encoded by the mitochondrial genome, and fibres stain brown (positive) in the 
presence of intact respiratory chain activity (Figure 3). Proportional COX defect was 
determined by counting ≥500 fibres per biopsy, and normalised by log10 transformation. 
There was no correlation between serum FGF-21 levels and percentage COX defects on 
biopsy (r = -0.02, p = 0.9, Figure 4). 
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Discussion 
We have shown that serum FGF-21 levels are frequently elevated in contemporary anti-
retroviral treated HIV-infected patients, but do not correlate with the severity of muscle 
mitochondrial (COX) defect. In contrast, a previous study has shown a very strong 
correlation between these parameters in patients with inherited mitochondrial disorders 
(Suomalainen et al., 2011). Ours is the first study to attempt to link serum FGF-21 
levels with biopsy-proven mitochondrial defects in HIV-infected patients. What is the 
reason for this apparent discrepancy in findings? Firstly, the prior study demonstrating 
serum FGF-21 elevation in mitochondrial disease included a large number of patients 
with childhood-onset disease. Such patients typically have very severe muscle COX 
defects (affecting up to ~60% of fibres). In contrast, patients with late-onset inherited 
mitochondrial disorders typically have more modest COX defects, comparable with 
those seen in our HIV-infected patients (up to ~10% of fibres). The fact that some 
patients in our study with a biopsy COX defect of >5% of fibres had relatively normal 
FGF-21 levels suggests that this serum measure is not particularly sensitive for mild to 
moderate muscle mitochondrial defects. Secondly, the markedly abnormal serum FGF-
21 levels seen in some patients with no significant COX defect suggest a non-
mitochondrial origin, as has been observed in other metabolic disorders (Chen et al., 
2008; Zhang et al., 2008; Dushay et al., 2010). In the only previous study of FGF-21 
levels in HIV infection, the authors found associations of FGF-21 levels with obesity, 
glycaemia, dyslipidaemia and liver dysfunction, in line with literature from HIV-
uninfected patients (Domingo et al., 2010). In our study, we specifically excluded 
diabetic and obese subjects (as we wished to maximise the likelihood of detecting any 
association with NRTI-induced mitochondrial dysfunction). Interestingly however, the 
strongest predictor of serum FGF-21 levels seen in our study was a novel association 
with total CD4 lymphocyte count gain. This is an intriguing finding. It is plausible that 
patients who have low nadir CD4 lymphocyte counts may experience more profound 
metabolic changes as they undergo immune reconstitution on anti-retroviral therapy, 
switching from a catabolic state to an excessively anabolic state associated with a 
‘return to health’. This association with CD4 count gain should be further explored by 
longitudinal study.  
 
In conclusion, serum FGF-21 levels do not appear to be a sensitive or specific marker of 
muscle mitochondrial dysfunction in contemporary anti-retroviral treated patients. 
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Nevertheless they are commonly elevated in association with immune recovery. As 
serum FGF-21 levels in the HIV-uninfected population are elevated in conditions 
associated with increased cardiovascular risk, it is very plausible that serum FGF-21 
elevation in anti-retroviral treated HIV infection may also be a marker of an adverse 
metabolic risk in this patient group. Given the known increase in cardiovascular disease 
in anti-retroviral treated patients (Friis-Moller et al., 2003), the prognostic significance 
of our findings merits further research. 
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Figure 1. Correlation of serum FGF-21 levels with immune reconstitution.  
Correlation of log10 serum FGF-21 (fibroblast growth factor 21) levels in HIV-infected 
subjects and CD4 lymphocyte count gain on treatment (current minus nadir) (r = 0.45, p 
= 0.016). (* Serum FGF-21 >1920 pg/ml, the upper limit of quantitation of the assay.) 
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Figure 2. Correlation of serum FGF-21 levels with plasma glucose.  
Correlation of log10 serum FGF-21 (fibroblast growth factor 21) levels in HIV-infected 
subjects and random plasma glucose concentration (r = 0.34, p = 0.06). (* Serum FGF-
21 >1920 pg/ml, the upper limit of quantitation of the assay.) 
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Figure 3. COX histochemistry.  
Example of mitochondrial COX/SDH (cytochrome c oxidase / succinate 
dehydrogenase) histochemistry on lower limb skeletal muscle biopsy of an anti-
retroviral treated HIV-infected patient. Normal (COX positive) fibres stain brown, 
whereas COX deficient fibres counterstain blue due to preserved SDH activity. 
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Figure 4. Correlation of serum FGF-21 levels and mitochondrial defects.  
Correlation of log10 serum FGF-21 (fibroblast growth factor 21) levels in HIV-infected 
subjects and percentage COX (cytochrome c oxidase) defect on lower limb skeletal 
muscle biopsy (r = -0.02, p = 0.9). (* Serum FGF-21 >1920 pg/ml, the upper limit of 
quantitation of the assay.) 
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Table 1. Patient characteristics.  
Summary characteristics of individual HIV-infected subjects. (WB, white British; BA, black African; ART, anti-retroviral therapy; LDS, lipodystrophy 
syndrome; AZT, zidovudine; d4T, stavudine; ddI, didanosine; ddC, zalcitabine; 3TC, lamivudine; ABC, abacavir; TDF, tenofovir; FTC, emtricitabine; 
EFV, efavirenz; NVP, nevirapine; ATV, atazanavir; DRV, darunavir; LPV, lopinavir; SQV, saquinavir; NFV, nelfinavir; IDV, indinavir; RTV, 
ritonavir at therapeutic dose; /r, ritonavir at pharmacokinetic boosting dose; RAL, raltegravir; COX, cytochrome c oxidase; FGF-21, fibroblast growth 
factor 21; NA, not available.) 
 
Age (y) Gender Ethnicity
Duration of 
diagnosed 
HIV (mo)
ART 
duration 
(mo)
nadir CD4 
count (cells/uL)
current CD4 
count (cells/uL) LDS ART (current) ART (lifetime)
COX defect 
(%)
serum FGF-21 
(pg/mL)
71 M WB 130 130 UK 530 Y TDF FTC EFV ddi AZT 3TC EFV TDF FTC 3.0% 232
48 F BA 100 99 10 487 N TDF FTC NVP AZT 3TC EFV TDF FTC NVP 0.1% >1920
34 F WB 88 86 218 1121 Y ABC 3TC NVP AZT 3TC NVP ABC 0.0% 560
55 F BA 64 27 112 426 N TDF FTC AZT DRV/r TDF FTC LPV/r AZT DRV/r 0.8% 164
43 M BA 87 87 152 306 N TDF FTC EFV AZT 3TC EFV TDF FTC 0.8% 20
42 M WB 185 147 150 636 N AZT 3TC NVP AZT 3TC NVP 0.0% 342
63 M WB 97 97 169 870 N ABC 3TC EFV AZT 3TC EFV ABC 0.0% 204
29 M WB 84 32 197 401 N TDF FTC EFV TDF FTC EFV 0.0% 809
63 M WB 238 221 NA 438 N ABC 3TC NVP AZT ddI d4T 3TC ddC IDV NVP ABC 2.2% 440
62 M WB 63 62 56 190 N TDF FTC NVP TDF FTC NVP 0.2% 156
52 M WB 225 225 120 728 Y TDF FTC ATV/r AZT ddC ddI 3TC d4T SQV NVP IDV NFV ABC TDF LPV/r FTC ATV/r 1.3% 328
36 M WB 139 138 197 627 N AZT 3TC EFV AZT 3TC EFV TDF FTC 0.3% 214
51 M WB 190 183 10 747 N ABC TDF NVP AZT ddI d4T 3TC RTV NVP IDV ddC ABC ATV/r TDF 4.9% 252
33 F WB 96 95 83 1289 N TDF FTC EFV AZT 3TC EFV TDF FTC 0.0% 177
48 M WB 102 100 259 1329 Y AZT 3TC EFV AZT 3TC EFV 0.4% 409
51 M WB 145 144 151 421 N AZT 3TC NVP AZT 3TC NVP 1.4% 254
66 M WB 71 26 287 455 N TDF FTC EFV TDF FTC EFV 11.2% 470
46 M WB 158 157 250 1452 N TDF FTC EFV AZT 3TC IDV EFV ABC TDF FTC 1.4% 1218
61 M WB 116 113 NA 498 Y TDF FTC NVP AZT 3TC EFV NVP TDF FTC 2.4% 182
30 M WB 88 23 283 661 N TDF FTC DRV/r TDF FTC EFV DRV/r 0.1% 207
62 M WB 284 202 NA 422 N ABC NVP LPV/r SQV AZT ddC 3TC d4T ddI IDV ABC NVP NFV LPV/r 0.8% 92
45 M WB 159 158 176 660 N TDF FTC NVP AZT 3TC IDV NVP TDF FTC 0.0% 60
54 M WB 79 38 244 638 N TDF FTC DRV/r TDF FTC EFV DRV/r 3.4% 178
52 M WB 166 164 0 662 Y TDF FTC NVP AZT d4T IDV NFV SQV 3TC NVP ddI TDF FTC 2.8% 525
51 M WB 243 171 327 539 Y TDF FTC EFV AZT ddI RTV NFV TDF FTC EFV 1.5% 231
35 F BA 62 25 380 638 N TDF FTC EFV TDF FTC EFV 0.0% 82
53 M WB NA 48 301 804 N TDF FTC EFV TDF FTC EFV NA 490
36 M WB 130 130 18 898 N TDF FTC ATV/r AZT 3TC EFV TDF FTC ATV/r 0.0% 530
48 M WB 53 14 332 443 N TDF FTC EFV TDF FTC EFV 0.0% 56
52 F BA 83 81 17 485 Y TDF FTC EFV AZT 3TC EFV TDF FTC 0.7% 224
38 M WB 129 128 4 761 Y TDF FTC EFV AZT 3TC EFV TDF FTC 0.0% 935
47 M WB 183 164 305 668 Y ABC RAL ATV/r d4T 3TC NVP ddI IDV ABC ATV/r RAL 9.8% 114
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Table 2. Associations of serum FGF-21 levels.  
(a) binary variables; (b) continuous variables. (PI, protease inhibitor; AZT, zidovudine; 
d-drug, dideoxynucleoside analogue; ART, anti-retroviral therapy; ALT, alanine 
transaminase; HDL, high density lipoprotein). 
 
(a) 
Variable (n) 
Log10 Serum FGF-21, 
mean (SD) 
p value 
Gender Male (26) 2.39 (0.40)  
 Female (6) 2.46 (0.48) 0.71 
Ethnicity Caucasian (27) 2.44 (0.33)  
 Black African (5) 2.21 (0.72) 0.27 
Current ART PI (7) 2.29 (0.26)  
 No PI (25) 2.43 (0.44) 0.43 
Lifetime ART d-drugs (8) 2.38 (0.26)  
  No d-drugs (24) 2.41 (0.45) 0.86 
 AZT (23) 2.44 (0.42)  
 No AZT (9) 2.30 (0.39) 0.41 
Lipodystrophy Yes (10) 2.50 (0.27)  
 No (22) 2.36 (0.46) 0.39 
Lipid-lowering therapy Yes (8) 2.32 (0.52)  
 No (24) 2.43 (0.38) 0.53 
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(b) 
Variable  
Correlation 
coefficient (r) 
p 
value 
Age  -0.07 0.69 
Duration of diagnosed HIV 
infection 
 -0.08 0.67 
Duration of lifetime ART Total 0.12 0.50 
 d-drug 0.01 0.97 
 AZT 0.13 0.47 
CD4 lymphocyte count Nadir -0.29 0.14 
 Current 0.36 0.042 
CD4 count gain 
(Current minus 
nadir) 
0.45 0.016 
Serum ALT  0.27 0.14 
Plasma glucose  0.34 0.06 
Serum lipids Total cholesterol -0.03 0.87 
 HDL cholesterol 0.02 0.90 
 
Non-HDL 
cholesterol 
-0.06 0.75 
Mitochondrial histochemistry COX defect (log10) -0.02 0.91 
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Abstract 
Modern anti-retroviral therapy is highly effective at suppressing viral replication and 
restoring immune function in HIV-infected persons. However, such individuals show 
reduced physiological performance and increased frailty compared with age-matched 
uninfected persons. Contemporary anti-retroviral therapy is thought to be largely free 
from neuromuscular complications, whereas several anti-retroviral drugs previously in 
common usage have been associated with mitochondrial toxicity. It has recently been 
established that patients with prior exposure to such drugs exhibit irreversible cellular 
and molecular mitochondrial defects. However the functional significance of such 
damage remains unknown.  
 
Here we use phosphorus magnetic resonance spectroscopy (
31
P-MRS) to measure in 
vivo muscle mitochondrial oxidative function, in patients treated with contemporary 
anti-retroviral therapy, and compare with biopsy findings (cytochrome c oxidase (COX) 
histochemistry). 
 
We show that dynamic oxidative function (post-exertional ATP (adenosine 
triphosphate) resynthesis) was largely maintained in the face of mild to moderate COX 
defects (affecting up to ~10% of fibers): τ½ ADP (half-life of adenosine diphosphate 
clearance), HIV-infected 22.1 ±9.9 s, HIV-uninfected 18.8 ±4.4 s, p = 0.09. In contrast, 
HIV-infected patients had a significant derangement of resting state ATP metabolism 
compared with controls: ADP / ATP ratio, HIV-infected 1.24 ±0.08 x10
-3
, HIV-
uninfected 1.16 ±0.05 x10
-3
, p = 0.001.  
 
These observations are broadly reassuring in that they suggest that in vivo mitochondrial 
function in patients on contemporary anti-retroviral therapy is largely maintained at the 
whole organ level, despite histochemical (COX) defects within individual cells. Basal 
energy requirements may nevertheless be increased. 
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Introduction 
Combination anti-retroviral therapy (cART) has transformed the prognosis for HIV-
infected persons since the late 1990s. However, patients are at risk of mitochondrial 
toxicity, thought to be mediated very largely through exposure to certain nucleoside 
analog reverse transcriptase inhibitor (NRTI) anti-retrovirals. NRTIs were the first class 
of licensed anti-retroviral drug, and several of the older members of this class, 
zidovudine, stavudine, zalcitabine and didanosine, are known to inhibit the sole 
mitochondrial DNA (mtDNA) polymerase, pol γ, resulting in chain termination during 
mtDNA replication. During therapy, the molecular consequence of this inhibition is 
reduction in cellular mtDNA content (mtDNA depletion). A wealth of previous studies 
has demonstrated this phenomenon both in vitro, and in a variety of tissues in vivo 
(Arnaudo et al., 1991; Cherry et al., 2002; Cote et al., 2002; Hoschele, 2006). These 
older NRTIs are no longer in common usage in industrialized countries owing to 
concerns over their toxicity profiles, although zidovudine and stavudine have been very 
extensively used in anti-retroviral therapy ‘roll-out’ programs in developing countries in 
recent years. Currently used NRTIs, such as tenofovir (a nucleotide RTI) and abacavir, 
have been shown to be essentially free from pol γ inhibition in vitro and to cause no 
significant mtDNA depletion in vivo (Lim and Copeland, 2001; Birkus et al., 2002). If a 
patient’s therapy is switched away from a pol γ inhibiting NRTI, the impairment of 
mtDNA replication is removed and mtDNA content returns to normal (McComsey et 
al., 2005). Therefore, although most patients are no longer exposed to pol γ inhibiting 
NRTIs, a significant cohort of long-term patients will have extensive prior exposure to 
such drugs. Although such patients do not have persistent mtDNA depletion, it has 
recently been established that they may have persistent histochemical mitochondrial 
defects evidenced by an increased proportion of COX (cytochrome c oxidase) deficient 
skeletal muscle fibers. These COX deficient fibers contain high levels of individual 
somatic (acquired) mtDNA mutations (principally large-scale deletion mutations) 
(Payne et al., 2011). The relevance of this persistent cellular and molecular damage on 
mitochondrial function remains unknown. It is therefore unclear to what extent 
mitochondria may be functionally impaired in HIV-infected patients treated with 
contemporary cART. 
 
Phosphorus magnetic resonance spectroscopy (
31
P-MRS) allows the dynamic 
measurement of in vivo skeletal muscle oxidative function through assessment of ATP 
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(adenosine triphosphate) metabolites as well as acid handling. 
31
P-MRS has previously 
been employed in the longitudinal study of subjects with inherited mitochondrial 
disorders, both primary mtDNA defects, and secondary mtDNA defects consequent on 
nuclear gene disorders of mtDNA maintenance (Penn et al., 1992; Trenell et al., 2006; 
Yu-Wai-Man et al., 2011). Limited data also suggests that 
31
P-MRS abnormalities in 
skeletal muscle may be demonstrated in the setting of acute exposure to pol γ inhibiting 
NRTIs: early in the HIV epidemic, in infected patients exposed to high-dose zidovudine 
therapy; and in uninfected volunteers treated with stavudine. Such measurements have 
not been performed in contemporary cART treated patients (Sinnwell et al., 1995; 
Fleischman et al., 2007).  
 
We have therefore used 
31
P-MRS to determine whether patients on contemporary anti-
retroviral therapy have abnormal in vivo mitochondrial oxidative function, and whether 
this correlates with biopsy COX defects. 
 
Methods 
Participants.  
Participants were adult HIV-1 infected patients, receiving ambulatory care at one of 
four specialist clinics (2 hospital-based, 2 community-based setting). Patients with 
current active hepatitis B or C co-infection were excluded. Participants were unselected 
with respect to the presence or absence of complications of HIV or anti-retroviral 
therapy. Patients with known inherited or non-HIV-associated neuromuscular disease 
were excluded. Demographic data, surrogate markers (CD4 T lymphocyte count, and 
HIV-1 RNA plasma viral load) and detailed lifetime anti-retroviral treatment history 
were obtained by case note review.  
 
HIV-uninfected control subjects for 
31
P-MRS studies were age and sex matched to our 
cases, and we excluded persons with diabetes mellitus or abnormal glucose handling, 
thyroid disease, previous muscle injury, or diagnosed neuromuscular disease. 
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Research was approved by the Newcastle and North Tyneside Local Research Ethics 
Committee (ref. 06/Q0905/137). All subjects gave informed written consent for 
participation. 
 
Phosphorus magnetic resonance spectroscopy.  
MR studies were performed on calf muscle using a 3T Intera Achieva magnet (Philips). 
31
P-MRS measurements were obtained using a calf coil with a voxel within soleus 
muscle during: a 1 minute baseline resting period; a 3 minute period of calf flexion 
exercise at 25% of maximal voluntary contractile force; and a 6 minute recovery period 
(Trenell et al., 2006; Hollingsworth et al., 2008). This exercise paradigm was 
specifically designed to keep metabolism within the aerobic phase. Analysis was 
performed in jMRUI v3.0 (Java Magnetic Resonance User Interface) using AMARES 
with appropriate prior knowledge parameters for skeletal muscle (Naressi et al., 2001) 
and metabolite levels were calculated as previously described (Hollingsworth et al., 
2008). Phosphorylation potential was calculated from the concentration of ATP ([ATP], 
buffered at 8.2 mM), and the empirically calculated concentrations of adenosine 
diphosphate and inorganic phosphate ([ADP], [Pi]), as [ATP]/([ADP][Pi]) (Harris et al., 
1974).  
 
Skeletal muscle biopsies and mitochondrial (COX) histochemistry.  
Percutaneous lower limb skeletal muscle biopsies were performed under local 
anesthesia and snap-frozen in the liquid phase of isopentane, cooled in liquid nitrogen 
within 20 minutes of collection. Sequential COX-SDH (cytochrome c oxidase / 
succinate dehydrogenase) histochemistry was performed on 20µm transverse cryo-
sections. COX contains respiratory chain subunits encoded by the mitochondrial 
genome, and fibers stain brown (positive) in the presence of intact respiratory chain 
activity. SDH contains subunits encoded entirely by the nuclear genome and thus 
provides an effective counterstain (blue) as activity will be preserved in the presence of 
a cellular mtDNA defect. Proportional COX defect was determined by counting ≥500 
fibers per biopsy.  
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Statistical comparisons.  
Student’s paired t-test was used to compare MRS parameters between cases and 
controls. Correlation coefficients were calculated between COX and MRS data. All 
analyses were performed in SPSS 19. 
 
Results 
Patient characteristics.  
23 HIV-infected subjects participated; 78% were male. Mean age was 57.6 years, with 
age range of 45-74 years. Mean duration of diagnosed HIV infection was 11.8 years. 
Mean current CD4 T lymphocyte count was 551 cells/µl; mean nadir CD4 count was 
183 cells/µl. All subjects were currently receiving cART, of whom 96% had a fully 
suppressed HIV plasma viral load (<40 HIV-1 RNA copies/ml). In addition to their 
NRTIs, 70% of treated subjects were receiving a non-nucleoside reverse transcriptase 
inhibitor (NNRTI) and 35% a protease inhibitor (PI). With respect to the pol γ inhibiting 
NRTIs, 61% of patients had a prior history of zidovudine exposure, and 48% had 
dideoxynucleoside analog (stavudine, zalcitabine or didanosine) exposure (treatment 
details of individual patients are shown in Table 1). 
 
Measures of muscle ATP and acid metabolism by 
31
P-MRS.  
In the resting state, baseline ATP metabolites and pH values were significantly higher in 
cART-treated HIV-infected subjects compared to age and gender-matched controls 
(mean ±SD):  ADP/ATP ratio, HIV-infected 1.24 ±0.08 x10
-3
, HIV-uninfected 1.16 
±0.05 x10
-3
, p = 0.001; phosphocreatine/ATP (PCr/ATP) ratio, HIV-infected 5.04 
±1.89, HIV-uninfected 3.75 ±0.26, p = 0.004; pH, HIV-infected 7.07 ±0.03, HIV-
uninfected 7.04 ±0.02, p = 0.002. Correspondingly, calculated basal phosphorylation 
potential was significantly lower in HIV-infected subjects compared with controls: 
HIV-infected 227 ±86 mM
-1
, HIV-uninfected 292 ±53 mM
-1
, p = 0.003 (Figure 1a-c). 
(Further details of calculated 
31
P-MRS parameters are shown in the Supplementary 
Table.) 
 
In terms of dynamic oxidative function, mean post-exercise ATP metabolite recovery 
rates did not differ significantly between HIV-infected subjects and controls. For 
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example, τ½ ADP: HIV-infected 22.1 ±9.9 s, HIV-uninfected 18.8 ±4.4 s, p = 0.09 
(Figure 1d). None of the clinical variables (age, duration of diagnosed HIV infection, 
CD4 T lymphocyte count, or anti-retroviral treatment history) correlated significantly 
with any of the baseline or post-exercise 
31
P-MRS parameters in HIV-infected subjects.  
 
Mitochondrial (COX) histochemistry and correlation with ATP metabolism.  
A wide range of COX defects were observed across the subject group (0 to >10% of 
muscle fibers affected per biopsy). Interestingly, we observed significant COX defects 
both in patients with prior exposure to pol γ inhibiting NRTIs, and in some patients 
without such exposure (COX defects for individual patients are shown in Table 1). 
Resting state ADP/ATP ratio showed a moderate correlation with biopsy proportional 
COX defect (Kendall’s τ = 0.34, p = 0.034) (Figure 2a). There was no correlation 
between dynamic ATP metabolism, for example as estimated by τ½ ADP, and biopsy 
COX defect (Figure 2b).  
 
Discussion 
In our study, most anti-retroviral treated HIV-infected subjects demonstrated dynamic 
in vivo tissue mitochondrial function comparable with uninfected control subjects, 
whereas it is generally impaired in inherited mitochondrial disorders. Our subject group 
included patients with very long durations of HIV infection and extensive anti-retroviral 
drug treatment histories, including past exposure to pol γ inhibiting NRTIs. 
Interestingly, in the present study we observed COX defects both in subjects with prior 
exposure to pol γ inhibiting NRTIs, and in some subjects without such exposure. This 
observation contrasts with our previous work in younger HIV-infected patients (all aged 
≤50 years), where COX defects appeared to be attributable almost entirely to exposure 
to pol γ inhibiting NRTIs (Payne et al., 2011). In the present study, the heterogeneous 
COX defects are most likely to reflect the significantly older subject age range (45-74 
years). In this age group it is expected to see some COX defects due to normal aging 
(Brierley et al., 1996), although it is also possible that there are other unmeasured HIV 
or treatment-associated factors driving COX defects in some of these patients. As with 
NRTI-associated COX defects, these COX deficient fibers also contain high levels of 
individual somatic mtDNA mutations (Bua et al., 2006). What is therefore the likely 
explanation of our finding of largely normal in vivo muscle mitochondrial function? 
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COX-deficient fibers contain high levels of mutant mtDNA, whereas COX positive 
fibers contain almost exclusively wild-type mtDNA. Therefore function at the whole 
tissue level is presumably compensated by the larger number of fibers with normal 
COX function. In contrast, in the historical context when patients were actively treated 
with a pol γ inhibiting NRTI, the molecular defect was one of mtDNA depletion, and 
the impairment of oxidative function would be expected to affect all fibers (Sinnwell et 
al., 1995). We therefore conclude that although somatic mtDNA mutations and 
associated cellular COX defects are frequently present in contemporary cART treated 
patients, there is some ability to compensate for in vivo exertional oxidative function in 
the muscle as a whole.  
 
The decreased basal phosphorylation potential, as we have observed in our patients, 
implies an increased rate of ATP synthesis at rest (Jeneson et al., 1996). Cytosolic ATP 
concentration is tightly buffered, and results from the balance of the ATP hydrolysis 
required for the maintenance of cellular integrity and the synthesis of ATP from 
oxidative phosphorylation (Harris et al., 1974). The rate of ATP synthesis is strongly 
dependent on the phosphorylation potential in resting muscle, with a decreased 
phosphorylation potential, as we have observed in our patients, implying an increased 
rate of ATP synthesis (Jeneson et al., 1996). This notion suggests that there is a 
requirement for an increased basal rate of intracellular ATP hydrolysis in HIV-infected 
subjects, and an increased basal rate of ATP synthesis is therefore required to maintain 
ATP homeostasis. Although this might imply increased basal energy expenditure in 
these patients compared with healthy subjects, given that dynamic in vivo mitochondrial 
function is unimpaired, the physiological significance of this observation remains 
uncertain. Further work should therefore examine correlates of this finding, such as 
fatigue (Payne et al., 2013).  
 
In conclusion, in a cohort of predominantly older HIV-infected patients with 
longstanding cART, we observed frequent histochemical COX defects both in patients 
with and without prior exposure to pol γ inhibiting NRTIs. It is, however, broadly 
reassuring that in vivo whole tissue mitochondrial function in most contemporary anti-
retroviral treated patients appears to be largely maintained, despite the presence of this 
frequent mitochondrial damage within individual cells.  
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Figure 1. Phosphorus magnetic resonance spectroscopy. Resting state metabolic 
parameters differed significantly between HIV-infected subjects (HIV+) and HIV-
uninfected controls (HIV-): ADP/ATP (adenosine diphosphate/ATP) ratio (a), 
phosphorylation potential (b), and pH (c) (n = 23 each; ADP/ATP, p = 0.001; 
phosphorylation potential, p = 0.003; pH, p = 0.002). In contrast, the rate of ATP re-
synthesis (estimated as τ½ ADP) following exertion was not significantly impaired in 
HIV-infected subjects compared with controls (p = 0.09) (d).   
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Figure 2. Relationship of phosphorus magnetic resonance spectroscopy and muscle 
histochemistry. Resting state ADP/ATP ratio showed moderate correlation with the 
percentage frequency of COX deficient muscle fibers in treated HIV-infected subjects 
(Kendall’s τ = 0.34, p = 0.034) (a), whereas the rate of ATP re-synthesis following 
exertion (estimated as τ½ ADP) did not (Kendall’s τ = 0.04) (b).  
  
171 
 
(a) 
 
  
172 
 
(b) 
 
 
 
 
173 
 
Table 1. Characteristics of HIV-infected subjects.  
 
 
VL, plasma HIV-1 RNA viral load; (c)ART, (combination) anti-retroviral therapy; AZT, zidovudine; d4T, stavudine; ddI, didanosine; ddC, zalcitabine; 
3TC, lamivudine; ABC, abacavir; TDF, tenofovir; FTC, emtricitabine; EFV, efavirenz; NVP, nevirapine; ATV, atazanavir; DRV, darunavir; LPV, 
lopinavir; SQV, saquinavir; NFV, nelfinavir; IDV, indinavir; FOS-APV, fosamprenavir; RTV, ritonavir at therapeutic dose; /r, ritonavir at 
pharmacokinetic boosting dose; MVC, maraviroc; RAL, raltegravir; UK, unknown; NA, not available; COX, cytochrome c oxidase. COX data (but not 
MRS data) from 5 subjects has been previously described (Payne et al., 2011). 
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Supplementary Table. Phosphorus magnetic resonance data.  
 
 
HIV  
(n = 23) 
Control  
(n = 23) 
   mean SD mean SD p-value 
Basal (Resting state)         
 Pi/ATP 0.52 0.27 0.37 0.06 0.010 
PCr/ATP 5.04 1.89 3.75 0.26 0.004 
ADP/ATP (x10
-3
) 1.24 0.08 1.16 0.05 0.001 
Phosphorylation potential (mM
-1
) 227 86 292 53 0.003 
pH 7.07 0.03 7.04 0.02 0.002 
 
        
 Post-exercise (Recovery)         
 Initial PCr resynthesis (mM/min) 15.6 14.8 12.2 4.9 0.22 
τ½ PCr (s) 30.2 13.6 27.1 8.3 0.31 
τ½ ADP (s) 22.1 9.9 18.8 4.4 0.09 
Qmax[ATP] (mM/min) 27.5 19.2 23.3 10.2 0.28 
Minimum pH 6.98 0.14 7.00 0.03 0.48 
Initial proton efflux (mM/min) 2.37 2.10 1.69 1.70 0.10 
 
(Pi, inorganic phosphate; PCr, phosphocreatine; ADP, adenosine diphosphate; ATP, 
adenosine triphosphate.) 
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Abstract 
Objective 
The aim of the study was to determine the prevalence and risk factors for HIV-
associated fatigue in the era of highly active antiretroviral therapy (HAART). 
Methods 
A cross-sectional survey of 100 stable HIV-infected out-patients was carried out. 
Severity of fatigue was measured using the Fatigue Impact Scale (FIS). Symptoms of 
orthostatic intolerance (dysautonomia) were evaluated using the Orthostatic Grading 
Scale (OGS). Data for HIV-infected patients were compared with those for 166 
uninfected controls and 74 patients with chronic fatigue syndrome (CFS) / myalgic 
encephalomyelitis (encephalopathy) (ME). 
Results 
Ninety-one per cent of HIV-infected patients were on HAART and 78% had suppressed 
plasma HIV viral load (≤ 40 HIV-1 RNA copies/mL). Fifty-one per cent of HIV-
infected patients reported excessive symptomatic fatigue (FIS ≥ 40), and 28% reported 
severe fatigue symptoms (FIS ≥ 80). The mean FIS score among HIV-infected patients 
was 50.8 [standard deviation (SD) 41.9] compared with 13.0 (SD 17.6) in uninfected 
control subjects, and 92.9 (SD 29.0) in CFS patients (P < 0.001 for comparison of HIV-
infected patients and uninfected controls). Among HIV-infected patients, fatigue 
severity was not significantly associated with current or nadir CD4 lymphocyte count, 
HIV plasma viral load, or whether on HAART. Prior dideoxynucleoside analogue (d-
drug) exposure (P = 0.016) and the presence of clinical lipodystrophy syndrome 
(P = 0.011) were associated with fatigue. Additionally, fatigue severity correlated 
strongly with symptomatic orthostatic intolerance (r = 0.65; P < 0.001). 
Conclusions 
Fatigue is very common and often severe in HIV-infected out-patients, despite viral 
suppression and good immune function. In a subgroup of patients, prior d-drug 
exposure may contribute to fatigue, suggesting a metabolic basis. Dysautonomia may 
also drive fatigue associated with HIV infection, as in other chronic diseases, and 
CFS/ME, and should be further evaluated with the potential for a shared therapeutic 
approach. 
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Introduction 
Fatigue was a very common symptom in HIV-infected persons in the pre-highly active 
antiretroviral therapy (HAART) era, when it appeared to be associated with advanced 
immunosuppression and clinical AIDS (Darko et al., 1992). It is unclear to what extent 
fatigue remains a problem in the modern era. 
 
Fatigue is a symptom which patients and physicians may respectively find difficult to 
articulate and manage (Woodward et al., 1995). The pathological basis of fatigue is 
poorly understood; in particular, the contribution that biological, as opposed to 
psychological, factors may make has received little attention. However, recent research 
suggests that common mechanisms including dysautonomia (orthostatic intolerance) 
may plausibly drive fatigue in diverse chronic diseases (Freeman and Komaroff, 1997; 
Barendregt et al., 1998; Rowe and Calkins, 1998; Flachenecker et al., 2003; Newton et 
al., 2007b; Jones et al., 2009). 
 
We therefore aimed to quantify the prevalence of excessive fatigue and its associated 
factors in a contemporary HIV-infected cohort. 
 
Patients and methods 
Participants 
We evaluated fatigue and associated symptoms in consecutive unselected adult HIV-
infected out-patients attending our regional infectious diseases unit. Demographic data, 
HIV surrogate markers, and antiretroviral treatment data were retrieved by case note 
review. Patients with another probable physical or psychiatric reason for fatigue 
symptoms were excluded, using the approach outlined in the Centers for Disease 
Control and Prevention (CDC) 1994 Fukuda criteria for the diagnosis of chronic fatigue 
syndrome / myalgic encephalomyelitis (encephalopathy) (CFS/ME) (Fukuda et al., 
1994). HIV-uninfected control subjects of comparable age from the same geographical 
area had been previously recruited through notices in local press and hospitals asking 
for volunteers to participate in research projects (no selection was made for presence or 
absence of fatigue). CFS/ME patients were receiving out-patient care in our institution 
and fulfilled the CDC 1994 Fukuda criteria. 
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Symptom assessment tools 
We administered self-rating scales comprising the Fatigue Impact Scale (FIS) (Prince et 
al., 2000) and the Orthostatic Grading Scale (OGS) (Schrezenmaier et al., 2005). The 
FIS is a 40-item generic fatigue impact scale. A score ≥ 40 indicates excessive fatigue 
and ≥ 80 severe fatigue. The OGS reports symptoms of orthostatic intolerance resulting 
from orthostatic hypotension. It comprises five items (frequency of orthostatic 
symptoms, severity of orthostatic symptoms, conditions under which orthostatic 
symptoms occur, interference with activities of daily living, and standing time before 
experiencing orthostatic symptoms), each rated from 0 to 4, with the total score as the 
sum of the items. Studies have shown good correlation between OGS scores and 
conventional physiological measures of the autonomic nervous system (Schrezenmaier 
et al., 2005). A score of ≥ 4 is considered consistent with at least moderate orthostatic 
intolerance and ≥ 9 consistent with a formal diagnosis of orthostatic hypotension. These 
tools have been validated for self-completion in a range of other fatigue-associated 
chronic diseases, such as primary biliary cirrhosis (PBC) (Prince et al., 2000). 
 
Statistical analyses 
Comparisons of test scores between patient groups and by dichotomous variables were 
made using Student's t-test. Univariate relationships between FIS and continuous linear 
variables were assessed using Pearson correlation. Multivariate analysis was performed 
using linear regression. Statistical analyses were performed in SPSS 19 (IBM, Armonk, 
NY). 
 
Results 
Patient and control group characteristics 
One hundred self-rating scales from HIV-infected patients were evaluated. 
Demographic, disease and treatment data were as follows: mean age 46.9 years (range 
27–70 years); 64% male; median duration of diagnosed HIV infection 8.0 years (range 
1–27 years); mean current CD4 lymphocyte count 520 cells/μL (range 151–
1569 cells/μL); mean nadir CD4 count 194 cells/μL (range 11–928 cells/μL); 91% 
currently receiving HAART; 78% of total group with plasma HIV viral load ≤ 40 HIV-1 
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RNA copies/ml; 1% hepatitis C virus coinfected. A total of 166 HIV-uninfected control 
subjects were analysed. The group was well age-matched (mean 47.5 years; range 21–
77 years), although it contained a lower proportion of men (33%). Seventy-four patients 
with CFS/ME were included in the analysis (mean age 54.0 years; range 24–80 years; 
24% male). 
 
Fatigue, HIV disease activity and HAART 
Half of the HIV-infected patients (50 of 99; 51%) reported excessive fatigue (FIS ≥ 40), 
and 28 (28%) reported severe fatigue (FIS ≥ 80) (one rating scale was insufficiently 
complete for FIS analysis). Mean FIS scores were significantly higher in HIV-infected 
patients compared with uninfected control subjects [HIV-infected, 50.8 (SD 41.9); HIV-
uninfected, 13.0 (SD 17.6); P < 0.001]. The highest FIS scores observed in HIV-
infected patients were comparable with those seen in CFS/ME patients (Fig. 1a). The 
following demographic and disease factors showed no significant association with 
fatigue severity (FIS score) in the HIV-infected group: gender [mean FIS (SD): male 
patients, 54.6 (41.8); female patients, 44.6 (43.2); P = 0.79], age (r = 0.04; P = 0.70), 
current or nadir CD4 lymphocyte count (current, r = 0.04; P = 0.70; nadir, 
r = 0.05; P = 0.66), detectable plasma HIV viral load [mean FIS (SD): viral load ≤ 40 
copies/ml, 50.0 (43.1); viral load > 40, 54.8 (40.0);P = 0.64], or whether on HAART 
[mean FIS (SD): on HAART, 50.3 (42.0); off HAART, 58.9 (47.0); P = 0.56] (Table 1). 
Duration of diagnosed HIV infection (r = 0.26; P = 0.010), current treatment with non-
efavirenz-based HAART [mean FIS (SD): no EFV, 59.0 (44.2); EFV, 40.2 
(37.4);P = 0.036], prior dideoxynucleoside analogue (d-drug) exposure [mean FIS (SD): 
d-drug, 68.9 (39.9); no d-drug, 43.8 (41.1); P = 0.016; Fig. 1b], and the presence of 
clinically ascertained lipodystrophy syndrome (LDS) [mean FIS (SD): LDS, 76.5 
(40.5); no LDS, 46.4 (41.2); P = 0.011] were all significantly associated with FIS score 
on univariate analysis. There was a nonsignificant trend towards an association of 
fatigue severity with current protease inhibitor (PI) use [mean FIS (SD): PI, 62.0 (42.9); 
no PI, 45.4 (41.0); P = 0.09]. None of these factors remained independently significantly 
associated with FIS on multivariate analysis, as a result of strong co-segregation of 
these exposures. 
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Fatigue and orthostatic intolerance 
Symptoms of dysautonomia were common among HIV-infected patients, with 38 of 99 
(38%) reporting significant orthostatic intolerance (OGS ≥ 4) and 12 (12.1%) with more 
severe symptoms, suggestive of orthostatic hypotension (OGS ≥ 9) (Schrezenmaier et 
al., 2005). OGS and FIS scores showed a highly significant correlation 
(r = 0.65; P < 0.001; Fig. 1c). Mean OGS scores were significantly higher in HIV-
infected patients compared with uninfected controls [3.57 (SD 3.70) vs. 1.25 (SD 
1.47); P < 0.001], but lower than in CFS/ME patients [6.82 (SD 4.31); P < 0.001]. Both 
OGS (P < 0.001) and history of d-drug exposure (P = 0.006) remained significantly 
associated with FIS score in HIV-infected patients on multivariate analysis. 
 
Discussion 
Fatigue remains a very common and often severe symptom in HIV-infected patients. 
Prior to this study, very few of these patients had been identified clinically as having 
symptomatic fatigue and it is likely that this condition is significantly under-recognized. 
This surprisingly high level of fatigue was seen despite the vast majority of patients 
receiving suppressive HAART therapy, and no association was seen with routine 
markers of HIV disease (CD4 lymphocyte count or plasma viral load). This is in 
contrast to data from the pre-HAART era, where fatigue appeared to correlate with 
clinical disease stage, and suggests different aetiological factors may now be 
important (Darko et al., 1992). 
 
What may be driving HIV-associated fatigue in the HAART era? The pathogenesis of 
fatigue remains poorly understood, but is likely to be complex and involve both 
physiological and psychological factors. Our data suggest two novel physiological 
contributors. Firstly, fatigue severity was increased in patients with long-standing HIV 
infection, past d-drug exposure and LDS. As a result of the strong co-segregation of 
these factors, it was not possible to establish which factor was the most important 
predictor of fatigue in this group, but rather patients with these factors represent a 
subgroup of highly treatment-experienced HIV-infected patients. Given the established 
associations between nucleoside reverse transcriptase inhibitor (NRTI) exposure, LDS 
and acquired mitochondrial injury, it is certainly plausible that such patients show 
fatigue resulting from metabolic/mitochondrial dysfunction (Carr et al., 2000; Zaera et 
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al., 2001; Payne et al., 2011). Consistent with this notion, limited data from magnetic 
resonance spectroscopy (MRS) studies point to a role of muscle mitochondrial 
dysfunction in fatigue associated with CFS/ME and PBC (Hollingsworth et al., 2010; 
Jones et al., 2010). Secondly, we have shown that symptoms of dysautonomia 
(orthostatic intolerance) are independently associated with fatigue in HIV-infected 
patients. Recent evidence suggests that dysautonomia is a key biological driver of 
fatigue in several chronic diseases including multiple sclerosis (MS) and PBC, as well 
as CFS/ME (Freeman and Komaroff, 1997; Rowe and Calkins, 1998; Flachenecker et 
al., 2003; Newton et al., 2007a). Furthermore, fatigue is well described in vasovagal 
syncope (VVS), a primary dysautonomia syndrome (Legge et al., 2008). Fuller 
understanding of the mediators of a causal relationship between fatigue and 
dysautonomia (for example, regulation of oxygen delivery to muscles) is the subject of 
ongoing research (Jones et al., 2010). 
 
None of the patients included in this study had untreated major depression, based on 
case note review, and explicit pathways exist in our unit for the management of 
depression. Nevertheless, it is well recognised that symptoms of depression are very 
common in HIV-infected patients and may be under-recognized (Asch et al., 2003). 
Given the high prevalence of fatigue in this cohort in the absence of diagnosed 
depression, it seems unlikely that mood disorder is the prime mediator of fatigue in 
HIV-infected patients; however, as this is a correlative cross-sectional study it is not 
possible to draw firm conclusions regarding causality. 
 
How might HIV-associated fatigue be approached clinically? The National Institute for 
Clinical Excellence (NICE) has recently recommended a model for assessment and 
treatment of CFS/ME in the UK (NICE, 2007). It is important that fatigue is more 
actively looked for in HIV-infected individuals, even when their HIV infection is 
effectively treated. Our data and those of others suggest that fatigue and associated 
symptomatology in CFS/ME is very similar to that seen in many chronic diseases 
including HIV infection (Jones et al., 2009). Given our evolving understanding of 
fatigue associated with HIV infection and other chronic diseases, we suggest that a 
holistic symptom-based approach to management, similar to that proposed for CFS/ME, 
may therefore prove to be the most helpful (Jones et al., 2008). 
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Figure 1.  
(a) Distribution of Fatigue Impact Severity (FIS) scores in HIV-infected out-patients (HIV+), uninfected volunteers (HIV-), and chronic fatigue 
syndrome/myalgic encephalomyelitis (encephalopathy) (CFS/ME) out-patients. FIS ≥ 40 indicates excessive fatigue. (b) Distribution of FIS scores in 
HIV-infected patients according to the presence or absence of prior dideoxynucleoside analogue (d-drug) exposure. (c) Correlation between FIS and 
Orthostatic Grading Scale (OGS) scores in HIV-infected patients. OGS ≥ 4 indicates symptomatic orthostatic intolerance. 
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Table 1. Demographic, HIV and highly active antiretroviral therapy (HAART) 
factors associated with fatigue severity [Fatigue Impact Scale (FIS) score] in HIV-
infected patients 
 
Continuous variables 
Correlation, r, 
with FIS score 
p value 
Age 0.04 0.70 
Duration of diagnosed HIV infection 0.26 0.010 
Current CD4 lymphocyte count 0.03 0.74 
Nadir CD4 lymphocyte count 0.05 0.66 
Binary variables Mean FIS (SD)  p value 
Gender 
Male (n =63) 54.6 (41.8) 
0.79 
Female (n =34) 44.6 (43.2) 
HIV VL 
≤40 copies/ml (n =75) 50.0 (43.1) 
0.64 
>40 copies/ml (n =22) 54.8 (40.0) 
Current HAART 
On HAART (n =88) 50.3 (42.0) 
0.56 
Off HAART (n =9) 58.9 (47.0) 
No EFV (n = 47) 59.0 (44.2) 
0.036 
EFV (n = 41) 40.2 (37.4) 
Non PI-based (n = 62) 45.4 (41.0) 
0.09 
PI-based (n = 26) 62.0 (42.9) 
Lifetime HAART 
No d-drugs (n = 66) 43.8 (41.1) 
0.016 
d-drugs (n = 22) 68.6 (39.9) 
Clinical LDS 
No LDS (n = 82) 46.4 (41.2) 
0.011 
LDS (n = 15) 76.5 (40.5) 
 
Significant p values are shown in bold. d-drugs, dideoxynucleoside analogues; EFV, 
efavirenz; LDS, lipodystrophy syndrome; PI, protease inhibitor; SD, standard deviation.  
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